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Abstract 
This thesis is separated in three main parts including a general introduction, three 
chapters based on research projects and the last chapters with the experimental 
procedures and analytical data. The focus of this work is based on the isolation of natural 
products and their application in chemistry and biology. 
Chapter 1 
The first chapter consists in a general introduction about natural products, where 
their importance in drug discovery and in the interaction between living organisms is 
highlighted. Several examples of natural products from different origins are described.  
Chapter 2 
The study of a system living in obligatory symbiosis is addressed in this chapter. 
Psychotria kirkii is a plant having the particularity to be in symbiosis with a bacterial 
strain named Candidatus Burkholderia kirkii and the presence of this microorganism was 
found to be essential for the plant’s survival. Interestingly, the bacterial genomic 
sequencing and analysis revealed the presence of a putative C7N aminocyclitol. This 
project led to the isolation, total synthesis and biological evaluation of kirkamide, a new 
C7N aminocyclitol from Candidatus Burkholderia kirkii. In the course of the chemical 
composition analysis of Psychotria kirkii, another new natural product (streptol 
glucoside) was isolated and its structure was elucidated. The last part of this chapter 
focuses on detection and quantification methods for the analysis of these natural 
products. 
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Chapter 3 
After completing a genome-driven bioassay-guided fractionation, a natural product 
possessing an unusual N-nitrosohydroxylamine functional group was isolated. The 
formation of the N-N bond in biological system has yet to be elucidated. Chapter 3 
addresses the question regarding the biosynthetic analysis of the N-nitrosohydroxylamine 
compound. Furthermore, the mechanism of the N-N bond formation was investigated in 
detail using model compounds. 
Chapter 4 
The potential of secondary metabolites has been recognized for the discovery of 
biological active compounds. The strength of natural products resides in the diversity and 
complexity of their chemical structures. In this chapter the isolation, structure elucidation 
and biological evaluation of new natural products from cyanobacteria are described. 
Three new cyanobactins were isolated from the cyanobacteria Microcystis 
aeruginosa EAWAG 251. The stereoassignement of these natural products, named 
balgacyclamides A–C, is presented with their biological activity investigations against 
the parasite Plasmodium falciparum. 
 
The last part of the chapter describes a bioassay-guided fractionation leading to the 
discovery of two new glycolipopeptides from cyanobacteria. The efforts achieved 
towards the structure elucidation using HRMS tandem mass spectrometry, NMR and 
amino acid analysis are presented. N
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1.  Natural Products: a Prolific Source of Knowledge 
Isolation of natural products has been since many years a powerful tool for the 
discovery of new biologically active compounds and to gain a better understanding of 
biological systems. In this chapter, the importance of natural products in drug discovery 
will be presented followed by the role of these compounds in interactions between 
organisms. 
1.1. Natural Products in Drug Discovery 
The development of combinatorial libraries has brought a new route for the 
discovery of biological active compounds without the requirement for isolation nor 
structure elucidation. One of the main limitations of this approach is the generation of a 
library covering a broad diversity in chemical space.1 For this reason, the interest was 
brought back to natural products, which were found to provide a wide chemical structure 
variation and accessiblility at moderate costs. Examples of natural products will be 
described in the following sections.2 
1.1.1. Natural Products Isolated from Plants 
In the 17th century, the bark of the cinchona tree was used to treat malaria. In 1820, 
Pelletier and Caventou isolated the natural product responsible for the antiprotozoal 
activity and the structure was elucidated to be quinine (1) in 1908.3 The first total 
synthesis, reported in 1944, confirmed the structure of the natural product.4  
The discovery of artemisinin (2) is another example of traditional medicine leading 
to the isolation of an antimalarial drug. Artemisia annua (sweet wormwood or qinghao in 
Chinese) is an herb that was recognized for a long time in China for its antimalarial 
property. The active compound was isolated in 1972 and the structure was characterized 
in 1979. The natural product was named artemisinin or qinghaosu (2), meaning active 
principle of qinghao in chinese.5 Interestingly, artemisinin (2) is the only natural product 
possessing a 1,2,4 trioxane (figure 1). A semisynthetic derivative of artemisinin in 
                                                
1 J. Hong, Curr. Opin. Chem. Biol. 2011, 15, 350–354. 
2 G. M. Cragg, D. J. Newman, Biochim. Biophys. Acta 2013, 1830, 3670–3695. 
3  A. R. Butler, Y. L. Wu, Chem. Soc. Rev. 1992, 85–90. 
4 R. B. Woodward, W. E. Doering, J. Am. Chem. Soc. 1944, 66, 849–849. 
5  D. L. Klayman, A. J. Lin, N. Acton, J. P. Scovill, J. M. Hoch, W. K. Milhous, A. D. 
Theoharides, A. S. Dobek, J. Nat. Prod. 1984, 47, 715–717. 
 
2 
combination with lumefantrine was recently approved by FDA and is now an available 
antimalarial drug (Coartem®).6 
 
 
Figure 1: Antimalarial natural products quinine (1) and artemisinin (2).The 1,2,4 trioxane is 
highlighted in red. 
1.1.2. Natural Product Isolated from Marine Organisms 
In an early stage, some secondary metabolites of the marine sponge Halichondria 
okadai (H. okadai) were found to possess potent anticancer properties.7 To further 
investigate the potential of this marine organism, 600 kg of H. okadai were collected, the 
compounds were extracted and subject to a bioassay-guided fractionation to finally obtain 
12.5 mg of halichondrin B (3). The natural product 3 was found to possess an IC50 value 
of 0.093 ng/mL against B-16 melanoma cells, which encouraged the development of an 
alternative route to obtain the natural product.8 The first total synthesis was achieved by 
Kishi and coworkers in 47 steps for the longest linear sequence.9 During the course of 
this work the activity of synthetic precursors was tested and a truncated analogue was 
shown to possess similar anticancer activity as halichondrin B (3). After structure and 
reactivity studies, eribulin mesylated (4)7 was chosen for clinical trials and was recently 
approved by the FDA for the treatment of breast cancer.10 
                                                
6 Z. G. Premji, Malar. J. 2009, 8, S3. 
7 K. L. Jackson, J. A. Henderson, A. J. Phillips, Chem. Rev. 2009, 109, 3044–3079. 
8 Y. Hirata, D. Uemura, Pure Appl. Chem. 1986, 58, 701–710. 
9 T. D. Aicher, K. R. Buszek, F. G. Fang, C. J. Forsyth, S. H. Jung, Y. Kishi, M. C. Matelich, P. 
M. Scola, D. M. Spero, S. K. Yoon, J. Am. Chem. Soc. 1992, 114, 3162–3164. 
10 U. Swami, I. Chaudhary, M. H. Ghalib, S. Goel, Crit. Rev. Oncol. Hematol. 2012, 81, 163–
184. 
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1.1.3. Natural Product Isolated from Microorganisms 
During a search for new antifungal compounds directed by Merck, two natural 
products, pneumocandins A0 and B0 (5), were isolated from an extract of the fungus 
Glarea lozoyensis.11 Pneumocandin B0 (5) was selected for further investigation due to its 
potent antifungal activity against several Candida species.12 The development of the 
natural product to the FDA approved drug CANCIDAS® included: 1) genetic 
modifications of Glarea lozoyensis to obtain a mutant producing larger amount of 
pneumocandin B0 (5), 2) optimization of the isolation strategy using different extraction 
procedures combined with normal phase HPLC separation and finally, 3) chemical 
modifications to improve pharmacokinetic and pharmacodynamic properties.11 
                                                
11  J. M. Balkovec, D. L. Hughes, P. S. Masurekar, C. A. Sable, R. E. Schwartz, S. B. Singh, Nat. 
Prod. Rep. 2014, 31, 15–34. 
12  D. M. Schmatz, G. Abruzzo, M. A. Powles, D. C. Mcfadden, J. M. Balkovec, R. M. Black, K. 
Nollstadt, K. Bartozal, J. Antibiot. 1992, 45, 1886–1891. 
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1.2. Natural Products as Chemical Messengers  
The communications between various living organisms occurs via an exchange of 
natural product(s). The isolation of these compounds and the study of their biological role 
provide crucial information for the understanding of the interaction between various 
species. Herein we will present two example of natural product acting as the chemical 
language between different organisms.13 
1.2.1. Hydroxydanaidal 
Meinwald and coworkers reported a particular behavior of the moth Utetheisa 
ornatrix (U. ornatrix). The authors observed that male moths fed with the plant 
Crotalaria sp. were more successful in courtship when compared to male moths fed with 
pinto bean. Hydroxydanaidal (6) was isolated from the successful males and was 
proposed to be the pheromone responsible for this behavior. Additionally, this natural 
product 6 was proposed to be biosynthetically prepared from the plant alkaloid 
monocrotaline (7).14 It was later found that males fed with the plant Crotalaria sp. 
accumulate the alkaloid 7, which is feeding deterrent, and can transfer the compound to 
                                                
13 J. Meinwald, J. Org. Chem. 2009, 74, 1813–1825. 
14 W. E. Conner, T. Eisner, R. K. Vander Meer, A. Guerrero, J. Meinwald, Behav. Ecol. 
Sociobiol. 1981, 9, 227–235. 
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5 
the eggs and to the female.15 It was proposed that hydroxydanaidal (6) was an indication 
for the female that the male possesses the toxic alkaloid monocrotaline (7).13 
 
1.2.2. Bacterium Messengers N-Acyl-L-homoserine Lactones 
Bacteria have developed a communication system based on the production of N-
acyl-L-homoserine lactones (AHLs) acting as signaling molecules. For example, one 
bacterium will produce and export these natural products into the media, which will be 
detected via a specific receptor (LasR) by another congener. It was found that this 
communication is essential for biofilm formation and virulence of theses organisms. 
AHLs were found to possess a similar lactone core structure with variation in the 
oxidation and length of the acyl chain.16 The natural products N-butyryl-L-homoserine 
lactone (C4-HSL, 8)17 and N-(3´-oxodecanoyl)-L-homoserine lactone (3-oxo-C12-HSL, 
9)18 were isolated from Pseudomonas aeruginosa (P. aeruginosa) culture. 
 
Figure 2: Examples of AHLs produced by P. aeruginosa. 
  
                                                
15 D. E. Dussourd, K. Ubik, C. Harvis, J. Resch, J. Meinwald,  T. Eisner, Proc. Natl. Acad. Sci. 
U. S. A. 1988, 85, 5992–5996. 
16 J. S. Dickschat, Nat. Prod. Rep. 2010, 27, 343–369. 
17 J. P. Pearson, K. M. Gray, L. Passador, K. D. Tucker, A. Eberhard, B. H. Iglewski, E. P. 
Greenberg, Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 197–201. 
18 J. P. Pearson, L. Passador, B. H. Iglewski, E. P. Greenberg, Proc. Natl. Acad. Sci. U. S. A. 
1995, 92, 1490–1494. 
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2. C7N Aminocyclitol Kirkamide and Streptol Glucoside 
2.1. The C7N Aminocylitol Natural Products Family 
The natural products of the C7N aminocyclitol family are characterized by a 
cylcohexane or cyclohexene core structure having attached to the ring a CH2OH, one 
amine and 3 to 5 hydroxyl groups (figure 3). Most of the members possess the amino 
group at C-2 and a saccharide or polysaccharide as R1 and/or R2.19 Additionally, these 
natural products shared a common biosynthetic pathway with the use of 2-epi-5-epi-
valiolone synthases.20,21,22 
 
 
Figure 3: General structure of the C7N aminocyclitols, where R1 and R2 can be hydrogen or 
carbohydrate and R3 and R4 can be hydrogen or hydroxyl group. 
 
Herein, the C7N aminocyclitol natural products will be presented in relation to their 
numerous biological activities such as antifungal, α-glucosidase inhibitor, antibacterial 
and cytotoxicity. 
  
                                                
19  T. Mahmud, Nat. Prod. Rep. 2003, 20, 137–166. 
20  P. M. Flatt, T. Mahmud, Nat Prod Rep 2007, 24, 358–392. 
21  T. Mahmud, P. M. Flatt, X. Wu, J. Nat. Prod. 2007, 70, 1384–1391. 
22  T. Mahmud, Curr. Opin. Chem. Boil. 2009, 13, 161–170. 
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2.1.1. Antifungal and Insecticide 
Validamycin A (10) and B (11) were isolated from Streptomyces hygroscopicus 
var. limoneus in 1970, in an effort to find new antifungal compounds to control the sheath 
blight causing damage to rice production.23,24 These two natural products were the first 
from the C7N aminocyclitol family to be discovered. 
 
 
 
Many compounds sharing similar scaffold with variation in the number of 
carbohydrates were isolated from the same bacteria and named validamycins C–H (12-
17) for those that contains 2 or more carbohydrates,25,26,27 validoxylamine A (18), B (19) 
and G (20) with one carbohydrate25,26 and valienamine (21) for the core structure (table 
1).28 
  
                                                
23 T. Iwasa, H. Yamamoto, M. Shibata, J. Antibiot. 1970, 23, 595–602. 
24 T. Iwasa, E. Higashide, H. Yamamoto, M. Shibata, J. Antibiot. 1971, 24, 107–113. 
25 S. Horii, Y. Kameda, K. Kawahara, J. Antibiot. 1972, 25, 48–53. 
26 Y. Kameda, N. Asano, T. Yamaguchi, K. Matsui, S. Horii, H. Fukase, J. Antibiot. 1986, 39, 
1491–1494. 
27 N. Asano, Y. Kameda, K. Matsui, S. Horii, H. Fukase, J. Antibiot. 1990, 43, 1039–1041. 
28 Y. Kameda, N. Asano, M. Yoshikawa, M. Takeuchi, T. Yamaguchi, K. Matsui, S. Horii, H. 
Fukase, J. Antibiot. 1984, 37, 1301–1307. 
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Table 1. The natural products validamycins and validoxylamines. 
 R1 R2 R3 R4 R5 R6 
validamycin A (10) H H β-D-Glc H H H 
validamycin B (11) H H β-D-Glc H OH H 
validamycin C (12) H α-D-Glc β-D-Glc H H H 
validamycin D (13) H H H H H α-D-Glc 
validamycin E (14) H H α-D-Glc-(1-4)- 
β-D-Glc 
H H H 
validamycin F (15) α-D-Glc H β-D-Glc H H H 
validamycin G (16) H H β-D-Glc OH H H 
validamycin H (17) H H α-D-Glc-(1-4)- 
β-D-Glc 
H H H 
validoxylamine A (18) H H H H H H 
validoxylamine B (19) H H H H OH H 
validoxylamine G (20) H H H OH H H 
     
Antifungal activities were reported for validamycin A (10), B (11), E (14), F (15), 
G (16), H (17) and validoxylamine A (18) and G (20). The inhibition of the enzyme 
trehalase was suggested as the mechanism of action, which prevents the degradation of 
trehalose (22) into glucose. The activity of the compounds was tested in vitro and 
validoxylamine A (18) was found to be the most potent compound from this family with 
an IC50 value of 0.14 µM. Surprisingly, 14 and 15 showed no inhibition up to a 
concentration of 10 mM although they exhibit an antifungal activity. Furthermore, 
validamycin A (10) exhibited a strong antifungal activity but only a weak trehalase 
inhibition and for validoxylamine A (18) exactly the reverse phenomenon was observed, 
strong trehalase inhibition and weak antifungal activity. 10 was suggested to be a prodrug 
harboring good pharmacokinetic properties and activated within the organism into 18 
HO
R1O
OH
HN
OR2
HO
OH
OR3
OR6
R5
R4
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after glucolysis. The same mode of action could be applied to 14 and 15 as they would be 
converted to validoxylamine A (18) after glucolysis.27,29 
 
Validamycins A–E (10-14) and validoxylamine A (18), B (19) and G (20) were 
tested for their insecticide activity performing in vivo and in vitro assays. 10, 12, 13, 14 
and 18 were found to be active in vivo using 20 larvae. Validoxylamin A (18) showed the 
strongest activity. Furthermore, all the compounds were found to possess IC50 values in 
the micromolar and even nanomolar range for their inhibition against trehalase, from 
insect origin, with the most potent activity for validoxylamine A (18).30 
Salbostatin (23) and suidatrestin were found to possess a trehalase inhibition in the 
nanomolar range and picomolar range respectively. 31 , 32  The promising activity of 
suidatrestin was further investigated on insect and essentially no effect was observed.33 
Additionally, the structure of this natural product remained unknown and was proposed 
to be similar as validoxylamin A (18) based on C NMR data analysis.33 
  
                                                
29 N. Asano, T. Yamaguchi, Y. Kameda, K. Matsui, J. Antibiot. 1987, 40, 526–532. 
30 N. Asano, M. Takeuchi, Y. Kameda, K. Matsui, Y. Kono, J. Antibiot. 1990, 43, 722–726. 
31 L. Vértesy, H. W. Fehlhaber, A. Schulz, Angew. Chem. Int. Ed. 1994, 33, 1844–1846. 
32 S. Murao, T. Shin, K. Sugawa, A. Teruo (S. Murao) US005494812A, 1996 
33 I. Knuesel, S. Murao, T. Shin, T. Amachi, H. Kayser, Comp. Biochem. Physiol. B, Biochem. 
Mol. Biol. 1998, 120, 639–646. 
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2.1.2. α-Glucosidase Inhibitor 
Acarbose (24), discovered in 1977, is one of the mostly used α-glucosidase 
inhibitor,34 nowadays to treat patients suffering from type 2 diabetes.35 The compound is 
ingested at the same time as the meal and its inhibitor effect will prevent that the 
concentration of glucose rises in the blood.35 The mechanism of action was suggested to 
be related to the presence of valienamine (21), which its half chair conformation would 
mimic an oxocarbenium (degradation intermediate of glucose) and block the active site of 
the enzyme.19 Several other naturals products containing 21 were reported to possess α-
glucosidase activities as adiposin-1 (25),36 adiposin-2 (26)36 and the more complex 
trestatins A-C (27-29),37,38 Ro 09-0766 (30),39 Ro 09-0767 (31)39 and Ro 09-0768 (32).39 
The structure of these natural products was elucidated by NMR spectroscopy data 
analysis and degradation studies. 
 
 
 
                                                
34 D. D. Schmidt, W. Frommer, B. Junge, L. Müller, W. Wingender, E. Truscheit, D. Schäfer, 
Naturwissenschaften 1977, 64, 535–536. 
35 M. F. McCarty, J. J. DiNicolantonio, Open Heart 2015, 2, e000205. 
36 S. Namiki, K. Kangouri, T. Nagate, H. Hara, K. Sugita, S. Omura, J. Antibiot. 1982, 35, 1234–
1236. 
37 K. Yokose, K. Ogawa, T. Sano, K. Watanabe, H. B. Maruyama, Y. Suhara, J. Antibiot. 1983, 
36, 1157–1165. 
38 K. Yokose, K. Ogawa, Y. Suzuki, I. Umeda, Y. Suhara, J. Antibiot. 1983, 36, 1166–1175. 
39 K. Yokose, M. Ogawa, K. Ogawa, J. Antibiot. 1984, 37, 182–186. 
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It was also found that valienamine (21), hydroxyvalidamine (33), valiolamine (34) 
and validamine (35) were active at a micromolar and even nanomolar range, for 35, 
against some α-glucosidase.28 This result was unexpected due the fact that these 
carbohydrates are not all in a half-chair conformation. Furthermore, the C7N aminocylitol 
oligostatins C–E (36–38) possessing a core structure in chair conformation was found to 
be active against α-amylase.40,41 
 
                                                
40 J. Itoh, S. Omoto, T. Shomura, H. Ogino, K. Iwamatsu, S. Inouye, H. Hidaka, J. Antibiot. 
1981, 34, 1424–1428. 
41 S. Omoto, J. Itoh, H. Ogino, K. Iwamatsu, N. Nishizawa, S. Inouye, J. Antibiot. 1981, 34, 
1429–1433. 
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Several oxirane pseudooligosaccharides were isolated and patented for their use as 
α-glucosidase inhibitors. The compounds W-46 A (39), W-46 B (40), W-46 C (41),  
W-46 H (42), W-46 P (43),42 CKD-711 (44)43, CKD-711a (45)43 and from the NS and 
CK-4416 complexes,44,45 contained carbohydrates attached at C-2 and/or C-4 to the C7N 
core structure. 
 
 
                                                
42 L. Vertesy, J. Betz, H.-W. Felhaber, K. Geisen (Hoechst Aktiengesellschaft) US4990500, 
1991. 
43 H.-B. Chang, S.-H. Kim, Y.-I. Kwon, D.-H. Choung, W.-K. Choi, T. W. Kang, S. Lee, J.-G. 
Kim, H.-S. Chun, S. K. Ahn, C. I. Hong, K.-H. Han, J. Antibiot. 2002, 55, 467–471. 
44 J. W. Kim, K. M. Lee, H. S. Chun, J. G. Kim, H. B. Chang, S. H. Kim, K. B. Min, K. S. Moon 
(Chong Kun Dang Corporation) US5866377A, 1999. 
45 T. Haruki, N. Yoshio, K. Akira (Tokyo Tanabe CO), JPS58172400, 1983. 
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2.1.3. Antibacterial Activity 
Pyralomicin 1a–1d (46-49) were isolated from a Microtetraspora spiralis strain and 
their structures were elucidated by NMR spectroscopic data analysis and by X-ray 
crystallography analysis on the bromo derivative of 46.46,47 The natural products were 
found to be active against various bacterial strains especially against Micrococcus 
luteus.46 Pyralomicin 1d (49), which contained an additional chloride attached to the 
cyclopentadiene, had a significantly lower potency indicating the importance of this 
position for the biological activity. 
 
                                                
46 N. Kawamura, R. Sawa, Y. Takahashi, K. Issiki, T. Sawa, N. Kinoshita, H. Naganawa, M. 
Hamada, T. Takeuchi, J. Antibiot. 1995, 48, 435–437. 
47 N. Kawamura, N. Kinoshita, R. Sawa, Y. Takahashi, T. Sawa, H. Naganawa, M. Hamada, T. 
Takeuchi, J. Antibiot. 1996, 49, 706–709; N. Kawamura, R. Sawa, Y. Takahashi, K. Isshiki, T. 
Sawa, H. Naganawa, T. Takeuchi, J. Antibiot. 1996, 49, 651–656; N. Kawamura, H. 
Nakamura, R. Sawa, Y. Takahashi, T. Sawa, H. Naganawa, T. Takeuchi, J. Antibiot. 1997, 50, 
147–149. 
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The natural products epoxyquinomicins A-D (50-53), produced by Amycolatopsis 
sp., were discovered during a screening for new antibiotics.48,49 Epoxyquinomicins A and 
B (50-51) inhibited the growth of several bacteria but their reduced forms 52 and 53 lost 
their activities.48 Additionally, the compounds possessed an antiarthritic effect by 
inhibiting the articular lesions without antiinflammatory properties.50 
 
                                                
48 T. Tsuchida, M. Umekita, N. Kinoshita, H. Iinuma, H. Nakamura, K. Nakamura, H. 
Naganawa, T. Sawa, M. Hamada, T. Takeuchi, J. Antibiot. 1996, 49, 326–328. 
49 N. Matsumoto, T. Tsuchida, M. Umekita, N. Kinoshita, H. Iinuma, T. Sawa, M. Hamada, T. 
Takeuchi, J. Antibiot. 1997, 50, 900–905; N. Matsumoto, T. Tsuchida, R. Sawa, H. Iinuma, H. 
Nakamura, H. Naganawa, T. Sawa, T. Takeuchi, J. Antibiot. 1997, 50, 912–915. 
50 N. Matsumoto, H. Iinuma, T. Sawa, T. Takeuchi, S. Hirano, T. Yoshioka, M. Ishizuka, J. 
Antibiot. 1997, 50, 906–911. 
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Others compounds discussed previously were identified as antibacterial agents as 
adiposins (25-26), oligostatins (36-38), CKD-711 (44) and CKD-711a (45) 
2.1.4. Antitumor Activity 
Cetoniacytones A and B (54-55) were isolated from the insect, Cetonia aurata, 
bacterial endosymbiont. The epoxide 54 was tested against human cancer cell lines and 
was found to be active at a few µg/mL. 51  Interestingly the natural products 
epoxyquinomicins A and B (50-51) and not C nor D (52-53), which shared the same core 
structure as 54, have been also reported for their cytotoxicity activity.  
 
  
                                                
51 O. Schlörke, P. Krastel, I. Müller, I. Usón, K. Dettner, A. Zeeck, J. Antibiot. 2002, 55, 635–
642. 
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2.2. Psychotria kirkii, an Obligatory Symbiosis System 
 
Psychotria kirkii (P. kirkii) is a flowering plant from the Rubiaceae family that 
lives in obligatory symbiosis with bacteria from the genus Burkholderia. 52 Candidatus 
Burkholderia kirkii (B. kirkii) forms nodules on the lower surface of the plant’s leaves 
and the presence of the microorganism is essential for the development of the plant 
host.53 However, it is unknown how the formation of these nodules by B. kirkii can 
account for the survival of the plant. This gap in the understanding of their symbiosis is 
mainly due to the impracticality of culturing the B. kirkii bacteria in the absence of their 
plant host.54 
 
Analysis of the genome of uncultured B. kirkii revealed that there is a biochemical 
pathway leading to the production of a C7N aminocyclitol compound. 55,56 This family of 
secondary metabolites features a wide range of biological activities. It was thus 
hypothesized that this unknown C7N aminocyclitol compound might be the key molecule 
for the establishment of the obligate symbiosis between the bacteria and the plant. To 
verify this hypothesis, we decided to embark on the isolation and structure elucidation of 
the C7N aminocyclitol from the symbiont of P. kirkii. 
  
                                                
52 A. Zimmermann, Jahrb. Wiss. Bot. 1902, 37, 1–11. 
53 S. Van Oevelen, R. De Wachter, P. Vandamme, E. Robbrecht, E. Prinsen, Int. J. Syst. Evol. 
Microbiol. 2004, 54, 2237–2239. 
54 I. M. Miller, in Advances in Botanical Research (Ed.: J.A. Callow), Academic Press, 1990, pp. 
163–234. 
55 A. L. Carlier, L. Eberl, Environ. Microbiol. 2012, 14, 2757–2769. 
56 A. L. Carlier, U. Omasits, C. H. Ahrens, L. Eberl, Mol. Plant-Microbe Interact. 2013, 26, 
1325–1333. 
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2.3. Results and Discussion57 
This project was carried out in collaboration with Dr. Aurélien Carlier from the 
research group of Professor Leo Eberl at the Institute of Plant Biology, University of 
Zürich. My contribution was the isolation and structure elucidation as well as the 
development methods for the detection and quantification of kirkamide (56) and streptol 
glucoside (57). I also devised and successfully carried out a total synthesis of kirkamide. 
For the preparation of synthetic kirkamide, I want to mention the help of M. Sc. Darja 
Kolbin, M. Sc. Ina Ontiveros Casas and B. Sc. Joel Rösslein in the course of their project 
during their master program. This chapter will be separated into three parts, starting with 
the isolation, structure elucidation, total synthesis and biological investigations of 
kirkamide (56), followed by the isolation and structure elucidation of streptol glucoside 
(57) and finally the last chapter will be dedicated to the analytical methods developed for 
the detection and quantification of kirkamide (56) and streptol glucoside (57). 
2.3.1. Isolation of Kirkamide 
It is crucial for the isolation of natural products to find a unique chemical or 
biological characteristic of the desired compound. Bio-guided fractionation is a method 
frequently used, which consists of the separation of a bioactive extract by 
chromatography generating fractions that are further tested in biological assays. The 
active fractions are further separated and the process is then repeated until a pure natural 
product is obtained.  
The project started with the isolation of the putative C7N aminocyclitol predicted, 
by genomic analysis, to be present in the P. kirkii leaves extract. The first isolation 
strategy applied was based on a bio-guided fractionation targeting the biological activities 
shared by most of the members of the C7N aminocyclitol family members. Unfortunately 
neither a α-glucosidase inhibitor nor antibacterial or antifungal activity was observed.19 
For this reason we decided to analyze the chemical properties of the members from the 
C7N aminocylitol family taking validamycin A (10) as an example. The 1H NMR 
spectrum of this natural product displays a characteristic methylene proton around δ = 6 
                                                
57 Part of this project is currently subject of two publications and a Sinergia grant; S. Sieber, A. 
Carlier, M. Neuburger, G. Grabenweger, L. Eberl, K. Gademann, Ang. Chem. Int. Ed. Engl. 
2015, 54, 7968–7970; M. Pinto-Carbó, S. Sieber, S. Dessein, T. Wicker, B. Verstraete, K. 
Gademann, L. Eberl, A. Carlier, manuscript submitted; Sinergia grant CRSII3_154430. 
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ppm (figure 4), and this property is ideally suited to serve as a characteristic mark in 1H 
NMR guided fractionation.58 This isolation strategy is similar to bio-guided fractionation. 
The crude extract is separated in several fractions, which are analyzed by 1H NMR and 
those possessing the specific chemical shift are further separated by chromatography 
methods. 
         
Figure 4: Structure of validamycin A (10) and characteristic 1H NMR peak at 5.9. 
2.3.1.1. Methods for the Separation and Detection of Kirkamide 
The high polarity and the absence of chromophore were the two main challenges 
that had to be addressed for the isolation of the unknown C7N aminocylitol compound 
from the leaves plant extract of P. kirkii. To overcome these difficulties and to avoid any 
derivatization, reversed phase high performance liquid chromatography (RP-HPLC) was 
used with water and acetonitrile as eluents. A Synergi Hydro column consisting of a polar 
endcapped C-18 stationary phase, was chosen due to its ability to retain polar compounds 
while using a RP solvent system.59 The UV detector was set at a wavelength of λ = 190 
nm and mass spectrometric (MS) detection was used in negative atmospheric pressure 
chemical ionization (APCI) mode, as this method has been previously reported for the 
analysis of saccharide.60 
  
                                                
58 W. Z. Jin, K. L. Rinehart, T. Toyokuni, J. Antibiot. 1987, 40, 329–339. 
59 Z. Liu, S. Rochfort, J. Chromatogr. B 2013, 912, 8–15. 
60 G. Ricochon, C. Paris, M. Girardin, L. Muniglia, J. Chromatogr. B 2011, 879, 1529–1536. 
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2.3.1.2. 1H NMR-Guided Fractionation of the Leaves Extract of P. kirkii 
The crude extracts from P. kirkii leaves were subjected to multiple RP-HPLC 
separations using a semi-preparative Synergi Hydro column operating at a flow of 2 
mL/min. A natural product possessing a 1H NMR peak with a chemical shift at 5.86 ppm 
was found in a fraction. However, the separation of the desired compound was found to 
be difficult due to the presence of a contaminant possessing an identical rentention time. 
Fortunately, the contaminant was identified to be sucrose, based on the NMR comparison 
between the fraction and the sugar. To remove sucrose, the crude extract was treated 
under acidic conditions to cleave the glycosidic bond of the disaccharide. The separation 
of the mixture was then achieved by a combination of RP-HPLC using the Synergi Hydro 
column and a Cu(II)-coated preparative thin layer chromatography, which has been 
previously reported for the separation of saccharides.61 With this strategy a new C7N 
aminocyclitol (figure 5), named kirkamide (56), was isolated from the leaves of the plant 
P. kirkii. 
 
Figure 5: Configuration and conformation of kirkamide (56). 
2.3.2. Structure Elucidation of Kirkamide 
High resolution ESI-MS of kirkamide (56) displayed an exact mass of m/z 
240.0844 Da, which supports the molecular formula C9H15NO5Na for the [M+Na]+ 
pseudo-molecular ion. 1H and 13C NMR spectroscopic data (DMSO-d6) of kirkamide (56) 
were compared with those reported for streptol (58),62 which suggested a different 
functionality at C-2, as well as the presence of an acetyl group. This group was 
established as an NH-acetyl fragment based on 1H 13C HMBC correlations between the 
                                                
61 O. Hadžija, B. Špoljar, L. Sesartić, Fresenius' J. Anal. Chem. 1994, 348, 782–782.; R. 
Bhushan, S. Kaur, Biomed. Chromatogr. 1997, 11, 59–60. 
62 P. Sedmera, P. Halada, S. Pospíšil, Magn. Reson. Chem. 2009, 47, 519–522. 
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quaternary carbonyl C-8 with the NH and H-9 proton signals. The assignment of the 
carbocyclic core structure was then deduced based on 1H 13C HMBC correlations 
between H-5, H-7a and H-7b with C-6 as well as between H-5 and C-1. 1H 1H COSY 
correlations between H-1 and H-2, H-2 and H-3, H-3 and H-4, NH and H-3, H-4 and H-5 
and H-5 and H-1 further supported this structural proposition. The relative configuration 
was assigned comparing the 3JH-H coupling constants between H-2 and H-3, H-3 and H-4, 
and H-4 and H-5 in DMSO-d6 (table 2) with those reported for streptol (58) in D2O.62 To 
exclude the influence of the solvent, the recorded NMR spectroscopic data of kirkamide 
were compared to those of valienamine (21) in DMSO-d6, which showed that theses two 
compounds feature the same conformation with H-2 in equatorial position and H-3, H-4 
and H-5 in axial position. Finally, single crystal X-ray structure analysis (Figure 6) 
unambiguously established the constitution and configuration of kirkamide (56). 
 
 
Table 2. NMR spectroscopic data (500 MHz, DMSO-d6) of kirkamide (56). 
C/N no. δC, type δH (3JH-H in Hz) HMBC[a] 
1 121.5, CH 5.63, dq[b] (4.8, 1.5) 3, 5, 7 
2 64.3, CH 3.99, m  
3 53.1, CH 3.63, ddd (10.9, 8.1, 3.9)  
NH  7.36, d (8.1) 8 
4 70.4, CH 3.56, dd (10.9, 7.1) 3, 5 
5 72.9, CH 3.79, d (7.1) 1, 4, 6 
6 142.5, C   
7a 60.8, CH2 4.01, d (14.8) 1, 6 
7b  3.95 d (14.8) 1, 6 
8 169.2, C   
9 23.0, CH3 1.85, s 8 
[a] HMBC correlations are given from proton(s) stated to the indicated carbon atom. 
[b] Apparent splitting pattern. 
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Figure 6: Single crystal X-ray analysis of kirkamide (56). Cambridge Crystallographic Data 
Centre accession number: CCDC 1054238. 
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2.3.3. Enantioselective Total Synthesis of Kirkamide 
A total synthesis was developed using a cheap and readily available starting 
material in order to obtain larger quantities of the compound for biological tests regarding 
its role in the symbiosis with P. kirkii. 
2.3.3.1. Overview of Existing Syntheses of Valienamine 
During the past decades, many studies have been directed towards the synthesis of 
C7N aminocyclitol compounds particularly valienamine (21). Paulsen and coworkers 
developed the first enantioselective synthesis of this natural product in 1972 using 
quebrachitol (59) as the initial reagent (scheme 1).63 The synthesis started with the 
installation of the protective groups followed by an oxidation with ruthenium 
tetraoxide/sodium periodate affording the ketone intermediate 60. Using sequentially 
Corey-Chaykovsky and basic conditions furnished the diol 61, which was activated and 
its protection groups exchanged to obtain the mono or di mesylated 62 and 63. With both 
compounds 62 and 63, the formation of an epoxide followed by its elimination afforded 
the cyclohexene 64. The insertion of the amine was achieved via azide formation and the 
final deprotections delivered valienamine (21). Many synthetic strategies have been focus 
on the variation of the starting material with different key step for the ring formation; e.g 
an alkene or enyne ring-closing metathesis or an aldol reaction with amino acids or 
carbohydrate derivatives,64,65,66 or a Diels-Alder cycloaddition with achiral substrates.67 
Furthermore quininic acid and inositol were investigated as chiral pool.68 
                                                
63 H. Paulsen, F. R. Heiker, Angew. Chem., Int. Ed. Engl. 1980, 19, 904–905. 
64  Selected examples: R. R. Schmidt, A. Köhn, Angew. Chem. Int. Ed. 1987, 26, 482–483; P. 
Kapferer, F. Sarabia, A. Vasella, Helv. Chim. Acta 1999, 82, 645–656; K. Tatsuta, H. Mukai, 
M. Takahashi, J. Antibiot. 2000, 53, 430–435; I. Cumpstey, Tetrahedron Lett. 2005, 46, 6257–
6259; Y.-K. Chang, B.-Y. Lee, D. J. Kim, G. S. Lee, H. B. Jeon, K. S. Kim, J. Org. Chem. 
2005, 70, 3299–3302; I. Cumpstey, S. Gehrke, S. Erfan, R. Cribiu, Carbohydr. Res. 2008, 343, 
1675–1692; T. K. M. Shing, H. M. Cheng, J. Org. Chem. 2010, 75, 3522–3525; Q. R. Li, S. I. 
Kim, S. J. Park, H. R. Yang, A. R. Baek, I. S. Kim, Y. H. Jung, Tetrahedron 2013, 69, 10384–
10390. 
65  P. Radha Krishna, P. Srinivas Reddy, Synlett 2009, 0209–0212; B. Zhou, Z. Luo, S. Lin, Y. Li, 
Synlett 2012, 23, 913–916. 
66  Y.-K. Chang, H. J. Lo, T. H. Yan, Org. Lett. 2009, 11, 4278–4281; H. J. Lo, C. Y. Chen, W. L. 
Zheng, S. M. Yeh, T. H. Yan, Eur. J. Org. Chem. 2012, 2780–2785. 
67  B. M. Trost, L. S. Chupak, T. Lübbers, J. Am. Chem. Soc. 1998, 120, 1732–1740. 
68  Selected examples: Tony K M Shing, A. Tin Y Li, S. H. L. Kok, J. Org. Chem. 1999, 64, 
1941–1946; S. Mondal, A. Prathap, K. M. Sureshan, J. Org. Chem. 2013, 78, 7690–7700; S. 
Ogawa, N. Chida, T. Suami, J. Org. Chem. 1983, 48, 1203–1207. 
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Scheme 1: First enantioselective synthesis of valienamine (21). 
 
 
 
2.3.3.2. Retrosynthetic Analysis of Kirkamide 
Bearing the results of other aminocyclitol syntheses in mind (2.3.3.1), a D-glucose 
derivative appeared to be a good starting material due to its availability and low cost. For 
the retrosynthetic analysis of kirkamide (56) (scheme 3), we were inspired by Scaffidi’s 
work on β-N-acetylglucosaminidase inhibitors. Starting from N-acetyl-D-glucosamine 
(65), Scaffidi’s synthetic route to cyclohexanone 66 features a Ferrier carbocyclization as 
key step (scheme 2).69,70 
                                                
69 A. Scaffidi, K. A. Stubbs, R. J. Dennis, E. J. Taylor, G. J. Davies, D. J. Vocadlo, R. V. Stick, 
Org. Biomol. Chem. 2007, 5, 3013–3019. 
70 A. Scaffidi, K. A. Stubbs, D. J. Vocadlo, R. V. Stick, Carbohydr. Res. 2008, 343, 2744–2753. 
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Scheme 2: Synthetic strategy of Scaffidi and coworkers affording the cyclohexanone 66 a) HCl, 
MeOH; b) PhCH(OMe)2, CSA, DMF; c) BnBr, NaH, THF; d) aq. AcOH soln. (80%); e) TsCl, 
Et3N, CH2Cl2; f) NaI, DMF; g) NaH, BnBr, DMF; h) HgSO4, dioxane: aq. H2SO4 (5 mM) 2:1. 
Cyclohexanone 72 was chosen as a key intermediate for the synthesis of kirkamide 
(56). This compound could be transformed to the enol triflate 71 using Comins’ reagent 
in the presence of a hindered base. Kirkamide (56) could then by prepared via a Stille 
cross-coupling followed by final deprotections. This synthetic pathway was chosen for 
the availability of the starting material and its flexibility. 
 
 
Scheme 3: Retrosynthetic analysis of kirkamide (56). 
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2.3.3.3. Towards Enol Ether, Strategy I 
The first strategy (scheme 4), for our total synthesis of the natural product 
kirkamide (56), is based on the synthesis of valienamine (21) by Scaffidi and 
coworkers.69 We started with methyl ether protection of the N-acetyl-D-glucosamine’s 
(65) anomeric position using an acidic resin.71 Next, the hydroxyl groups at C-4 and C-6 
were jointly protected by reaction with (dimethoxymethyl)benzene to give the 
corresponding benzylidene.72,73 After installation of a benzyl protecting group at the C-3 
hydroxyl group, the benzylidene protecting group was selectively cleaved by treating the 
fully protected pyranose 67 with acetic acid. The free hydroxyl group at C-6 was 
activated by tosylation to form a good leaving group. Nucleophilic substitution with 
sodium iodide then gave compound 69 with 29% over six steps from 65 to 69. After the 
first column chromatography required in this route, elimination of the iodide and 
protection of the free OH group at C-4 were achieved in one pot by treating 69 with 
benzyl bromide and sodium hydride. The desired enol ether key intermediate 70 was 
obtained from this step in 77% yield. This strategy proved to be robust, and all steps were 
suitable for multigram scale preparation. 
 
Scheme 4: a) Amberlite® IR-120 (H+ form), MeOH reflux, 16 h; b) PhCH(OMe)2, pTSOH, DMF; 
c) BnBr, BaO, Ba(OH)2, DMF, 2 h 40, RT; d) aq. AcOH soln. (aq., 80%), 70 °C, 1 h; e) TsCl, 
Et3N, CH2Cl2, 0 °C to RT, 3 h 20; f) NaI, DMF, 100 °C, 3 h, 29% over 6 steps; g) NaH, BnBr, 
DMF, RT, 1 h, 77%. 
                                                
71  F. Gao, X. Yan, T. Shakya, O. M. Baettig, S. Ait-Mohand-Brunet, A. M. Berghuis, G. D. 
Wright, K. Auclair, J. Med. Chem. 2006, 49, 5273–5281. 
72  D. P. G. Emmerson, W. P. Hems, B. G. Davis, Tetrahedron: Asymmetry 2005, 16, 213–221. 
73  E. Petrakova, U. Spohr, R. U. Lemieux, Can. J. Chem. 1992, 70, 233–240. 
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2.3.3.4. Towards Enol Ether, Strategy II 
In order to develop a shorter synthetic pathway another strategy was developed to 
obtain the key intermediate 70 in large amount (scheme 5). The known methyl-N-acetyl-
D-glucosamine (75) was subject to a Garegg-Samuelsson reaction using Ph3P, I2 and 
imidazole and we were pleased to report the formation of the iodide 76 in good yield.74 
However, due to the high polarity of the product 76 separation by column 
chromatography was found to be challenging on a large scale (20 g). Therefore, the crude 
product mixture, containing iodide 76 and imidazole, was used directly for the next 
synthetic step without any purification. Various methods were tested for the direct 
introduction of the benzyl protecting groups, but nucleophilic attack of the hydroxyl 
group on C-3 on C-6 forming bicycle 77 was always observed as a side reaction. 
Consequently, the two free hydroxyl groups in diol 76 were protected by acetylation. 
Then, AgF-mediated elimination was successfully executed.75 Finally the protection 
groups were exchanged to obtain the desired benzyl-protected enol ether 70 in five steps, 
on a multigram scale and only requiring two purifications by column chromatography.75 
 
Scheme 5: a) Ph3P, imidazole, I2, THF, reflux, 15 min; b) Ac2O, pyridine, RT, 24 h; c) AgF, 
pyridine, RT, 48 h, exclusion of light, 50% over 3 steps; d) NH3(gas), MeOH, RT, 3 h; e) NaH, 
BnBr, DMF, 0°C, 12 h, 36% over 2 steps. 
  
                                                
74 P. J. Garegg, B. Samuelsson, J. Chem. Soc., Chem. Commun. 1979, 978–980. 
75 F. Chretien, R. Wolf, Y. Chapleur, Nat. Prod. Lett. 1993, 2, 69–75. 
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2.3.3.5. Ferrier Carbocylization 
The Ferrier carbocyclization was developed by Ferrier in 1979 using mercury 
chloride to transform an enol ether in a cyclohexanone. 76 Following this result other 
transition metals, for example palladium or titanium salts were found to catalyze this 
reaction.77,78 As for the reaction conditions, the use of a microwave reactor was shown to 
improve the yield and diastereoselectivity of the reaction (figure 7, line 2).79 Scaffidi and 
coworkers reported the use of HgSO4 as catalyst under acidic conditions to give the 
desired cyclohexanone 66 (figure 7, line 1).70 To optimize the reaction conditions, we 
tested palladium chloride as a less toxic catalyst, but unfortunately the yield dropped 
substantially. However, by use of microwave irradiation the reaction time was lowered 
and the yield of the cyclohexanone 66 improved to 74 % (figure 7, line 3) 
 
Figure 7:Ferrier carbocylization reaction conditions: a) reported by Scaffidi and coworkers,70 b) 
reported by Ko and coworkers79 and c) used for the synthesis of kirkamide 56. 
  
                                                
76 R. J. Ferrier, J. Chem. Soc., Perkin Trans. 1 1979, 1455–1458. 
77 S. Adam, Tetrahedron Lett. 1988, 29, 6589–6592. 
78 M. Sollogoub, J.-M. Mallet, P. Sinaÿ, Tetrahedron Lett. 1998, 39, 3471–3472. 
79 K.-S. Ko, C. J. Zea, N. L. Pohl, J. Am. Chem. Soc. 2004, 126, 13188–13189. 
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2.3.3.6. Final Steps of Kirkamide Synthesis 
Cyclohexanone 66 obtained by Ferrier carbocyclization (1.1.3.5) was directly 
protected with TBS80 to prevent the elimination of the free hydroxyl group. A single 
crystal X-ray structure of the protected cyclohexanone 80 confirmed the antiperiplanar 
relation between the oxygen from C-2 and the axial hydrogen of C-1 (Figure 8). 
  
Figure 8: Single crystal X-ray structure of the protected cyclohexanone 80 and its representation 
with the antiperiplanar relation between the TBS protective group and the hydrogen at C-2 
highlighted in red. 
The reaction conditions had to be carefully controlled for the formation of the enol 
triflate 81. It was mandatory to premix the starting material cyclohexanone 80 with 
Comins’ reagent before the base (NaHMDS) was slowly added at –78 °C.81 When the 
reaction was executed on a gram scale, the temperature was controlled with a cryostat 
and the solution of NaHMDS was added using a syringe pump. Furthermore, triethyl 
amine was required as an additive to the eluent for the purification of product 81 by 
column chromatography in order to prevent its degradation. 
A Stille cross-coupling gave primary alcohol 82. This strategy was inspired by the 
work of Li and coworkers, who used similar conditions on an enol triflate substrate for 
                                                
80 M. Nevalainen, A. M. P. Koskinen, J. Org. Chem. 2002, 67, 1554–1560. 
81  P. Jakubec, A. Hawkins, W. Felzmann, D. J. Dixon, J. Am. Chem. Soc. 2012, 134, 17482–
17485. 
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the synthesis of (±)-minfiensine. 82  Having the core structure completed, TBS was 
smoothly removed. For the benzyl deprotection, various reagents were tested: standard 
literature procedures using Pd/C with H2 or HCOOH,83,84 EtSH85 or FeCl369 only led to 
decomposition of the starting material. Finally, we successfully achieved the total 
synthesis of kirkamide (56) by applying Birch conditions.86 
 
Scheme 6: a) HgSO4 dioxane: aq. H2SO4 (aq., 5 mM) 2:1, µw, 60 °C, 15 min; b) TBSOTf, 2,6-
lutidine, THF, 0°C, 12 h, 63% over 2 steps; c) Comins’ reagent, NaHMDS, THF, −78°C, 5 min, 
62%; d) n-Bu3SnCH2OH, Pd(PPh3)4, LiCl, dioxane, µw, 105°C, 1 h, 85%; e) TBAF, THF, RT, 3 
h, 98%; f) Na/NH3(liq), THF, −78 °C, 30 min, 59 %. 
  
                                                
82  G. Li, A. Padwa, Org. Lett. 2011, 13, 3767–3769. 
83  J. Chen, P.-Q. Huang, Y. Queneau, J. Org. Chem. 2009, 74, 7457–7463. 
84 Y. Oikawa, T. Tanaka, K. Horita, O. Yonemitsu, Tetrahedron Lett. 1984, 25, 5397–5400. 
85 Z. Liu, H.-S. Byun, R. Bittman, J. Org. Chem. 2011, 76, 8588–8598. 
86 A. J. Birch, J. Chem. Soc. 1944, 430–436; X. Lu, G. Arthur, R. Bittman, Org. Lett. 2005, 7, 
1645–1648. 
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2.3.4. Biological Activity of Kirkamide 
The biological activity of kirkamide (56) was investigated in order to understand its 
role in the relation between the symbiont B. kirkii and the plant host P. kirkii. A 
protective role of the C7N aminocyclitol was postulated by Aurelien Carlier et al. to 
explain the unique obligatory character of the symbiosis.55,56 Since the natural product 
kirkamide (56) was produced by total synthesis, a large amountof compound was 
available to perform various activity assays (antibacterial, antifungal, glucosidase 
inhibitor, N-acetyl-glucosaminidase inhibitor, insecticidal and cytotoxic). In section the 
cytotoxicity test, conducted by Dr. Aurélien Carlier, and the insecticide test, conducted 
by Dr. Giselher Grabenweger (Agroscope, Switzerland) are discussed. 
2.3.4.1. Brine Shrimp Toxicity Assay 
The cytotoxicity of kirkamide (56) was evaluated using a brine shrimp assay. This 
assay has been widely used for the discovery of novel bioactive compounds, especially 
those possessing an antitumor activity. 87 A correlation was found between the ED50 
values measured on the human epidermoid carcinoma cytotoxicity test with the LC50 
values of the brine shrimp assay: the ED50 values were approximately ten times less than 
the IC50 values.87 The activity of kirkamide (56) was determined and a LC50 value of 850 
ng/mL with a standard deviation of ± 310 ng/mL was found. This result implies that 
kirkamide (56) possesses antitumor activity. In the light of the structural similarities of 
kirkamide and the anticancer agent cetoniacytone A (54), this result appears plausible.51 
 
Figure 9: Structure of kirkamide (56) and cetoniacytone A (54). Common structural features with 
kirkamide (56) are highlighted in red.  
                                                
87  J. L. McLaughlin, L. L. Rogers, J. E. Anderson, Drug Inf. J. 1998, 32, 513–524. 
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2.3.4.2. Insecticidal Activity of Kirkamide 
The insecticidal activity of kirkamide (56) was determined on the pollen beetle 
Meligethes aeneus. Controlling the population of this insect is of importance due to the 
damage that they afflict to the structure of the Danish oilseed rape flowers.88 
The mortality of the pollen beetle fed with 0.3% w/w of kirkamide (56) were found 
to be up to 90% after 14 days. Interestingly, validoxylamine A (18) a member of the C7N 
aminocylitol family, was found to possess an insecticidal activity by inhibiting the 
degradation of trehalose.89 A similar or related mechanism might be operative for 
kirkamide (56). Furthermore, structural similarities of the natural product kirkamide (56) 
with N-acetyl-D-glucosamine (65), which is the main component of the insect 
exosqueleton, also make kirkamide’s insecticidal properties appear plausible. 
 
 
Figure 10: Structures of kirkamide (56), validoxylamine A (18) and N-acetyl-D-glucosamine (65). 
Common structural features with kirkamide (56) are highlighted in red. 
  
                                                
88 L. M. Hansen, Pest Manage. Sci. 2003, 59, 1057–1059. 
89 Y. Kono, M. Takahashi, K. Matsushita, M. Nishina, Y. Kameda, E. Hori, J. Insect Physiol. 
1994, 40, 455–461. 
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2.3.5. Streptol Glucoside 
2.3.5.1. Isolation of Streptol Glucoside 
During a biological activity screening of the nodulated plant P. kirkii leaves extract, 
we found a growth inhibition effect on lettuce seeds. We used this property to perform a 
bioassay-guided fractionation. The targeted compound exhibited similar chemical 
properties as kirkamide (56), and for this reason a Synergi Hydro HPLC column  was 
chosen and the UV detector was set up at a wavelength of 190 nm. The separation of 88.6 
mg of the crude extract from nodulated plants, which was already purified by an 
aminopropyl solid phase extraction (SPE), gave eight fractions and the biological activity 
of each of them was tested in the lettuce seed growth inhibition test. The fraction 
designated P_II_3 was shown to be the most biologically active in this assay, and was 
chosen for further separation (image 1). 
 
 
Image 1: Lettuce seeds incubated with HPLC fractions (P_II_2, P_II_3, P_II_4, control and 
crude extract) after one day. 
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Fraction P_II_3_3 was then selected due to its high activity and by 1H NMR 
analysis, a major component with the spectral characteristics of a cyclohexene structure 
was detected. Due to the small amount of compound obtained, we decided to repeat the 
isolation procedure and we purified the desired product in the fraction P_III_3_3_3. After 
structure elucidation (see below) we found that the isolated natural product was similar to 
streptol (58) and we chose to name the new compound streptol glucoside (57). 
Interestingly, we found also that a similar natural product, named A-79197-2 (83), was 
isolated from bacteria living on the leaves of the plant Cucubalus sp.90 
 
  
                                                
90 M. Kizuka, R. Enokita, K. Shibata, Y. Okamoto, Y. Inoue, T. Okazaki, Actinomycetologica 
2002, 16, 14–16. 
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2.3.5.2. Structure Elucidation of Streptol Glucoside 
The high resolution ESI-MS spectrum of streptol glucoside (57) in negative mode 
displayed an exact mass of m/z 337.1144 Da, which supports the molecular formula 
C13H21O10– for the [M–H]– pseudo-molecular ion. 1H and 13C NMR spectroscopic data in 
DMSO-d6 were used for the core structure characterization, and 1H NMR spectroscopic 
data in D2O were compared with those reported for streptol (58) in D2O62 to assign the 
relative configuration (table 3). 
The assignment of the carbocyclic core structure of the cyclohexene part was 
established using the 1H 13C HMBC correlations between H-2, H-5, H-7a and H-7b with 
C-6 and 1H 1H COSY relations between H-1 and H-2, H-2 and H-3, H-3 and H-4 and H-4 
and H-5. Applying the same method, the carbon skeleton of the pyranoside was assigned 
based on 1H 1H COSY correlations between H-1’ and H-2’, H-2’ and H-3’, H-3’ and H-
4’, H-4’ and H-5’, and H-5’ and H-6’. Attachment of the pyranoside at position C-5 was 
confirmed by the observation of a 1H 13C HMBC correlation peak between H-1’ and C-5. 
The relative configuration of the cyclohexene was assigned by comparing the J-coupling 
constants with those reported for streptol (58) in D2O showing that both compounds 
possess H-2 is in the equatorial position, and H-3, H-4 and H-5 in the axial position. For 
the glucoside, the values of the J-coupling constants of the multiplets found in the region 
between 8.0 and 10.0 ppm for the couplings between H-1’, H-2’, H-3’, H-4’ and H-5’ 
were characteristic for protons in axial-axial relations (Karplus curve).91 Furthermore, the 
1H NMR chemical shifts of glucose in disaccharides, linked by an α− or β−glycosidic 
bond (table 4), were compared with those of streptol glucoside (57) and confirmed the 
attachment of glucose by a β-glycosidic bond.92 
 
                                                
91 M. U. Roslund, P. Tähtinen, M. Niemitz, R. Sjöholm, Carbohydr. Res. 2008, 343, 101–112. 
92 P. E. Jansson, L. Kenne, I. Kolare, Carbohydr. Res. 1994, 257, 163–174. 
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Table 3. NMR spectroscopic data (D2O, 399.87 MHz for 1H 
NMR and 100.55 MHz for 13C NMR) of streptol (58).62 
C no. δH (3JH-H in Hz) 
1 5.67, dddd (5.5, 1.7, 1.6, 1.5) 
2 4.10, ddd (5.5, 4.2, 0.6) 
3 3.40, dd (10.7, 4.2) 
4 3.52, dd (10.7, 7.8) 
5 3.90, dddd (7.8, 1.7, 1.5, 0.8) 
6  
7a 4.04, dddd (14.2, 1.5, 1.5, 0.6) 
7b 4.00, ddd (14.2, 0.8, 0.7) 
 
 
 
Table 4. 1H NMR spectroscopic data (D2O, 400 MHz, in ppm) comparison of 
glycoside attached in α (84) or β (85) position with the glycoside of streptol 
glucoside (57).92 
C no. α-D-Glc-(1→6)-β-D-GlcOMe β-D-Glc-(1→6)-β-D-GlcOMe 
streptol 
glucoside 
1’ 4.96 4.52 4.63 
2’ 3.57 3.34 3.33 
3’ 3.73 3.51 3.51 
4’ 3.44 3.41 3.41 
5’ 3.73 3.46 3.52 
6’a 3.76 3.74 3.72 
6’b 3.86 3.92 3.91 
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Table 5. NMR spectroscopic data (D2O, 500 MHz for 1H NMR) of streptol 
glucoside (57). 
C no. δH (3JH-H in Hz) COSY NOESY 
1 5.92, dd (5.4, 1.1) 2 2, 3, 7b 
2 4.27, t (4.8) 1, 3 1, 3, 
3 3.64, dd (10.5, 4.2) 2, 4 2, 4 
4 3.89, d (10.7, 7.2) 3, 5 3, 5, 1’ 
5 4.26, d (8.3) 4 4, 1’ 
6    
7a 4.29, dd (13.0, 0.8) 7b 7b, 1’ 
7b 4.18, d (13.9) 7a 7a, 1’ 
1’ 4.63, d (8.0) 2’ 
4, 5, 7, 2’, 3’, 
4’ 
2’ 3.33 dd (9.4, 8.0) 1’, 3’ 1’, 3’, 4’ 
3’ 3.51, t (9.3) 2’, 4’ 1’, 2’ 
4’ 3.41, t (9.4) 3’, 5’ 1’, 2’, 6’a, 6’b 
5’ 3.52, ddd (9.9, 6.1, 2.3) 6’ 6’a, 6’b 
6’a 3.72, dd (12.4, 6.2) 5’, 6’b 4’, 6’b 
6’b 3.91, dd (12.6, 2.2) 6’a 6’b, 5’ 
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Table 6. NMR spectroscopic data (DMSO-d6, 500 MHz for 1H NMR and 126 MHz 
for 13C NMR) of streptol glucoside (57). 
C no. δC, type δH (3JH-H in Hz) COSY HMBC[a] 
1 123.1, CH 5.69, d (5.3) 2, 5, 7a, 7b 3, 5, 7 
2 65.5, CH 3.98, t (4.6) 1, 3 1, 3, 4, 6 
3 70.7, CH 3.26, dd (10.1, 4.0) 2, 4 4 
4 71.1, CH 3.68, d (10.1,7.0) 3, 5 3, 5 
5 84.3, CH 3.88, d (6.9) 1, 4, 7a 1, 4, 6, 4’ 
6 140.6, C    
7a 61.2, CH2 4.07, d (14.4) 7b 1, 6 
7b  4.02, d (14.3) 1, 7a 1, 6 
1’ 104.2, CH 4.30, d (7.9) 2’ 5 
2’ 73.6, CH 3.03 t (8.6) 1’, 3’ 1’, 3’ 
3’ 76.6, CH 3.18, t (9.5) 2’, 4’ 4’ 
4’ 70.2, CH 3.04, t (9.6) 3’, 5’ 3’, 5’, 6’ 
5’ 76.9, CH 3.21, ddd (9.2, 7.5, 1.8) 6’  
6’a 61.2, CH2 3.72, dd (11.2, 1.4) 5’, 6’b  
6’b  3.40, dd (11.5, 7.1) 5’, 6’a 5’ 
[a] HMBC correlations are given from proton(s) stated to the indicated carbon atom. 
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2.4. Detection and Quantification of Kirkamide and Streptol Glucoside 
2.4.1. Derivatization and Detection by GC-MS  
The derivatization and GC-MS detection procedure was similar to a reported 
protocol with modifications regarding the use of N-methyl-N-(trimethylsilyl)tri-
fluoroacetamide (MSTFA) as derivatization agent.93,94 After derivatization, the sample 
was analyzed by GC-MS and two peaks possessing a retention time of 27.38 min and 
27.73 min were detected. The first peak displayed a mass of 505 Da corresponding to 
kirkamide modified with four TMS groups, and fragmentation ions of 490 Da and 415 Da 
(figure 12). The second compound displayed a mass of 577 Da corresponding to 
kirkamide modified with five TMS units (figure 11) and a fragment observed at 562 Da 
(figure 13). 
 
 
Figure 11: Proposed structure for the compound detected at 27.73 min. 
The masses of the two compounds with their specific degradation patterns were 
used as markers for the detection of kirkamide (56). In the extracts from the nodulated 
plants Psychotria humilis, Psychotria verschuerenii, Psychotria punctata (P. punctata), 
Psychotria kirkii and Psychotria pumila, at least one of the two compounds were 
successfully identified, corroborating the hypothesis of the production of kirkamide (56) 
by the bacteria living in obligate symbiosis with these plants. 
  
                                                
93 X. Wu, P. M. Flatt, H. Xu, T. Mahmud, ChemBioChem 2009, 10, 304–314. 
94 R. J. Molyneux, D. R. Gardner, L. F. James, S. M. Colegate, J. Chromatogr. A 2002, 967, 57–
74. 
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Figure 12: GC-MS chromatogram of kirkamide (56) after derivatization (top) and EI+ mass 
spectrum of the compound eluted at 27.38 min (excerpt: m/z =400 to m/z 600 Da). 
 
Figure 13: GC-MS chromatogram of kirkamide (56) after derivatization (top) and EI+ mass 
spectrum of the compound eluted at 27.73 min (excerpt: m/z =400 to m/z 600 Da). 
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2.4.2. Quantification by 1H NMR Spectroscopy 
Kirkamide (56) and streptol glucoside (57) were found to possess a characteristic 
methylene proton with a chemical shift of around 6 ppm in the 1H NMR spectrum. 
Additionally, during our isolation study, we determined the presence of asperuloside (86) 
in the P. kirkii extract, which was shown to give peaks in the same region of the 1H NMR 
spectrum. This situation was ideal to determine the concentration of these three natural 
products quantitatively by a single 1H NMR measurement. Maleic acid was chosen as the 
internal standard due to its solubility in D2O and a characteristic peak with a chemical 
shift in the desired range.95 Additionally, a precise amount of leave extracts from each 
plant was weighed in with an analytical balance for every measurement. 
 
Figure 14: Natural products quantified by 1H NMR, the protons highlighted in red were used for 
the measurement. 
The three natural products were quantified in the crude extracts from different parts 
of the plant P. kirkii. (table 7). The leaves and shoot extracts were found to contain all 
three compounds. This result was expected due to the presence of the nodules on the 
leaves and since the iridoid 86 was known to accumulate in the aerial part of the plant.96 
We observed a higher concentration of kirkamide (56) and streptol glucoside (57) in the 
shoot tip, where the symbiontic bacteria are found in large numbers for the colonization 
of new leaves.54 Furthermore, the detection of the two compounds in the root extract 
                                                
95  T. Rundlöf, M. Mathiasson, S. Bekiroglu, B. Hakkarainen, T. Bowden, T. Arvidsson, J. 
Pharm. Biomed. Anal. 2010, 52, 645–651. 
96  A. R. Trim, Biochem. J. 1952, 50, 319–326. 
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implied that the two compounds are up taking by the plant metabolism and travel up to 
the root of the plant. 
The percentage of kirkamide (56), streptol glucoside (57) and asperuloside (86) 
present in the dried leaves was determined for the plants P. kirkii and P. punctata. The 
dried leaves of the two organisms were blended, the compounds were extracted and a 
portion of the crude extract was dissolved in a solution containing a known amount of 
maleic acid. The concentration of the natural products was calculated by comparison of 
their proton integration with the one of maleic acid. Kirkamide (56) was identified in 
both plants at a similar concentration, which is in agreement with the GC-MS 
measurements. 
Table 7. Quantification of kirkamide (56), streptol glucoside (57) and  
asperuloside (86) by 1H NMR. 
Extracts Kirkamide [%] 
Streptol 
glucoside [%] 
Asperuloside [%] 
P. kirkii leaves 0.72[a] 1.29[a] 2.18[a] 
P. kirkii shoot 8.03[a] 6.81[a] 0.19[a] 
P. kirkii root 5.04[a] 4.34[a] - 
P. kirkii soil - - - 
P. kirkii leaves 0.37[b] 0.60[b] 0.19[b] 
P. punctata leaves 0.23[b]  0.07[b] 
[a] The values indicated the percentage present in the crude extract; [b] The values 
indicated the percentage present in the dried leaves. 
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2.5. Conclusion 
The analysis of the leaf extract of Psychotria kirkii, a plant living in an obligatory 
symbiosis with a bacterium forming nodules under the leaves of the host, led to the 
isolation of the two new natural products kirkamide (56) and streptol glucoside (57). 
 
 
 
 
Following a genome-driven 1H NMR-guided fractionation a C7N aminocyclitol, 
named kirkamide (56), was identified and the structure was elucidated by HRMS and 
NMR and confirmed by single crystal X-ray analysis. In order to obtain a larger amount 
of kirkamide (56) to understand its role in the symbiosis, a total synthetic route was 
developed to obtain the natural product in 11 steps from commercially available 
methyl-N-acteyl-D-glucosamine (75). The synthetic pathway proved its robustness 
allowing for a gram scale preparation at each step. Using this material, kirkamide (56) 
was shown to be cytotoxic in the brine shrimp assay and possessing insecticidal activity 
against the pollen beetle Meligethes aeneus. This last biological property of kirkamide is 
proposed to play a role in the symbiosis by protecting the plant against insects. 
Applying a growth inhibition bioassay-guided fractionation against lettuce seeds, a 
compound similar to streptol (58) was identified and named streptol glucoside (57). 
HRMS and NMR data analyses were used for the structure elucidation of 57. The role of 
streptol glucoside (57) in the symbiosis remains unclear and requires further 
investigation. A possible role of 57 could be the growth inhibition of other plant 
competitors or a bacterial defensive system against possible attacks from the host plant. 
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The last part of this chapter focus on the development of an analytical method 
towards the detection and quantification of the new natural products. Kirkamide (56) was 
detected by GC-MS after derivatization with MSTFA. Using this strategy, we were able 
to identify kirkamide in extracts from several plants in symbiosis as Psychotria humilis, 
Psychotria verschuerenii, Psychotria punctata, Psychotria kirkii and Psychotria pumila. 
The detection of 56 in another species showed that this phenomenon is not restricted at 
the plant P. kirkii.  
The quantification of kirkamide (56), streptol glucoside (57) and asperuloside (86) 
was achieved in extracts from different parts of the plant P. kirkii and also from leaf 
extract of P. punctata. The determination of 56 in extracts from leaves, shoot and root 
indicate that the natural product travels to these different locations within plant. 
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3.  Isolation and Biosynthesis Investigation of Fragin 
3.1. Biosynthesis of Natural Products Possessing a Nitrogen-Nitrogen Bond 
Only few natural products containing a nitrogen-nitrogen (N-N) bond have been 
reported with approximately 200 compounds isolated up to 2013. They are categorized in 
several classes such as azine, azo compound, azoxy, cinnoline, diazo, hydrazine, 
hydrazide, hydrazone, indazole, nitrosamine, N-nitrosohydroxylamine, N-N linked 
heterocycle, pyradazine, pyrazole, triazine and triazole.97 An example for each class of 
compound is shown in figure 15 with the functional group highlighted in red. 
The biosynthesis of some of the natural products belonging to the azoxy, diazo and 
hydrazide classes has been investigated with special interest in the mechanism of 
formation of the N-N bond.98,99 In this chapter, the biosynthesis of these compounds will 
be presented using valanimycin (87), kutzneride 1 (88), kinamycin D (89) and 
azamerone (90) as main examples. 
  
                                                
97 L. M. Blair, J. Sperry, J. Nat. Prod. 2013, 76, 794–812. 
98 C. C. Nawrat, C. J. Moody, Nat. Prod. Rep. 2011, 28, 1426–1444. 
99 Le Goff, J. Ouazzani, Bioorg. Med. Chem. 2014, 22, 6529–6544. 
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Figure 15: Examples of natural products containing a N-N bond. 
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3.1.1. Biosynthesis of Azoxy Compounds  
3.1.1.1. Valanimycin 
An unstable azoxy compound, showing antibacterial and antitumor activity, was 
isolated from the bacterial culture of Streptomyces viridifaciens (S. viridifaciens). Part of 
the structure elucidation of valanimycin (87) was achieved by a combination of NMR and 
IR analyses. However, mass spectroscopy or elemental analysis could not be performed 
due to the fast degradation of the natural product.100 The structure of 87 was confirmed 
then by the full characterization of its ammonium adduct. 
 
Biosynthetic investigations of 87 was firstly achieved with isotopic labeling 
experiments leading and led to the discovery that valine (91), isobutylamine (92) and 
isobutylhydroxylamine (93) were precursors for the left part of the compound and serine 
(94) for the right part.101,102  
 
Scheme 7: Proposed biosynthetic pathway after feeding experiments with different isotopic 
labeled precursors.  
                                                
100 M. Yamato, H. Iinuma, H. Naganawa, Y. Yamagishi, M. Hamada, T. Masuda, H. Umezawa, 
Y. Abe, M. Hori, J. Antibiot. 1986, 39, 184–191. 
101 M. Yamato, T. Takeuchi, H. Umezawa, N. Sakata, H. Hayashi, M. Hori, J. Antibiot. 1986, 39, 
1263–1269. 
102 R. J. Parry, Y. Li, F. L. Lii, J. Am. Chem. Soc. 1992, 114, 10062–10064. 
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Furthermore, the results from the feeding experiments indicated that the two 
nitrogens come from different sources; one from the amino acid serine (94) and the other 
one from valine (91). Additionally, the nitrogen bond formation was proposed to be the 
result of the reaction between 93 and 94. It was found during in vitro assay that 
VlmH/VlmR enzymes (predicted as a two components flavin monooxygenase) from S. 
viridifaciens catalyzed the oxidation of the nitrogen atom of isobutylamine.103 
 
DNA sequencing and analysis of valanimycin genes allowed the function 
assignment of the different enzymes responsible for the production of the natural product. 
The gene responsible for valine decarboxylase (VlmD) producing isobutylamine (92) was 
determined and the enzymes isobutylamine N-hydroxylase (VlmH) and FAD reductase 
(VlmR) were identified.104 
However, one gene responsible for a seryl tRNA synthetase (VlmL) was present in 
a cluster and its role in the biosynthesis was unclear.104 This enzyme was purified and 
in vitro assay experiments performed using radiolabeled compounds showed the catalytic 
role of the protein towards the formation of seryl-tRNA.105 Additionally, the reaction 
between seryl-tRNA and isobuthylhydroxylamine (93) was found to be an enzymatic 
process catalyzed by VlmA (scheme 8). By taking into account these recent results a new 
biosynthesis was suggested including two proposed mechanisms for the formation of the 
N-N bond (scheme 9).106 
                                                
103 R. J. Parry, W. Li, Arch. Biochem. Biophys. 1997, 339, 47–54. 
104 R. P. Garg, Y. Ma, J. C. Hoyt, R. J. Parry, Mol. Microbiol. 2002, 46, 505–517. 
105 R. P. Garg, J. M. Gonzalez, R. J. Parry, J. Biol. Chem. 2006, 281, 26785–26791. 
106 R. P. Garg, X. L. Qian, L. B. Alemany, S. Moran, R. J. Parry, Proc. Natl. Acad. Sci. U. S. A. 
2008, 105, 6543–6547. 
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Scheme 8: Biosynthesis suggestion of the hydroxylamine intermediate 95. 
 
Scheme 9: Proposed mechanisms for the N-N bond formation. A) Mechanism involving the 
reaction of an amine and a nitroso. B) Proposed mechanism via imine formation. 
Finally, the dehydration of 96 into valanimycin (87) required two enzymes VlmJ 
and VlmK and the addition of ATP. It was therefore proposed that the last step undergoes 
via the addition of a phosphate, which triggered the reduction of 96 to 87 (scheme 10).107 
                                                
107 R. P. Garg, L. B. Alemany, S. Moran, R. J. Parry, J. Am. Chem. Soc. 2009, 131, 9608–9609. 
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Scheme 10: Dehydration mechanism of 96 to the natural product 87. 
3.1.1.2. Elaiomycin, Lyophillin and Malleobactin D 
Similar biosynthetic pathways as valanimycin, including the reaction of two 
partners for the N-N bond formation, were proposed for other natural products as 
elaiomycin (97), lyophyllin (98) and malleobactin D (99).108,109 
 
 
Scheme 11: The labeled precursors (100, 94, 101 and 102) were synthesized and the results of the 
feeding experiments indicated an isotopic enrichment of the natural products.  
                                                
108 R. J. Parry, H. S. P. Rao, J. Mueller, J. Am. Chem. Soc. 1982, 104, 339–340; R. J. Parry, J. V. 
Mueller, J. Am. Chem. Soc. 1984, 106, 5764–5765; Y. Ye, K. Aulinger, N. Arnold, W. Spahl, 
W. Steglich, Tetrahedron Lett. 1997, 38, 8013– 8016. 
109 J. Franke, K. Ishida, M. Ishida-Ito, C. Hertweck, Angew. Chem. Int. Ed. Engl. 2013, 52, 8271–
8275. 
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Malleobactin B (103), C (104) and D (99) were isolated from crude extracts of 
Burkholderia thailandensis. 99 was proposed to be the product of the reaction between 
malleobactins B (103) and C (104). These two natural products were incubated in 
physiological conditions and after several hours the formation of 99 was observed.109 
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3.1.2. Biosynthesis of Hydrazide/Hydrazine 
3.1.2.1. Kutzneride 
Piperazic acid (105) is present in various cyclic peptides isolated from bacteria as in 
kutzneride 1 (88).110 During the biosynthetic analysis of 88 important information was 
obtain about the N-N bond formation of 105. 
 
Nine kutznerides have been isolated from the actinomycete Kutzneria sp. 744 with 
variations in the piperazic acid moiety such as enamine, oxidation and chloride 
insertion.111,112 The gene cluster of these compounds was identified and the function of 
the enzymes was assigned. A flavoprotein monooxygenase KtzI was found to show high 
similarities in their DNA with a lysine/ornithine N-monooxygenase from Pseudomonas 
aeruginosa and was predicted to be involved in the formation of 105.113 To test this 
hypothesis, the enzyme was produced by heterologous expression and evaluated with 
different substrates (L/D-Lys, L/D-Gln, L/D-Gln and L/D-Orn). Only L-ornithine (106) was 
significantly transformed to its N-oxidized form, which was detected by HPLC after 
Fmoc protection (scheme 12). The confirmation of this compound as substrate was 
obtained by labeling experiment with 13C5-Orn (107) and 13C5-N5-OH-Orn (108) resulting 
                                                
110 A. J. Oelke, D. J. France, T. Hofmann, G. Wuitschik, S. V. Ley, Nat. Prod. Rep. 2011, 28, 
1445–1471. 
111 A. Broberg, A. Menkis, R. Vasiliauskas, J. Nat. Prod. 2006, 69, 97–102. 
112 A. Pohanka, A. Menkis, J. Levenfors, A. Broberg, J. Nat. Prod. 2006, 69, 1776–1781.  
113 D. G. Fujimori, S. Hrvatin, C. S. Neumann, M. Strieker, M. A. Marahiel, C. T. Walsh, Proc. 
Natl. Acad. Sci. U. S. A. 2007, 104, 16498–16503. 
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in the detection by HRMS2 of the piperazic acid (105) containing the isotopically 
enriched carbon atoms (scheme 13).114 
 
Scheme 12: Enzymatic N-oxidation of L-Orn (106). 
 
Scheme 13: Feeding experiment with isotopically labeled ornithine (107) and N5-OH-ornithine 
(108). 
An hydroxylamine was proposed to play a key role in the formation of the N-N 
bond as it was found for the azoxy compound. The main difference would result in an 
intramolecular process for the case of the piperazic acid (105). 
  
                                                
114 C. S. Neumann, W. Jiang, J. R. Heemstra Jr., E. A. Gontang, R. Kolter, C. T. Walsh, 
Chembiochem 2012, 13, 972–976. 
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3.1.2.2. Monamycin D1 and Polyoxypeptin A 
Monamycin D1 (109) and polyoxypeptin A (110) were isolated from different 
Streptomyces strains and were found to possess piperazic acids (105) in their core 
structure.115,116 The biosynthesis of these natural products was investigated by feeding 
experiments with isotopic labeled ornithine and glutamic acid resulting mainly in the 
incorporation of glutamic acid (scheme 14). 117 , 118  This result indicated that the 
biosynthesis of the piperazic acid (105) would take a different pathway as the one 
proposed for kutzneride 1 (88). However, the difficulties during the uptake of ornithine 
by the bacteria were advanced as an hypothesis to explain the lack of incorporation of 
this amino acid into the natural products.114 Interestingly, two genes homologs as ktzI 
were found in the genome of the bacteria which produced polyoxypeptin.119 
 
Scheme 14: Substrates predicted for the piperazic acid (105) moiety based on feeding 
experiments. 
                                                
115 C. H. Hassall, K. E. Magnus, Nature 1959, 184, 1223–1224. 
116 K. Umezawa, K. Nakazawa, T. Uemura, Y. Ikeda, Tetrahedron Lett. 1998, 39, 1389–1392. 
117 V. Arroyo, M. J. Hall, C. H. Hassall, J. Chem. Soc. 1976, 845–846.  
118 K. Umezawa, Y. Ikeda, O. Kawase, H. Naganawa, S. Kondo, J. Chem. Soc., Perkin Trans. 1 
2001, 1550–1553. 
119 Y. Du, Y. Wang, T. Huang, M. Tao, Z. Deng, S. Lin, BMC Microbiol. 2014, 14:30. 
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3.1.3. Biosynthesis of Pyridazine 
3.1.3.1. Pyridazomycin 
Pyridazomycin (112) was isolated in 1987 from the Streptomyces violaceoniger sp. 
griseofuscus strain Tü 2557.120 Its biosynthesis was investigated by labeled amino acids 
feeding experiment. The results showed that ornithine (106) and glycine (113) were the 
initial substrates. Additionally, a nucleophilic attack from the amine of 113 to the 
proposed N oxidized 106 was suggested as the mechanism for the N-N bond formation.121 
It is interesting to note that the biosynthesis of pyridazomycin (112) and kutzneride 1 (88) 
required the oxidation of ornithine as a key step for the synthesis of the N-N bond. 
 
Scheme 15: Proposed mechanism for the formation of the N-N bond in pyridazomycin (112). 
Hypothetic oxidation of ornithine and the decarboxylation of glycine (113) are highlighted in red.  
3.1.3.2. Azamerone 
The terpenoid azamerone (90) was isolated from the bacterium Streptomyces sp. 
CNQ-766 and the structure, which contained the unusual pyranophtalazinone ring, was 
elucidated by NMR and single crystal X-ray analysis.122 
 
  
                                                
120 R. Grote, Y. Chen, A. Zeeck, Z. X. Chen, H. Zähner, P. Mischnick-Lübbecke, W. A. König, J. 
Antibiot. 1988, 41, 595–601. 
121 H. Bockholt, J. M. Beale, J. Rohr, Angew. Chem. Int. Ed. Engl. 1994, 33, 1648–1651. 
122 J. Y. Cho, H. C. Kwon, P. G. Williams, P. R. Jensen, W. Fenical, Org. Lett. 2006, 8, 2471–
2474. 
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The analysis of the gene cluster of azamerone (90) was achieved123 and the natural 
products, SF2415A1 (114), SF2415A3 (115), SF2415B1 (116), SF2415B3 (117), 
A80915C (118) and A80915D (119), isolated from the culture of Streptomyces 
aculeolatus,124 were proposed as biosynthetic precursors.125  
 
The compounds A80915C (118), A80915D (119) and SF2415A3 (115) were 
identified in the azamerone (90) producer bacterium strain. Feeding experiments with 
Na15NO3 and Na15NO2 indicated a specific isotopic enrichment only at N-2 for the 
natural products 115, 119 and 90. Furthermore, the compound 115 was biosynthetically 
obtained with isotopic labeled at N-2 and C-9 and the bacterium fed with the labeled 
natural product 115 produced azamerone (90) labeled at position N-2 and C-8 
                                                
123 J. M. Winter, M. C. Moffitt, E. Zazopoulos, J. B. McAlpine, P. C. Dorrestein, B. S. Moore, J. 
Biol. Chem. 2007, 282, 16362–16368. 
124 S. Gomi, S. Ohuchi, T. Sasaki, J. Itoh, M. Sezaki, J. Antibiot. 1987, 40, 740–749; T. Shomura, 
S. Gomi, M. Ito, J. Yoshida, E. Tanaka, S. Amano, H. Watabe, S. Ohuchi, J. Itoh, M. Sezaki, J. 
Antibiot. 1987, 40, 732–739; D. S. Fukuda, J. S. Mynderse, P. J. Baker, D. M. Berry, L. D. 
Boeck, R. C. Yao, F. P. Mertz, W. M. Nakatsukasa, J. Mabe, J. Ott, J. Antibiot. 1990, 43, 623–
633; T. Henkel, A. Zeeck, J. Antibiot. 1991, 44, 665–669. 
125 J. M. Winter, A. L. Jansma, T. M. Handel, B. S. Moore, Angew. Chem. Int. Ed. Engl. 2009,  
48, 767–770. 
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(scheme 16).125 A stepwise process via a diazo compound was proposed for the 
mechanism of formation of the N-N bond of the azamerone pyradizine.  
 
Scheme 16: Proposed mechanism, based on isotopic labeled experiments, for N-N bond formation 
in azamerone (90). 
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3.1.4. Biosynthesis of Diazo Compounds 
3.1.4.1. Kinamycins  
Several natural products sharing similar core structure have been isolated from 
different bacteria and named kinamycins A–J (120–129).126 The diazo functional group 
was initially assigned as cyano and the structure was finally elucidated in 1994 by the 
research groups of Gould and Dmitrienko.127,128 
 
Table 8. The natural products kinamycins. 
Compound R1 R2 R3 R4 
kinamycin A (120) H Ac Ac Ac 
kinamycin B (121) H Ac H H 
kinamycin C (122) Ac H Ac Ac 
kinamycin D (123) Ac H Ac H 
kinamycin E (124) Ac H H H 
kinamycin F (125)  Η H H H 
kinamycin G (126) Ac C(O)i-Pr Ac Ac 
kinamycin H (127) C(O)i-Pr H Ac Ac 
kinamycin I (128) C(O)i-Pr H C(O)i-Pr Ac 
kinamycin J (129) Ac Ac Ac Ac 
 
  
                                                
126 S. Itŏ, T. Matsuya, S. Omura, M. Otani, A. Nakagawa, J. Antibiot. 1970, 23, 315–317;  
T. Hata, S. Omura, Y. Iwai, A. Nakagawa, M. Otani, J. Antibiot. 1971, 24, 353–359; S. Omura, 
A. Nakagawa, H. Yamada, T. Hata, A. Furusaki, T. Watanabe, Chem. Pharm. Bull. 1971, 19, 
2428–2430; S. Omura, A. Nakagawa, H. Yamada, T. Hata, A. Furusaki, Chem. Pharm. Bull. 
1973, 21, 931–940; M. C. Cone, P. J. Seaton, K. A. Halley, S. J. Gould, J. Antibiot. 1989, 42, 
179–188; P. J. Seaton, S. J. Gould, J. Antibiot. 1989, 42, 189–197; K. Isshiki, T. Sawa, H. 
Naganawa, N. Matsuda, S. Hattori, M. Hamada, T. Takeuchi, M. Oosono, M. Ishizuka, Z. Z. 
Yang, J. Antibiot. 1989, 42, 467–469; T. A. Smitka, R. Bonjouklian, T. J. Perun, A. H. Hunt, 
R. S. Foster, J. S. Mynderse, R. C. Yao, J. Antibiot. 1992, 45, 581–583. 
127 S. J. Gould, N. Tamayo, C. R. Melville, M. C. Cone, J. Am. Chem. Soc. 1994, 116, 
2207–2208. 
128 S. Mithani, G. Weeratunga, N. J. Taylor, G. I. Dmitrienko, J. Am. Chem. Soc. 1994, 116, 
2209–2210. 
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The biosynthesis of these natural products has been subject to extensive 
research.129,130 Here, only the mechanism of the N-N bond formation will be discussed. 
The biosynthetic elucidation of kynamycin benefits from the isolation of a precursor 
named stealthin C (130) from the bacterial culture of S. murayamaensis. To confirm the 
role of 130 in the biosynthesis of kinamycin D (123), a deuterated labeled stealthin C was 
prepared. A feeding experiment with this precursor resulted in the production of labeled 
kinamycin D131 and indicated that the N-N bond formation undergoes via a stepwise 
mechanism involving stealthin C (130). One hypothesis for the second nitrogen source 
was proposed to be nitric oxide or one of its derivatives.132 
 
Scheme 17: Labeled experiment demonstrating the involvement of stealthin C (130) in the 
biosynthesis of kinamycin D (123). 
  
                                                
129 S. J. Gould, Chem. Rev. 1997, 97, 2499–2510. 
130 S. B. Herzon, C. M. Woo, Nat. Prod. Rep. 2012, 29, 87–118. 
131 S. J. Gould, C. R. Melville, M. C. Cone, J. Chen, J. R. Carney, J. Org. Chem. 1997, 62, 320–
324. 
132 G. L. Abbott, PhD Thesis, the University of Waterloo, Waterloo, Ontario, Canada, 2011. 
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3.1.4.2. Lomaiviticins 
Lomaiviticins are natural products containing a core structure composed of a 
glycosylated kinamycin dimer. These natural products were found to possess potent 
antibiotic and anticancer properties, as example lomaiviticin A (131) is shown below.133 
 
The gene cluster of lomaiviticin was discovered and sequenced from two different 
Salinispora strains. 134 , 135  Comparing the genes involved in the biosynthesis of 
kinamycin136 and those of lomaiviticin, a sub cluster (lom29, 30, 32-35), identified in 
both, was proposed as a good candidate for the diazo formation. The predicted gene 
functions are described in table 9 and interestingly, homologs were also found in the gene 
cluster of the hydrazide fosfazinomycin A (132).135,137  
                                                
133 H. He, W. D. Ding, V. S. Bernan, A. D. Richardson, C. M. Ireland, M. Greenstein, G. A. 
Ellestad, G. T. Carter, J. Am. Chem. Soc. 2001, 123, 5362–5363; C. M. Woo, N. E. Beizer, J. 
E. Janso, S. B. Herzon, J. Am. Chem. Soc. 2012, 134, 15285–15288. 
134 R. D. Kersten, A. L. Lane, M. Nett, T. K. S. Richter, B. M. Duggan, P. C. Dorrestein, B. S. 
Moore, Chembiochem 2013, 14, 955–962. 
135 J. E. Janso, B. A. Haltli, A. S. Eustáquio, K. Kulowski, A. J. Waldman, L. Zha, H. Nakamura, 
V. S. Bernan, H. He, G. T. Carter, F. E. Koehn, E. P. Balskus, Tetrahedron 2014, 70, 4156–
4164. 
136 S. J. Gould, S. T. Hong, J. R. Carney, J. Antibiot. 1998, 51, 50–57. 
137 J. Gao, K.-S. Ju, X. Yu, J. E. Velásquez, S. Mukherjee, J. Lee, C. Zhao, B. S. Evans, J. R. 
Doroghazi, W. W. Metcalf, W. A. van der Donk Angew. Chem. 2013, 126, 1358–1361. 
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Table 9. Predicted gene function for 
lomaiviticin diazo formation. 
Genes Predicted Function of the enzyme 
lom29 Unknown 
lom30 4Fe-4S ferrodoxin 
lom32 Glutamine synthase 
lom33 Amidase 
lom34  Adenylosuccinate lyase 
lom35 N-acetyltransferase 
 
 
 
 
 
Up to this date, the mechanism of N-N bond formation in natural products remains 
unclear. The examples presented above indicated that the insertion of the two nitrogens 
occurred via a stepwise mechanism, which can be intermolecular (e.g.: valanimycin (87)) 
or intramolecular (e.g.: azamerone (90)). In several natural products (87, 90, 99 and 112), 
a nucleophilic attack from an amine to a nitroso was proposed as the key step for the N-N 
bond formation. 
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3.1.5. Genomic Analysis of Burkholderia cenocepacia H111 
To acquire a better understanding of the N-N bond formation in natural products, 
the identification of genes involved in the biosynthesis of these compounds is crucial. We 
analyzed the genome of the opportunistic pathogen Burkholderia cenocepacia H111 (B. 
cenocepacia H111), isolated from a patient suffering from cystic fibrosis.138 A gene 
cluster containing two nonribosomal peptide synthetases (NRPS) modules was identified 
and found to be responsible for the production of a natural product possessing an 
antifungal activity.139 Using this biological property the gene cluster was named “ham” 
(H111 antifungal metabolite). Furthermore, the structure elucidation indicated the 
presence of N-N bond in the natural product and consequently we decided to investigate 
its biosynthesis. 
 
  
                                                
138 L. Eberl, Int. J. Med. Microbiol. 2006, 296, 103–110. 
139 A. Carlier, K. Agnoli, G. Pessi, A. Suppiger, C. Jenul, N. Schmid, B. Tümmler, M. Pinto-
Carbo, L. Eberl, Genome Announc. 2014, 2, e00298–14. 
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3.2. Results and Discussion 
This project was carried out in collaboration with Christian Jenul from the research 
group of Professor Leo Eberl at the Institute of Plant Biology, University of Zürich and 
Christophe Daeppen from the research group of Professor Karl Gademann. My 
contribution was the isolation, structure identification and biosynthesis proposal of fragin 
(133). I was also responsible for the analytical measurements involving HPLC and 
HPLC-MS. In this chapter the isolation and structure elucidation of 133 will be presented 
followed by biosynthetic proposals. 
3.2.1. Isolation and Structure Elucidation of Fragin 
The isolation of the natural compound produced by the NRPS gene cluster of B. 
cenocepacia H111 and possessing an antifungal activity was carried out. Since we knew 
the biological activity of the compound a bioassay-guided fractionation was applied. The 
HPLC-MS spectra were compared between the supernatant of the wild type and the 
knockout strain (ΔhamD) and a compound eluting with a retention time of 20.4 min was 
exclusively found in the wild type extract (figure 16). This compound (133) was isolated 
by RP-HPLC using a Gemini-NX column and its antifungal activity was confirmed. 
 
Figure 16: HPLC chromatograms of the wild type and ΔhamD extracts and mass chromatogram 
of the wild type extracted at 272 Da in negative mode.  
Wild type 
ΔhamD 
ESI negative mode, ion extract m/z = 272 Da of the wild type 
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HPLC-MS analysis of the isolated compound showing a m/z = 274.2 Da (pos. 
mode) and a m/z = 272.2 Da (neg. mode) indicated a molecular mass of 273.2 Da. 
Additionally a major fragment (m/z = 244.2 Da, pos. mode) was found. The loss of 30 Da 
was attributed of a homolytic cleavage of fragin (133) generating nitric oxide (134) 
(figure 18). The formation of positive and negative charge radical is a phenomenon, 
which has already been described for ESI-MS.140 
 
Scheme 18: Proposed mechanism of fragin (133) fragmentation in ESI-MS. 
The 1H 1H COSY correlations between H-1 to H-2, H-2 to H-3, H-3 to H-4 and H-4 
to NH assigned the core structure of the left part of the compound and those between H-6 
to H-7, H-7 to H-(8-11) and H-(8-11) to H-12 assigned the core structure of the right part. 
The presence of the N-nitrosohydroxylamine functional group was proposed due to the 
chemical shift of H-3 at 4.2 ppm and C-3 at 77.8 ppm indicating an electron-withdrawing 
group attached to C-3. A non-correlating deshielded proton at 11.72 ppm in addition with 
a ESI-MS fragment displaying a loss of 30 Da for 134 were further evidence for the 
presence of a N-nitrosohydroxylamine group. 
 
 
                                                
140 R. Vessecchi, A. E. M Crotti, T. Guaratini, P. Colepicolo, S. E. Galembeck, N. P. Lopes, 
Mini-Rev. Org. Chem. 2007, 4, 75–87. 
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Table 10. 1H-NMR Spectroscopic data (CDCl3, 500 MHz) of 
fragin (133). 
C/N no. δC, type δH (3JH-H in Hz) COSY 
1+1’ 19.2, CH3 0.90, d (6.7) 2 
 18.9, CH3 1.07, d (6.8) 2 
2 29.1, CH 2.25 - 2.17, m 1, 3 
3 78.0, CH 4.20, td (9.2, 3.1) 2, 4a, 4b 
NOH  11.72  
4 39.1, CH2 3.86, ddd (14.4, 6.0, 3.1) NH, 3, 4b 
  3.60, ddd (14.4, 9.4, 6.1) NH, 3, 4a 
NH  5.69 4a, 4b 
5 173.7, C   
6 36.7, CH2 2.14, td (7.4, 1.8) 7 
7 25.7, CH2 1.61 - 1.52, m 6, 8-11 
8 - 11 
22.8 29.1, 
29.3, 31.8, 
4xCH2 
1.31 - 1.23, m 7, 12 
12 14.2, CH3 0.87, t (6.8) 8-11 
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Fragin (133) was identified with a single crystal X-ray analysis of our isolated 
natural product (figure 17). 133 was isolated in 1967 from Pseudomonas fragi and was 
found to possess various biological activities as antifungal, growth inhibitor of lettuce 
seeds, antimicrobial, antiviral and antitumor. 141  The structure of fragin (133) was 
confirmed by a racemic total synthesis followed by an X-ray crystal structure analysis. 
142,143 So far the absolute configuration remained unknown. To elucidate the absolute 
configuration of fragin (133), we developed an enantioselective total synthesis and after 
single crystal X-ray analysis the stereocenter of the natural product could be assigned. 
Additionally it was found that the single crystal X-ray analyses from the synthetic and 
isolated compound gave an identical result. 
 
Figure 17: Single crystal X-ray analysis of fragin 133. 
  
                                                
141 A. Murayama, K. Hata, S. Tamura, Agric. Biol. Chem. 1969, 33, 1599–1605; A. Murayama, S. 
Tamura, Agric. Biol. Chem. 1970, 34, 122–129; A. Murayama, S. Tamura, Agric. Biol. 
Chem.1970, 34, 130–134. 
142 S. Tamura, A. Murayama, K. Kagei, Agric. Biol. Chem. 1967, 31, 996–997. 
143 R. Chang, W. Shin, Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1998, 54, 827–829. 
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3.2.2. Biosynthesis of Fragin 
The function of the enzymes, involved in the biosynthesis of fragin (133), was 
predicted based on the DNA similarities that they shared with known proteins. Using this 
result a chemical reaction was assigned to each enzyme and their role in the biosynthesis 
of fragin (133) was proposed. To test these hypotheses, knockout strains were prepared 
and their metabolites pr 
ofiles were analyzed by HPLC-MS. 
Table 11. Role of the ham gene cluster enzymes. 
Enzymes Predicted Function 
HamA β-Ketoacyl synthase 
HamB Dioxygenase 
HamC N-Oxygenase 
HamD NRPS complex 
HamE Unknown protein 
HamF NRPS condensation domain 
HamG Aminotransferase 
 
3.2.2.1. Chemical Function of Enzymes  
• HamA: β-ketoacyl synthase 
The β-ketoacyl synthases (KS) are typically present in polyketide synthase (PKS) 
complexes and are responsible for the chain elongation of fatty acids.144 
 
Scheme 19 Reaction catalyzed by β-ketoacyl synthase. 
                                                
144 Y. Chen, E. E. Kelly, R. P. Masluk, C. L. Nelson, D. C. Cantu, P. J. Reilly, Protein Sci. 2011, 
20, 1659–1667. 
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• HamB: dioxygenase, e. g.: acetylacetone dioxygenase 
The predicted function of the enzyme indicated similarities with several 
dioxygenases, as an example the acetylacetone dioxygenase (scheme 20).145 Therefore, 
we propose that HamB initiates an oxidative cleavage. 
 
Scheme 20: Acetylacetone dioxygenase reaction. 
• HamC: N-oxygenase, similarity with AurF 
The enzyme AurF was discovered during the study of aureothin biosynthesis and 
was found to oxidize para-aminobenzoic acid (PABA) (135) into para-nitrobenzoic acid 
(PNBA) (136).146 An amine in para position was found to be important for the substrate 
recognition by the enzyme and a two-steps oxidation was suggested for the mechanism 
(scheme 21).147,148 
 
Scheme 21: Enzymatic oxidation of PABA (135) catalyzed by AurF. 
  
                                                
145 I. Siewert, C. Limberg, Angew. Chem., Int. Ed. Engl. 2008, 47, 7953–7956. 
146 J. He, C. Hertweck, Chem. Biol. 2003, 10, 1225–1232. 
147 R. Winkler, M. E. A. Richter, U. Knüpfer, D. Merten, C. Hertweck, Angew. Chem. Int., Ed. 
Engl. 2006, 45, 8016–8018. 
148 R. Winkler, C. Hertweck, Angew. Chem., Int. Ed. 2005, 44, 4083–4087. 
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• HamD: NRPS complex  
The NRPS enzyme complex was predicted to contain an adenylation (A), a peptidyl 
carrier protein (PCP) and a reductase (Red) domain. The A and PP domains are known 
for the attachment of amino acid to the NRPS complex and the R domain for the release 
of the product from the NRPS complex. 
• HamE: unknown protein 
The function of this enzyme could not be assigned by comparison with other proteins. 
• HamF: NRPS condensation domain 
The condensation domain of the NRPS complex catalyzed the formation of an 
amide bond from a fatty acid and an amino acid moiety.149 
 
Scheme 22: Reaction of the NRPS condensation domain. 
• HamG: Aminotransferase 
Aminotransferases transfer ketoacid to amino acid and consequently are responsible 
for the introduction of a new stereocenter.150 
 
Scheme 23: Reaction catalyszed by aminotransferase. 
  
                                                
149 C. Rausch, I. Hoof, T. Weber, W. Wohlleben, D. H. Huson, BMC Evol. Biol. 2007, 7:78. 
150 P. P. Taylor, D. P. Pantaleone, R. F. Senkpeil, I. G. Fotheringham, Trends Biotechnol. 1998, 
16, 412–418. 
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3.2.2.2. Fragin Biosynthesis Proposal from L-Hydroxyleucine 
 
Scheme 24: Proposed biosynthesis with L-hydroxyleucine (137) as precursor. 
L-Hydroxyleucine (137) was chosen as the initial precursor of fragin biosynthesis 
and was proposed to react with HamD. The second step is the formation of the amide 
bond by the condensation domain of HamF. The release of 139 from the NRPS complex 
by the R domain of HamD followed by an oxidation of the hydroxyl to the ketone 
delivers the β-keto acid intermediate 141. This unstable intermediate 141 is typically 
reported as an ideal substrate for a spontaneous decarboxylation.151 
Next the aminotransferase, HamG, introduces the primary amine obtaining 143. 
The last steps of the biosynthesis include the oxidation of the nitrogen to the 
hydroxylamine (144) by HamC followed by the introduction of the second nitrogen to 
obtain fragin (133). We proposed that the formation of the N-nitrosohydroxylamine to 
undergo via nucleophilic attack of the hydroxylamine 144 to an electrophilic source of 
N=O. (scheme 25). The origin of the second nitrogen remained unclear and this question 
was the subject of the chapter 3.2.2.4. 
                                                
151 L. Du, L. Lou, Nat. Prod. Rep. 2010, 27, 255–278. 
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Scheme 25: Proposed mechanism for the N-N bond formation from the hydroxylamine 144 to 
fragin (133). 
Proposed Precursors Involved in the Biosynthesis of Fragin 
In order to obtain evidence for the proposed biosynthetic pathway via L-hydro-
xyleucine (137), several suggested intermediates were synthesized and their retention 
time and MS fragmentation pattern were recorded by HPLC-MS. We used this 
information to detect the compounds in the bacterial extracts. With this approach the 
derivatives ketone 142, amine 143, hydroxylamine 144, oxime 145, nitroso 146 and nitro 
147 were synthesized and their data were acquired by HPLC-MS (table 12). 
 
Figure 18: Synthetically prepared proposed intermediates involved in the biosynthesis of fragin 
(133). 
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Table 12. HPLC-MS Detection of Synthetic Intermediates. 
Intermediates Retention Time [min] MS [m/z] 
Amine 143 11.6 229s 
Hydroxylamine 144 12.3 245 
Oxime 145 19.1 226/243 
Ketone 142 20.3 228 
Nitro 147 22.3 259/300 
Nitroso 146 28.4 243 
 
The proposed biosynthetic precursors amine 143, hydroxylamine 144 and oxime 
145 were successfully identified in the extract from B. cenocepacia H111. However, the 
presence of the ketone 142, displaying a m/z = 228 Da, could not be determined due to its 
overlap in retention time with fragin (133). Additionally the nitroso 146 and the nitro 147 
could not be detected in this extract. 
Knockout Experiments  
Additional information about the function of the genes involved in the biosynthesis 
of fragin (133) was obtained by the generation of several mutants. These strains were 
obtained by selectively removing a gene from the wild type strain. The nomenclature of 
the knockout strains is presented in the table 13. We noticed the presence of fragin (133) 
in the extract of the mutant 869 implying than the enzyme HamB was not essential for the 
formation of the natural product fragin (133). To test if the knockout did not affect the 
other genes, a control experiment was executed where the gene hamE was inserted to the 
knockout strain ΔhamE. In this new strain 834 the production of fragin (133) was 
detected indicating that other genes are not affected. Unfortunately in the others knockout 
strains none of the proposed biosynthetic intermediates were found. This result indicates 
that fragin (133) is produced by another pathway. We deduced that the biosynthetic 
precursors stays attached to the NRPS domain and are released at a later stage (chapter 
3.2.2.3). 
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Table 13. Knockout strains from B. cenocepacia H111. 
Strain Gene mutated Detection of fragin 
811 None yes 
825 hamD  
826 hamE  
834 hamEa yes 
835 hamG  
841 hamC  
869 hamB yes 
[a] The gene hamE was reinserted to the knockout strain 826 as 
a control experiment. 
3.2.2.3. Proposed Biosynthesis of Fragin from D-Valine 
 
Scheme 26: Proposed biosynthesis of fragin (133) from D-valine (149). 
As the intermediates of the proposed biosynthesis from 137 were not detected in the 
knockout strains, it was deduced that the compounds 143, 144 and 145, identified in the 
wild type extract, were decomposition products of fragin (133).. A new biosynthetic 
pathway was proposed starting with the non-proteinogenic amino acid D-valine (148), 
which reacts first with HamD. Next the nitrogen atom of the amine 149 is oxidized by 
HamC to the hydroxylamine 150, which reacts with a second source of nitrogen to form 
the N-nitrosohydroxylamine 151. The release of 151 from the NRPS domain is catalyzed 
by the R domain of HamD giving an aldehyde, which is directly converted to the amine 
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152 by HamG. Similar mechanism of NRPS reductase was already proposed for the 
biosynthesis of the natural product myxochelin B (153) (scheme 27).152 The last step  of 
the biosynthesis of 133 involves the amide bond formation by the condensation domain 
of HamF. 
 
Scheme 27: Proposed release mechanism from the NRPS complex in the biosynthesis of 
myxochelin B (153). 
The validation of this proposal is currently investigated in our research groups. We 
are planning to perform feeding experiments with 15N labeled D and L-valine in order to 
confirm the role of the amino acid in the biosynthesis of fragin (133). 
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3.2.2.4. Origin of the Nitrogen Atoms of the N-N Bond of Fragin 
The mechanism of N-N bond formation in natural products remained unclear. Up to 
date no studies have been investigated the formation of N-nitrosohydroxylamine. In this 
work the predicted fragin precursors hydroxylamine 144 and nitroso 146 were 
synthesized and used as a model system to explore their reactivity and stability under 
various conditions. 
Reactivity of the Hydroxylamine 144 
In order to test the nucleophilic or electrophilic character of the hydroxylamine 144, 
the compound was treated with five nitrogen-containing salts (figure 19). Interestingly we 
found that the hydroxylamine 144 reacted with the salt NaNO2 to give fragin (133). 
 
Figure 19: Possible source for the second nitrogen atom. 
This result was unexpected due to the absence of strong acidic condition, which is 
usually required for the synthesis of the nitrosonium ion (Scheme 28). It is possible that 
the high concentration of NaNO2 (65 µM) compared to the hydroxylamine 144 (0.9 µM) 
produced the nitrosonium ion in small amount, which reacted with 144. This mechanism 
has to be further investigated but this result indicated that nitrite in presence with the 
hydroxylamine 144 can produce fragin (133). 
 
Scheme 28: Nitrosonium ion formation under acidic condition. 
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Further reactions with 144 and NaNO2, in buffer solutions fixed at a pH of 6.5 and 
7.85, showed the formation of fragin (133) mainly in weak acidic conditions (pH = 6.5). 
The oxime 145 was detected at the major product during the reaction in basic buffer. 
 
Figure 20: HPLC chromatograms of the reaction between NaNO2 and the hydroxylamine 144. 
From top to bottom the conditions used were without buffer, with buffer at pH 6.5 and with buffer 
at 7.85. 
To study in details the incorporation of the second nitrogen atom, a reaction with 
the hydroxylamine 144 and Na15NO2 was analyzed at three different time points; after the 
sample preparation, after 24 h and after 44 h. The incorporation of 15N to fragin was 
confirmed by ESI-MS experiment where the pseudomolecular ion with a m/z = 275 Da 
was detected. Additionaly, the fragment with a m/z = 244 Da was detected indicating the 
loss of 15NO showing that only one nitrogen was introduced to fragin (133). The results 
of the analysis over time showed the conversion of the labeled fragin (133) and the 
hydroxlamine 144 into the oxime 145 and the nitro 147 (figure 21). 
144 
133 
145 
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Figure 21: HPLC chromatograms of the reaction between Na15NO2 and hydroxylamine 144. 
From top to bottom: after simple preparation and after 24 h and after 44 h. 
 Prediction of Nitrite in Burkholderia Cenocepacia H111 
Knowing that the hydroxylamine 144 in presence of sodium nitrite gave fragin 
(133), we decided to investigate if this reaction may occur spontaneously in the 
bacterium. For this reason we searched for a source of nitrite. Interestingly, recently it 
was reported that B. cenocepacia H111 possesses genes responsible for nitrate reduction 
and nitrate/nitrite transporters.153 This implies that nitrate could be transformed to nitrite. 
The salts of the bacterial medium were analyzed and neither nitrate nor nitrite was added 
to the culture. However, the composition of a yeast extract, one component of the 
medium, was unknown and we decided to perform further tests. 
To test the presence of nitrite in the yeast extract, the hydroxylamine 144 was 
mixed with the yeast extract but fragin 133 could not be detected. The concentration of 
nitrate/nitrite in yeast extract solutions at different concentration was measured using a 
stripes test developed for the detection of NO3– and NO2–. The results indicated the 
presence of nitrate in the yeast extract. With this information we can now propose that the 
                                                
153 M. Lardi, C. Aguilar, A. Pedrioli, U. Omasits, A. Suppiger, G. Cárcamo-Oyarce, N. Schmid, 
C. H. Ahrens, L. Eberl, G. Pessi, Appl. Environ. Microbiol. 2015, DOI 10.1128/AEM.00694-
15. 
144 
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147 
 
78 
nitrate, from the yeast extract, is transformed by the bacteria into nitrite, which will be 
attacked by the hydroxylamine 144 to form fragin (133). To obtain evidence for this 
pathway in vivo, we are planning feeding experiments with Na15NO2 and Na15NO3 as it 
was performed for azamerone (90).125 
      
Figure 22: Stripes test detection done in various concentrations of aq. yeast extract soln. and 
with H2O as a control. A purple coloration indicated the presence of the specific ion; at the top 
nitrite and at the bottom nitrate. 
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3.3. Conclusion 
A fundamental question consisting in the N-N bond formation by nature is 
addressed in this chapter by the biosynthetic study of the natural product fragin (133) 
possessing the unusual N-nitrosohydroxylamine functional group. The structure of 133 
was elucidated and a gene cluster responsible for its biosynthesis was identified. The 
functions of seven enzymes involved in the production of 133 were predicted and based 
on this information, a biosynthetic pathway was proposed. To verify this route, mutant 
strains were produced and suggested biosynthetic intermediates were synthesized. 
Analysis of the mutant extracts indicated that the substrates were released only at a late 
stage of the biosynthesis. Additionally, evidence for a stepwise and spontaneous 
mechanism for the N-N bond formation was discovered. It was shown that the 
hydroxylamine 144 in presence of NaNO2 could produce fragin (133) non-enzymatically. 
 
 
3.4. Outlook 
The challenge of the biosynthetic elucidation of fragin (133) is the detection of its 
precursors. In the different mutant strains, no compounds were identified as potential 
precursors and we suspect that the biosynthetic intermediate(s) is/are released from the 
NRPS complex only at a late stage. To overcome this obstacle feeding experiments with 
proposed precursors would furnish crucial information. Additionally, in vitro assays 
using purified enzymes would unambiguously assign the role of each protein.  
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4. Cyanobacteria a Prolific Source of Natural Products 
Cyanobacteria constitute some of the oldest organisms on Earth, their presence 
dating back over 2.8 billion years, and are considered as the first producers of oxygen.154 
To harvest light, cyanobacteria are equipped with chlorophyll, absorbing maximum of 
light at 430-440 nm and 670 nm, and a complementary set of pigments named 
phycobilisome, absorbing light with a maximum at 500 nm. 155  Additionally, 
cyanobacteria possess heterocysts, which consist of specialized cells that fixe and 
transform N2 into NH3.156 An example of a cyanobacterium is presented at a macroscopic 
and microscopic level (figure 23).  
 
 
Figure 23: Pictures of the cyanobacterium Tolypothrix distorta var. symplocoides EAWAG 224a 
at a macroscopic and microscopic level (from left to right). 
Some cyanobacteria possess similar appearance to algae (figure 23, left side) and it 
is therefore why they have been considered, for long time, as eukaryotic organisms and 
were called blue-green algae. In the 1970s, the analysis of cyanobacteria cellular 
properties showed that these organisms do not belong to the eukaryotic kingdom. 
Therefore a new classification and their integration to the Bacteriological code were 
proposed.157 
                                                
154 R. E. Kopp, J. L. Kirschvink, I. A. Hilburn, C. Z. Nash, Proc. Natl. Acad. Sci. U. S. A. 2005, 
102, 11131–11136. 
155 Y. S. Deruyter, P. Fromme, Molecular structure of the photosynthetic apparatus. In 
Cyanobacteria, Molecular Biology, Genomics, and Evolution (Eds.: A. Herrero, E. Flores). 
Caister Academic Press, Norfolk, UK, 2008, pp. 217–269. 
156 A. Herrero, A. M. Muro-Pastor, E. Flores, J. Bacteriol. 2001, 183, 411–425. 
157 R. Y. Stanier, W. R. Sistrom, T. A. Hansen, B. A. Whitton, R. W. Castenholz, N. Pfennig, V. 
N. Gorlenko, E. N. Kondratieva, K. E. Eimhjellen, R. Whittenbury, R. L. Gherna, H. G. 
Trüper, Int. J. Syst. Bacteriol. 1978, 28, 335–336; R. Rippka, J. Deruelles, J. B. Waterbury, M. 
Herdman, R. Y. Stanier, J. Gen. Microbiol. 1979, 111, 1–61. 
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Cyanobacteria are particularly interesting for the field of drug discovery due to 
biological activities and the various scaffolds of their secondary metabolites.158 Among 
these natural products, peptides and their derivatives have been extensively reported.159 
Presented here is a collection of cyclic peptides with a particular attention on 
cyanobactins and cylic glycolipopeptides. 
4.1. Cyclic Peptides 
Cyclic peptides isolated from cyanobacteria have been investigated for their 
biological activities and for their biosynthesis. Interestingly, both non-ribosomal and 
ribosomal biosynthetic pathways were discovered to be responsible for the production of 
these compounds.160 As an example, the hepatotoxic microcystins, produced by many 
cyanobacterial genera as Microcystis, Anabaena, Planktothrix, Nostoc and Anabaena, are 
cyclic peptides containing the unusual amino acid ADDA (figure 24). The most study 
natural product from this class of compounds is microcystin-LR (154), which was found 
to be a common contaminant in drinking water. Due to its high toxicity the World Health 
Organization (WHO) determined a guideline value of 1 µg/L.161 Additionally, genomic 
analysis of M. aeruginosa PCC 7806 indicated that the biosynthesis of 154 involved a 
nonribosomal peptide synthetase (NRPS) gene cluster.162 
                                                
158 A. Burja, B. Banaigs, E. Abou-Mansour, J. Grant Burgess, P. Wright, Tetrahedron 2001, 57, 
9347–9377; K. Gademann, C. Portmann, Curr. Org. Chem. 2008, 12, 326–341; K. Gademann, 
Chimia 2011, 65, 416–419; K. Gademann, S. Sieber, Chimia 2011, 65, 835–838; J. K. 
Nunnery, E. Mevers, W. H. Gerwick, Curr. Opin. Biotechnol. 2010, 21, 787–793; G. E. 
Chlipala, S. Mo, J. Orjala, Curr. Drug Targets 2011, 12, 1654–1673; M. Costa, J. Costa-
Rodrigues, M. H. Fernandes, P. Barros, V. Vasconcelos, R. Martins, Mar. Drugs 2012, 10, 
2181–2207; F. Desriac, C. Jégou, E. Balnois, B. Brillet, P. Le Chevalier, Y. Fleury, Mar. 
Drugs 2013, 11, 3632–3660. 
159 A. Burja, B. Banaigs, E. Abou-Mansour, J. Grant Burgess, P. Wright, Tetrahedron 2001, 57, 
9347–9377. 
160 M. Welker, H. von Döhren, FEMS Microbiol. Rev. 2006, 30, 530–563. 
161 M. Zhou, W.-W. Tu, J. Xu, Toxicon 2015, 101, 92–100. 
162 E. Dittmann, B. A. Neilan, M. Erhard, H. Von Döhren, T. Börner, Mol. Microbiol. 1997, 26, 
779–787. 
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Figure 24: Microcystin-LR (154) with its amino acid ADDA in red. 
4.1.1. Cyanobactins 
The cyanobactin class of compounds was recently introduced to describe cyclic 
peptides containing a prenylated amino acid or a heterocyclic ring such as oxazole, 
oxazoline, thiazole or thiazoline. 163  The genome of the cyanobacterial symbiont 
Prochloron didemni was sequenced and it was found that the organism used a ribosomal 
biosynthetic pathway to obtain patellamide A (155) and C (156).164 In this section, 
examples of cyanobactins produced via a ribosomal biosynthetic pathway will be 
presented. 
 
                                                
163 M. S. Donia, J. Ravel, E. W. Schmidt, Nat. Chem. Biol. 2008, 4, 341–343; E. W. Schmidt, M. 
S. Donia, in Methods in Enzymology, Elsevier, 2009, pp. 575–596. 
164 E. W. Schmidt, J. T. Nelson, D. A. Rasko, S. Sudek, J. A. Eisen, M. G. Haygood, J. Ravel, 
Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 7315–7320. 
NH
O
HN
O
N NH
HN
O
O
H
N
H
NO
O O
HO O
OHO
HN
H2N NH
O
microcystin-LR (154)
ADDA
N
H
O
N
S
O
N
O
HN
N
O
O
H
N
N
S
O
NH
patellamide A (155)
N
H
O
N
S
O
N
O
HN
N
O
O
H
N
N
S
O
NH
patellamide C (156)
 
84 
Cyanobactins from Prochloron/Lissoclinum 
Cyanobactins have been isolated from the ascidian Lissoclinum sp. and it was 
proposed that the compounds were produced by the cyanobacterial symbiont Prochloron 
sp. This hypothesis was verified for patellamide A (155) and C (156) by Schmidt and 
coworkers with the identification of the biosynthetic gene cluster in the cyanobacterial 
genome.164 Several natural products have been isolated from this system with variation in 
the number of amino acids (from 6 to 8) in their core structure. As examples the 
hexapeptide patellin 2 (157),165 the cytoxic lissoclinamide 7 (158) 166 and the prenylated 
cyanobactin trunkamide A (159)167 highlight the structure variety of the natural products 
isolated from the symbiotic system Lissoclinum/Prochloron. Interestingly the elucidation 
of the absolute configuration of trunkamide A (159) required several total syntheses.168 
 
                                                
165 T. M. Zabriskie, M. P. Foster, T. J. Stout, J. Clardy, C. M. Ireland, J. Am. Chem. Soc. 1990, 
112, 8080–8084. 
166 J. M. Wasylyk, J. E. Biskupiak, C. E. Costello, C. M. Ireland, J. Org. Chem. 1983, 48, 4445–
4449; B. M. Degnan, C. J. Hawkins, M. F. Lavin, E. J. McCaffrey, D. L. Parry, A. L. Van den 
Brenk, D. J. Watters, J. Med. Chem. 1989, 32, 1349–1354; C. J. Hawkins, M. F. Lavin, K. A. 
Marshall, A. L. van den Brenk, D. J. Watters, J. Med. Chem. 1990, 33, 1634–1638; L. A. 
Morris, J. J. K. van den Bosch, K. Versluis, G. S. Thompson, M. Jaspars, Tetrahedron 2000, 
56, 8345–8353. 
167 A. R. Carroll, J. C. Coll, D. J. Bourne, J. K. MacLeod, T. M. Zabriskie, C. M. Ireland, B. F. 
Bowden, Aust. J. Chem. 1996, 49, 659–667. 
168 P. Wipf, Y. Uto, J. Org. Chem. 2000, 65, 1037–1049; B. McKeever, G. Pattenden, 
Tetrahedron Lett. 2001, 42, 2573–2577; J. M. Caba, I. M. Rodriguez, I. Manzanares, E. Giralt, 
F. Albericio, J. Org. Chem. 2001, 66, 7568–7574; B. McKeever, G. Pattenden, Tetrahedron 
2003, 59, 2713–2727. 
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Cyanobactins from Nostoc spongiaeforme var. tenue 
Tenuecyclamides A-D were isolated from the cyanobacterium Nostoc 
spongiaeforme var. tenue with an isolation yield of 0.05, 0.01, 0.02 and 0.06%, 
respectively. Tenuecyclamide C (160) was found to be the most potent of these 
compounds inhibiting the cellular division of sea urchins with an ED100 of 9.0 µM. 
 
Cyanobactins from Trichodesmium erythraeum IMS101 
Genomic analysis of the cyanobacterium Trichodesmium erythraeum ISM101 led 
to the discovery of a new cyanobactin named trichamide (161). The structure elucidation 
of trichamide (161) was based on genetic and crude extract MS2 analysis.169 This 
example shows the potential of a genome mining approach. 
 
                                                
169 S. Sudek, M. G. Haygood, D. T. A. Youssef, E. W. Schmidt, Appl. Environ. Microbiol. 2006, 
72, 4382–4387. 
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Cyanobactins from Lyngbya aestuarii CCY9616. 
The analysis of the lyngbya aestuarii CCY9616 genome led to the discovery of the 
gene cluster responsible for the production of lyngbyabactins A (162) and B (163). 
However, these compounds have not been isolated or detected from the crude extract of 
the cyanobacterium.163 
 
Cyanobactins from Microcystis aeruginosa 
Microcyclamides and aerucyclamides have been isolated from different species of 
Microcystis aeruginosa.170,171,172,173 The gene cluster of microcyclamide was identified 
and the biosynthesis was proposed to undergo via a ribosomal pathway. During their 
biosynthetic investigations, Ziemert and coworkers discovered two new natural products, 
microcyclamides 7806A (164) and 7806B.172 The same year, the structure of 
microcyclamide 7806A (164) was revised by NMR analysis and aerucyclamide C (165) 
degradation studies (scheme 29).173 
                                                
170 K. Ishida, H. Nakagawa, M. Murakami, J. Nat. Prod. 2000, 63, 1315–1317. 
171 C. Portmann, J. F. Blom, K. Gademann, F. Jüttner, J. Nat. Prod. 2008, 71, 1193–1196. 
172 N. Ziemert, K. Ishida, P. Quillardet, C. Bouchier, C. Hertweck, N. T. de Marsac, E. Dittmann, 
Appl. Environ. Microbiol. 2008, 74, 1791–1797. 
173 C. Portmann, J. F. Blom, M. Kaiser, R. Brun, F. Jüttner, K. Gademann, J. Nat. Prod. 2008, 71, 
1891–1896. 
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Scheme 29: Conversion of aerucyclamide C (165) into microcyclamide 7806A (164) under acidic 
condition. 
 Cyanobactin from Anabaena sp. 
Another example of natural product isolated following a genome mining approach 
led the discovery of anacyclamide A 10 (166). The genomic analysis of the 
cyanobacterium Anabaena sp. 90 indicated the presence of a cluster of genes similar to 
the one of patellamides.174 For this reason, it was proposed to include this compound, 
which possessed no modified and/or prenylated amino acid(s), into the cyanobactin 
class.174 
 
                                                
174 N. Leikoski, D. P. Fewer, J. Jokela, M. Wahlsten, L. Rouhiainen, K. Sivonen, Appl. Environ. 
Microbiol. 2010, 76, 701–709. 
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4.1.2. Glycolipopeptides 
Hassallidins and balticidins are the only natural products, to our knowledge, that 
have been isolated from cyanobacteria and that contain the unique glycolipopeptide 
scaffolds.175,176,177,178  
Hassallidin A (167) and B (168), produced by the cyanobacterium Hassallia sp., 
possess a macrolide core structure with one mannose molecule attached through a 
threonine side chain and a fatty acid forming an amide bond with the N-terminal of 
another threonine.175,176 In hassallidin B (168), an additional rhamnose molecule is 
attached to one of the hydroxyl of the fatty acid. Both natural products were found to 
possess antifungal activity against several strains.176 Recently, genomic analysis of 
Anabaena sp. 90 led to the discovery of hassallidins biosynthesis. During the course of 
this study, the natural product hassallidin D (169) was isolated and the structure was 
elucidated by MS and NMR analysis. The stereocenters configuration was assigned based 
on amino acids and genetic analysis. Furthermore, similar hassallidins’ biosynthetic 
pathways were detected in several species such as Aphanizomenon, Cylindrospermopsis 
raciborskii, Nostoc and Tolypothrix. The presence of glycolipopeptides in these 
organisms was confirmed by HPLC-MS analysis.177 
 
                                                
175 T. Neuhof, P. Schmieder, K. Preussel, R. Dieckmann, H. Pham, F. Bartl, H. von Döhren, J. 
Nat. Prod. 2005, 68, 695–700. 
176 T. Neuhof, P. Schmieder, M. Seibold, K. Preussel, H. von Döhren, Bioorg. Med. Chem. Lett. 
2006, 16, 4220–4222. 
177 J. Vestola, T. K. Shishido, J. Jokela, D. P. Fewer, O. Aitio, P. Permi, M. Wahlsten, H. Wang, 
L. Rouhiainen, K. Sivonen, Proc. Natl. Acad. Sci. U. S. A. 2014, 111, E1909–17. 
178 T.-H. Bui, V. Wray, M. Nimtz, T. Fossen, M. Preisitsch, G. Schröder, K. Wende, S. E. Heiden 
S. Mundt, J. Nat. Prod. 2014, 77, 1287–1296; T.-H. Bui, V. Wray, M. Nimtz, T. Fossen, M. 
Preisitsch, G. Schröder, K. Wende, S. E. Heiden, S. Mundt, J. Nat. Prod. 2015, 78, 345. 
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The antifungal compounds balticidins A-D (170-173) were isolated from the 
cyanobacterium Anabaena cylindrical strain Bio33 following a bioassay-guided 
fractionation. The main structural difference compared to hassallidins resides in a 
hydroxylated tyrosine and in the presence of a chloride attached to the fatty acid in the 
case of 170 and 171. Furthermore, the sugars’ composition was found to be different 
from hassallidins due to the presence of a disaccharide containing arabinose and 
galacturonic acid.178 
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4.1.3. Cyclic Peptides Discovered by the Gademann Group 
The search of new antimalarial natural products from cyanobacteria secondary 
metabolites have been of interest to our research group. We have access to more than 160 
different cyanobacteria strains resulting in a collection with large chemical diversity 
(figure 25). Previous results from Dr. Cyril Portmann and coworkers have led to the 
discovery of four new hexacyclopeptides (aerucyclamides A–D (174, 175, 165 and 176)) 
from the cyanobacterium strain Microcystis aeruginosa (M. aeruginosa) PCC 7806. It 
was found that the compounds possess a low micromolar and even submicromolar IC50 
value against the parasite Plasmodium falciparum (P. falciparum) and a cytotoxicity of 
more than 100 µM (IC50 value against rat myoblast L6 cells, figure 26).171,173  
 
 
Figure 25: Cyanobacteria collection at the University of Basel. 
 
 
92 
 
Figure 26: Structures of aerucyclamides A–D, the IC50 values against P. falciparum are indicated 
in red and in green, the cytotoxicity (IC50 against rat myoblast L6 cells). 
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4.2. Results and discussion 
In this chapter, the isolation and structure elucidation of the novel cyanobactins 
balgacyclamides A–C (177-179) and the isolation and preliminary structure elucidation 
towards two new glycolipopeptides are presented. There projects were carried out by  
M. Sc. Silvan Wirthensohn and by M. Sc. Darja Kolbin during their master thesis under 
my supervision. 
 
4.2.1. Balgacyclamides from M. aeruginosa EAWAG 251179 
Novel natural products, balgacyclamides A–C (177-179), sharing similar structure 
with aerucyclamides were detected in M. aeruginosa EAWAG 251 and isolated by Dr. 
Cyril Portmann. The core structure of these new natural products was determined by 
HRMS and NMR spectroscopy data analysis. Furthermore, balgacyclamide A (177) and 
balgacyclamide B (178) were found to possess an IC50 value of 9.0 µM and 8.2 µM, 
respectively, against the parasite P. falciparum and a cytotoxicity (IC50 against rat 
myoblast L6 cells) of more than 150 µM (figure 27). However limited by the low 
isolation yield of 0.55, 0.15 and 0.80 mg per 15 L tank culture for balgacyclamide A 
(177), B (178) and C (179), the absolute configuration could not be determined and will 
be the subject of this chapter. 
                                                
179  C. Portmann, S. Sieber, S. Wirthensohn, J. F. Blom, L. Da Silva, E. Baudat, M. Kaiser, R. 
Brun, K. Gademann, J. Nat. Prod. 2014, 77, 557–562. 
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Figure 27: Core structure of balgacyclamide A–C (177–179) with IC50 values against P. 
falciparum, indicated in red and in green the cytotoxicity (IC50 against rat myoblast L6 cells). 
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4.2.1.1. Extraction and Isolation 
The cyanobacterium M. aeruginosa EAWAG 251 was grown in a 20 L tank culture 
with constant aeration in order to ensure sufficient amount of material to complete the 
structure elucidation (the objective of this project). The cyanobacteria were harvested by 
removing the medium by centrifugation and then the compounds were extracted from the 
biomass by sonication in aqueous methanol solutions. 
 
Figure 28: Cyanobacteria 20 L tank cultures, M. aeruginosa EAWAG 251 is highlighted on the 
left side of the picture. 
Balgacyclamides were isolated by RP-HPLC equipped with a semi-preparative 
Gemini-NX C18 column. The identity of the natural products was confirmed by 
comparing the retention time, the m/z and the 1H-NMR spectra with previous results. 
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4.2.1.2. Ozonolysis and Hydrolysis 
The strategy used for the stereochemistry determination was similar as the one 
reported for the aerucyclamides.171, 173 The heterocycles of balgacyclamides (177-179) 
were opened by ozonolysis to prevent further epimerization of amino acids during 
hydrolysis.180 The amide bonds were cleaved by heating the compounds in strong acidic 
condition and the mixture of amino acids obtained was separated in two equal aliquots to 
perform HPLC and GC analysis in parallel. 
4.2.1.3. Marfey’s Method for Amino Acids Analysis 
To determine the absolute configuration of amino acids in balgacyclamides (177-
179) Marfey’s method was used. In this analytical method, the substrate reacts with a 
chiral reagent and the retention time of the product formed is compared by HPLC with 
analytical standards. 181  The design of the Marfey’s reagent (180), containing a 
chromophore and functional groups with enhanced ionization properties, offers high UV 
sensitivity and MS detection. An example of the derivatization using the Marfey’s 
reagent is shown for L-valine (181) in scheme 30. 
 
Scheme 30: Reaction of L-valine (181) with Marfey's reagent (180). 
Following a reported protocol for the derivatization with Marfey’s reagent (180) 
and HPLC analysis,182  we could determined the amino acids configuration of the 
balgacyclamides A-C (177-179) with the exception of isoleucine. In this case, the 
separation between D-Ile and D-allo-Ile derivatives was not sufficient by HPLC. 
Additionally, a coinjection with L-Thr and L-allo-Thr was necessary to confirm the 
presence of L-Thr. 
  
                                                
180 L. A. McDonald, C. M. Ireland, J. Nat. Prod. 1992, 55, 376–379. 
181 P. Marfey, M. Ottesen, Carlsberg Res. Commun. 1984, 49, 585–590. 
182 S. Hess, Methods Mol. Biol. 2012, 828, 63–75. 
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4.2.1.4. TFA Derivatization and GC Analysis 
To differentiate between D-Ile and D-allo-Ile, the amino acids were derivatized with 
freshly prepared trifluoroacetic anhydride (TFAA) and analyzed with a GC apparatus 
equipped with a chiral column. A coinjection confirmed the presence of D-allo-Ile in 
balgacyclamides A–C (177-179). 
Combining the results obtained from amino acids analysis by HPLC and chiral GC 
the absolute configuration of the natural products was determined as D-Ala, L-Thr, L-Val 
and D-allo-Ile for balgacyclamide A (177), D-Ala, L-Thr, L-Val and D-allo-Ile for 
Balgacyclamide B (178) and L-Phe, L-Thr, Gly and D-allo-Ile for balgacyclamide C 
(179).179 
 
 
Figure 29: Balgacyclamides A–C (177-179) with the absolute configuration assigned.  
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4.2.2. Conclusion 
Baglacyclamides A–C (177–179) were isolated from the cyanobacterium 
M. aeruginosa and the absolute configuration of these natural products was elucidated. 
We showed that with only 0.1 mg of natural product, the amino acids configuration could 
be determined using Marfey’s method and chiral-GC analysis.  
Since balgacyclamides A–C (177–179) contain heterocycles in their core structure, 
we proposed to include them in the cyanobactin class of compounds. Furthermore, we 
proposed that their biosynthesis undergoes via a ribosomal pathway as for several 
compounds sharing similar structures. 
Interestingly the non-proteinogenic amino acid D-allo-Ile was found in each 
balgacyclamide and was already reported for the aerucyclamides A–C (174, 175 and 
165). The formation of this non-proteinogenic amino acid was proposed to occur 
spontaneously and not enzymatically for lissoclinamide 7 (158) 183  and a similar 
mechanism can be envisaged for the balgacyclamides. Additionally, an interesting feature 
of D-allo-Ile is its position with respect to the thiazole/thiazoline. For 165, 174, 175, 177, 
178 and 179, D-allo-Ile is next to the fully unsaturated heterocycle. 
Furthermore, balgacyclamide A (177) and B (178) exhibit promising antimalarial 
activity with good selectivity relative to their cytotoxicity.  
                                                
183 B. F. Milne, P. F. Long, A. Starcevic, D. Hranueli, M. Jaspars, Org. Biomol. Chem. 2006, 4, 
631–638. 
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4.3. Glycolipopeptides from Tolypothrix distorta var. symplocoides EAWAG 
224a 
Based on a previous results on the evaluation of antiparasitic activity of several 
cyanobacteria strains, it was found that the crude extract of Tolypothrix distorta var. 
symplocoides (T. distorta var. symplocoides) EAWAG 224a exhibited micromolar 
activity against Trypanosoma brucei rhodesiense (T. b. rhodesiense), Leishmania 
donovani (L. donovani) and P. falciparum (Table 14).184 
 
Table 14: Crude extract activity of EAWAG 224a.[a] 
Tested against IC50 (µg/mL) 
T. b. rhodesiense 35.55 
T. cruzi >90 
L. donovani 58.53 
P. falciparum 9.61 
Rat myoblast L6 Cells >90 
[a]: T. distorta var. symplocoides EAWAG 224a. 
 
The result of the screening showed promising antimalarial activity for the 
cyanobacterium T. distorta var. symplocoides EAWAG 224a. Therefore, a bioassay-
guided fractionation following by our efforts towards the structure elucidation was 
carried out and will be discussed in this chapter. 
 
Figure 30: Microcscopic picture of T. distorta var. symplocoides EAWAG 224a. 
  
                                                
184 C. Portmann, PhD thesis, École Polythechnique Fédéral de Lausanne (CH), 2008, EPFL, 
Lausanne 
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4.3.1. Extraction 
The cyanobacterium T. tolypothrix distorta var. symplocoides EAWAG 224a was 
grown in several 250 mL cultures equipped with vented caps. The biomass was collected 
by centrifugation and the compounds were extracted from the biomass by repeated 
sonications in aqueous methanol. 
 
Figure 31: Picture of a T. distorta var. symplocoides EAWAG 224a 250 mL culture. 
4.3.2. Bioassay-guided Fractionation 
The crude extract was separated by semi-preparative HPLC into 10 fractions. Each 
fraction was tested for its antimalarial activity. Fraction 4 (F4) was found to be the most 
potent with an IC50 value of 4.87 µg/mL (figure 32). 
 
Figure 32: HPLC chromatogram of T. distorta var. symplocoides EAWAG 224a crude extract. 
F4 
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F4 was further separated to obtain an active fraction composed of only three 
compounds. By repeating the extraction and isolation process with careful control of the 
temperature (35°C) during evaporation, one peak disappeared from the HPLC 
chromatogram. The missing compound was then proposed to be an artifact of isolation 
and we decided to focus our effort on the purification and structure characterization of the 
two other natural products. 
4.3.3. Structure Elucidation Results 
The first indication of the structure of the two unknown compounds was obtained 
during the analysis of the UV and mass spectra recorded during the HPLC separation. 
Absorption maxima were found for both compounds around 193, 223 and 276 nm, which 
is characteristic for peptide containg amide bonds (190 and 220 nm) and aromatic side 
chains (250-300 nm).185 Furthermore, a m/z = 1634 Da for [M+1]+ was detected for the 
first compound and a m/z = 1677 Da for [M+1]+ for the second compound. A literature 
search of isolated peptides from Tolypothrix sp. with a molecular weight in the range of 
1600–1700 Da revealed that recently, a compound similar to hassallidin A (167) was 
detected in Tolypothrix sp. extract.175,177 Therefore it was proposed that the first and 
second isolated compounds were glycolipocyclopeptides, named GLCP-1 (182) and 
GLCP-2 (183), respectively, possessing a similar scaffold as 167. 
 
                                                
185 M. R. Liyanage, K. Bakshi, D. B. Volkin, C. R. Middaugh, in Methods Mol. Biol., Humana 
Press, Totowa, NJ, 2013, pp. 225–236. 
hassallidin A (167)
NH
O NH
O
NH
HO
O
H
N
N
O
O O
HO
OH
OH
OH
NHO
O
O
O
HO
N
H
H
N
O
O
N
H
HO O
OH
OH
H2N
O
NH2
O
 
102 
4.3.3.1. HRMS and HRMS2 Analysis 
The tandem mass spectrometry analyses for GLCP-1 (182) and GLCP-2 (183) were 
achieved by Dr. Nadine Bohni on a UHPLC-QTOFMS system. In both cases, the mass 
chosen for the experiment was the doubly charge pseudo-molecular ion [M+2H]2+, which 
was 817.90078 Da for GLCP-1 (182) and 839.40274 Da for GLCP-2 (183). The different 
MS fragments from the two natural products, with their structure interpretation, are 
shown below (figures 33 and 34). 
 
Figure 33: Fragments detected during HRMS2 experiment of GLCP-1 (182), a proposed structure 
for each ion is shown. 
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Figure 34: Fragments detected during HRMS2 experiment of GLCP-2 (183), a proposed structure 
for each ion is shown. 
GLCP-1 (182) and GLCP-2 (183) displayed an exact mass of m/z 817.90078 Da 
and 839.40274 Da, respectively, which supports the molecular formula of C75H117N11O29 
for the [M+2H]+ pseudo-molecular ion of 182 and C76H118N12O30 for the [M+2H]+ 
pseudo-molecular ion of 183. 
The core structure elucidation of GPLC-1 (182) and GPLC-2 (183) was deduced by 
comparing the fragment ion 185, found in 182 and 183, with the HRMS2 available data 
on hassallidins175–177 and balticidins.178 We realized that the same ion was reported for 
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hassallidin D (169) and therefore we proposed that our natural products shared the same 
aglycone core structure 185 (figure 35). 
 
Figure 35: Structure of hassallidin D (169) with the assigned stereochemistry. The aglycone core 
structure 185 is highlighted in red. 
The presence of a deoxyhexose in GLCP-1 (182) and GLCP-2 (183) was 
supporting by the fragment ion 186. Further evidence for this sugar was deduced by the 
ions 184 and 188, which represent GLCP-1 (182) and GLCP-2 (183), respectively 
without a deoxyhexose. 
The ion 187, also detected in both compounds, was proposed to be a hexose 
possessing one carboxamide group. In the case of GLCP-2 (183) a hexose possessing two 
carboxamide groups was proposed to correspond to the fragment 189. With these results 
it was deduced that GLCP-1 (182) possesses a hexose with one carboxamide group and 
GLCP-2 (183) possesses a hexose with two carboxamide groups. 
Furthermore, an analysis of hassallidins and balticidins composition revealed that 
mannose was the carbohydrate attached to N-Me-Thr and that the deoxyhexose of 
hassallidin B (168) was identified as rhamnose (table 15).175–178 Taking into account these 
results, we propose that the carbohydrates in GLCP-1 (182) and GLCP-2 (183) are 
rhamnose and mannose.  
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Table 15: Carbohydrates present in hassallidins and balticidins. 
Glycolipopeptides Attached to N-Me-Thr Attached to OH of fatty acid  
hassallidin A (167) mannose none 
hassallidin B (168) mannose rhamnose 
hassallidin C n.d. n.d. 
hassallidin D (169) mannose pentopyranose-(3-1)-GlcNAc 
balticidin A   (170) mannose Ara(3-1)GalA 
balticidin B   (171) mannose Ara(3-1)GalA 
balticidin C   (172) mannose Ara(3-1)GalA 
balticidin D   (173) mannose Ara(3-1)GalA 
n.d.: not determined; GlcNAc: N-acetyl-glucosamine; Ara: arabinose; GalA: 
galacturonic acid 
4.3.3.2. Marfey’s Method for Amino Acids Analysis 
Marfey’s and NMR analysis have been obtained only for GLCP-2 (183) and will be 
repeated for GLCP-1 (182). After isolation and hydrolysis of GLCP-2 (183) the amino 
acids configuration was determined by the Marfey’s method described in chapter 4.2.1.3. 
The elucidation of N-Me-Thr required the synthesis of the three non-commercially 
available diastereoisomers (N-Me-D-Thr, N-Me-D-allo-Thr, N-Me-L-allo-Thr) using a 
reported procedure.186 The results of the analysis indicated the presence of L-Tyr, D-Tyr, 
D-Glu, L-Thr (confirmed by coinjection with L-Thr), D-Thr, D-allo-Thr, Gly and N-Me-L-
allo-Thr (confirmed by coinjection with N-Me-L-allo-Thr and N-Me-D-Thr).  
The absence of glutamine was a result of its conversion to glutamic acid during the 
hydrolysis procedure as it was reported for balticidins.178 Therefore the presence of D-Glu 
is an indication that GLCP-2 (183) possesses D-Gln and this result will be confirmed by 
HRMS2 analysis of the aglycone core structure. 
The amino acids composition was found to be identical to the one reported for 
hassallidin D (169). Considering this result, we propose to have the same amino acid 
sequence. Additionally, our result showed unambiguously the presence of N-Me-L-allo-
Thr and we can reasonably by deduction assigned the absolute configuration of the 
unknown threonine in 169 to D-Thr. 
  
                                                
186 U. Groth, W. Halfbrodt, U. Schöllkopf, Liebigs Ann. Chem. 1992, 351–355. 
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4.3.3.3. NMR Analysis 
NMR spectroscopic data were recorded for GLCP-2 (183) in MeOD following the 
same procedure used for hassallidin D (169). It was found that both compounds were 
subject to hydrolysis and therefore the data are reported for the open form of the 
lactone.177 The 1H NMR and the 13C chemical shifts obtained from HSQC measurments 
were compared for the aglycone core structure of 169 and strong similarities were found 
except for the part close to the carbohydrates (table 16). 
Table 16: 1H and 13C chemical shift of GLCP-2 (183) and hassallidin D (169). 
Substructure Position δC (ppm) δH (ppm) 
  hassallidin D GLCP-2 hassallidin D GLCP-2 
Dhh1 1 176.1    
 2 73.5 73.3 4.15 4.16 
 3 75.8 76.7 4.05 3.99 
 4 28.6 29.0 1.69 1.66 
 5 26.0 26.3 1.36 1.36 
 6-13 29.8-30.5 30.5 1.34-1.29 1.29 
 14 32.8 32.8 1.28 1.28 
 15 23.4 23.5 1.32 1.32 
 16 14.1 14.2 0.89 0.89 
Thr2 1 172.3  -  
 2 60.3 60.7 4.28 4.32 
 3 67.8 68.1 4.13 4.15 
 4 19.8 20.1 1.25 1.24 
Thr3 1 174.1  -  
 2 59.7 60.7 4.38 4.32 
 3 68.5 68.1 4.32 4.32 
 4 19.8 20.0 1.23 1.23 
Thr4 1 172.6  -  
 2 61.6 60.7 4.24 4.32 
 3 67.9 68.1 4.07 4.07 
 4 19.7 19.4 1.13 1.10 
Tyr5 1 172.8  -  
 2 56.6 57.2 4.53 4.47 
 3/3’ 37.1 36.9 2.88/3.12 2.91/3.10 
 4 128.7  -  
 5 131.3 131.2 7.05 7.04 
 6 116.4 116.5 6.69 6.70 
 7 157.5  -  
Dhb6 1 167.2  -  
 2 131.0  -  
 3 126.9  5.80 5.79 
 4-CH3 13.5 13.6 1.94 1.95 
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Substructure Position δC (ppm) δH (ppm) 
  hassallidin D GLCP-2 hassallidin D GLCP-2 
Gln7 1 174.2  -  
 2 54.2 54.3 4.51 4.52 
 3/3’ 28.0 28.3 2.12/2.29 2.11/2.29 
 4 32.2 32.8 2.44 2.44 
 4-CO 178.2  -  
Gly8 1 171.4  -  
 2 42.1 42.2 3.92/4.13 4.14/3.94 
N-MeThr9 1 169.9  -  
 2 61.0 60.8 4.86 4.95 
 3 69.6 70.4 4.31 4.33 
 4 14.8 15.0 1.05 1.05 
 NCH3 30.9 30.9 2.68 2.64 
Tyr10 1 173.7  -  
 2 54.2 54.7 4.75 4.74 
 3/3’ 37.8 37.8 2.73/3.11 2.71/3.13 
 4 128.7  -  
 5/8 131.6 131.4 6.97 6.96 
 6/9 116.4 116.6 6.72 6.68 
 7 157.3    
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4.3.4. Conclusion 
A bioassay-guided fractionation targeting antimalarial activity led to the isolation 
of two new natural products, GLCP-1 (182) and GLCP-2 (183). Their aglycone core 
structure is proposed to be the same as for hassallidin D (169) based on HRMS2 analysis. 
Furthermore, applying marfey’s method, the amino acids composition of GLCP-2 (183) 
was found to be identical to hassallidin D (169) and as both compounds exhibit strong 
similarities in their 1H NMR data, the amino acid sequence of both natural products is 
proposed to be identical. Additionally, we determined for the first time, in this 
glycolipopeptide class of compounds, the absolute configuration of N-Me-L-allo-Thr. 
The carbohydrates of GLCP-1 (182) and GLCP-2 (183) were determined by 
HRMS2 analysis and identified as deoxyhexose and hexose containing functional groups. 
By comparison with hassallidins and balticidins, we propose that the natural products 
possess rhamnose as deoxyhexose and mannose as hexose. The presence of carboxamide 
has not been reported for this compound family but was observed in other natural 
products isolated from cyanobacteria such as banyaside A.187 
 
                                                
187 A. Pluotno, S. Carmeli, Tetrahedron 2005, 61, 575–583. 
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4.3.5. Outlook 
As GLCP-1 (182) and GLCP-2 (183) possess strong similarities in their HPLC 
retention time and HRMS2 data, we suggest that they have similar structures. This 
assumption will be tested by applying Marfey’s derivatization method and NMR analysis 
of GLCP-1 (182). Furthermore, NMR spectroscopic data has to be acquired in an aprotic 
solvent such as DMSO-d6 to confirm the amino acids sequence and the presence of 
glutamic acid as well as the identity of the carbohydrates. In parallel, the structure of the 
sugars and the fatty acid will be analyzed by GC-MS. Finally, the antimalarial activity of 
the natural products will be tested. 
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5. Conclusion 
In this thesis, the potential of natural products as a source of knowledge is 
highlighted with three different examples. Firstly, secondary metabolites represent a rich 
and powerful source of new biologically active compounds. This field of study remains 
of high importance due the constant discovery of multidrug-resistant organisms. 
Secondly, natural products play an important role in the communication between living 
organisms. The study of this chemical language brings essential information towards our 
understanding of these interactions. Finally, the formation of compounds by living 
organisms represents a fascinating field of research and requires the detection and 
isolation of natural products involved in biosynthetic pathways. 
 
P. kirkii is a plant living in obligatory symbiosis with the bacteria B. kirkii and the 
role of this microoganism on the plants’ survival remains unclear. This question is 
addressed in the first part of this thesis by the analysis of the secondary metabolites 
produced by B. kirkii. The genomic analysis of the bacteria revealed the presence of a 
gene cluster responsible for the production of a putative C7N aminocyclitol. The isolation 
of this predicted natural product was achieved using a 1H-NMR-guided fractionation and 
the structure was elucidated by HRMS, NMR and single crystal X-ray analysis. To 
investigate the biological role of this new natural product, named kirkamide, a total 
synthesis was developed and optimized for gram scale preparation. Biological assays 
were carried out and revealed that kirkamide possesses a cytotoxic and insecticidale 
activity. Taking into account these results kirkamide was proposed to possess a protective 
role in the symbiosis. Furthermore, during the study of the secondary metabolites 
composition from this symbiotic system another new natural product, streptol glucoside, 
was isolated and its structure elucidated. Finally, the methods for the detection and 
quantification of these natural products were achieved by GC-MS and 1H NMR. 
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A genome-driven bioassay-guided fractionation of the B. cenocepacia H111 extract 
led to the isolation of fragin, which possesses the unusual N-nitrosohydroxylamine 
functional group. The gene cluster of this compound was identified allowing the 
opportunity to study its biosynthesis and particularly the mechanism of the N-N bond 
formation, which remains unclear for all natural products. After the function assignment 
of the genes, a first biosynthetic pathway starting from L-hydroxyleucine was proposed. 
To test this hypothesis, predicted biosynthetic intermediates were synthesized and their 
presence in the crude extract was explored, which led to the detection of some of the 
proposed compounds. To obtain further evidence of their involvement in the 
biosynthesis, knockout strains were obtained and their molecular composition analyzed. 
Unfortunately, the intermediates were not found in these cultures leading to the 
conclusion that the compounds detected in the crude extract were degradation products of 
fragin. Furthermore, the gene cluster contained a NRPS domain, which could release the 
compound only at a later stage of the biosynthesis. On the base of this deduction, a 
second biosynthesis was proposed starting from D-valine and is currently being 
investigated. Additionally, the mechanism of N-N bond formation was investigated and a 
stepwise process involving a hydroxylamine compound and a nitrite ion is suggested. 
 
The last chapter, separated into two parts, describes the discovery of new natural 
products from cyanobacteria possessing antimalarial activity. Balgacyclamides A–C are 
novel cyanobactins isolated from Microcystis aeruginosa EAWAG 251 culture. The 
absolute configuration was elucidated using chiral GC and Marfey’s derivatization 
method followed by HPLC-MS measurement. Furthermore, balgacyclamides A and B 
were found to possess an antimalarial activity lower that 10 µM and a cytotoxicity of 
more than 150 µM. The second part of this chapter described the structure elucidation 
efforts of two new glycolipopeptides produced by Tolpyothrix distorta var. symplocoides 
EAWAG 224a. The natural products were isolated following a bioassay-guided 
fractionation and structural information was obtained by UV, HRMS fragmentation, 
amino acid analysis and NMR. These results indicated that the natural products shared 
the core structure of hassallidin D with variation in the attached carbohydrates.  
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6. Experimental Part 
6.1.General Remarks 
All reactions were performed in dry solvents under argon atmosphere unless stated 
otherwise. The anhydrous solvents were obtained by filtration and passing through 
activated anhydrous alumina columns (Innovative Technology solvent purification 
system) and from commercial suppliers without any purification. Syringes and stainless 
steel cannula were used to transfer air and moisture sensitive liquids and solutions. 
Analytical thin layer chromatography (Merck silica gel 60 F254 plates) was used to 
monitor reactions and the compounds were detected by UV light (254 nm and 350 nm) 
and by staining using ceric ammonium molybdate (CAM) solution followed by gentle 
heating with a heat gun. Flash chromatography was performed using SiliCycle silica gel 
60 (230-400 Mesh) and Rf values of compounds are indicated. NMR experiments were 
performed at 298 K on a Bruker Avance III NMR spectrometer operating at 400 MHz 
proton frequency, Bruker Avance III NMR spectrometer operating at 500 MHz proton 
frequency and at 126 MHz carbon frequency, Bruker Avance III NMR spectrometer 
operating at 600.13 MHz proton frequency and Bruker Avance III NMR spectrometer 
operating at 600.13 MHz proton frequency equipped with a 1.7 mm TCI cryoprobe. The 
spectra were calibrating using the residual solvent proton and carbon signals (δH 2.50, δC 
39.52 for DMSO-d6, δH 7.26, δC 77.16 for CDCl3, δH 5.32, δC 53.84 for CD2Cl2, δH 4.79 
for D2O and δH 3.31, δC 49.00 for CD3OD). Melting points (Mp) were determined using a 
Büchi B-545 apparatus in open capillaries and are uncorrected. IR spectra were recorded 
on a Varian 800 FT-IR ATR spectrometer and data are reported in terms of frequency of 
absorption (ν, cm-1). Optical rotations were recorded on a Jasco P-2000 digital 
polarimeter with a path length of 1 dm, using the 589.3 nm D-line of sodium. 
Concentrations (c) are quoted in g/100 mL. High-resolution masses (HRMS-ESI) were 
recorded by Dr. Heinz Nadig at the University of Basel on a Bruker max is 4G QTOF 
ESI mass spectrometer. Microwave reactions were performed using a Biotage® Initiator+ 
system. HPLC purifications were performed on a UHPLC Dionex Ultimate 3000 system 
equipped with Ultimate 3000 pump, Ultimate 3000 autosampler, Ultimate 3000 
thermostated column compartment and Ultimate 3000 photodiode array detector. HPLC-
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MS analyses were performed on a Dionex HPLC system equipped with a P680 pump, an 
ASI-100 automated sample injector, a TCC-100 thermostated column compartment, a 
PDA-100 photodiode array detector and a MSQ-ESI mass spectrometric detector. 
Lyophilization was performed using a Christ Alpha 1-2 LD plus system. 
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6.2. The C7N Aminocyclitol Kirkamide and Streptol Glucoside 
6.2.1. Kirkamide 
6.2.1.1. Isolation and Structure Elucidation of Kirkamide 
Extraction Procedure 
The leaves were collected from approximately 1 year-old Psychotria kirkii plants 
kept in the greenhouse of the Botanical Garden of the University of Zürich. Leaves were 
collected in the middle of the light cycle and washed with distilled water. About 10 g of 
leaf tissue were then grounded in liquid nitrogen and extracted by stirring the mixture in 
aq. MeOH soln. (80%, 2 x 100 mL) for 24 h. Extracts were concentrated under reduced 
pressure. 
Isolation of Fraction P_TLC_IV_1_5_2_2 
The extract from the leaves of Psychotria kirkii (160 mg) was subjected to 1H 
NMR-guided fractionation using multiple semi-preparative Hydro RP-HPLC runs 
(Phenomenex Synergi Hydro-RP 10 µm; 150 x 10 mm) at a flow of 2 mL/min. The 
column was equilibrated for 5 min with 100% H2O and the MeCN/H2O gradient applied 
was changed from 0% to 0.5% and finally to 100% MeCN in 10 and 2 min, respectively. 
The column was then washed with MeCN for 5 min. The fraction P_TLC_IV_1_5_2_2 
was shown to contain an inseparable mixture of kirkamide and sucrose eluting at 5.75 
min. 
Isolation of Kirkamide 
The extract from the leaves of Psychotria kirkii (859 mg) was dissolved in MeOH 
(6 mL), pTsOH (400 mg) was added and the reaction was stirred overnight at RT. The 
reaction mixture was then evaporated under reduced pressure, dissolved in H2O (600 µL), 
filtered and separated using multiple semi-preparative RP-HPLC runs (Phenomenex 
Synergi Hydro-RP 10 µm; 150 x 10 mm; 2 mL/min) and preparative RP-HPLC runs 
(Phenomenex Synergi Hydro-RP 10 µm; 250 x 21.2 mm; 7 mL/min). The preparative 
HPLC column was first equilibrated for 5 min with 100% H2O, then the MeCN/H2O 
gradient was changed from 0% to 0.5% and finally to 100% MeCN in 10 and 2 min 
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respectively. The column was washed with MeCN for 7 min. The elution conditions for 
the semi-preparative RP-HPLC were identical to those reported before. The compound 
was further purified using preparative TLC coated with Cu(II),61 and finally by semi-
preparative RP-HPLC using the same conditions as mentioned before to afford kirkamide 
(56) (1.31 mg) as a white solid. A single crystal was obtained by slow diffusion of Et2O 
into a solution of kirkamide (56) in MeOH. 
 
 
Kirkamide (56): white solid: [α]D = +21.6° (c 0.087, MeOH); Rf = 0.68 (Cu(II) coated 
TLC, iPrOH:H2O 3:2); IR (film): νmax = 3310, 2953, 2923, 2853, 1653, 1647, 1636, 
1558, 1541, 1458, 1376, 1310, 1099, 1074, 1061, 1045 cm-1; 1H NMR (500 MHz, 
DMSO-d6) δ = 7.36 (d, J = 8.1 Hz, 1H), 5.63 (dq apparent pattern, J = 4.8, 1.5 Hz, 1H), 
4.01 (d, J = 14.8 Hz, 1H), 3.99 (m, 1H), 3.95 (d, J = 14.8 Hz, 1H), 3.79 (d, 7.1 Hz, 1H), 
3.63 (ddd, J = 10.9, 8.1, 3.9 Hz, 1H), 3.56 (dd, J = 10.9, 7.1 Hz, 1H), 1.85 (s, 3H); 1H 
NMR (500 MHz, D2O) δ = 5.86 (dq apparent pattern, J = 5.0, 1.5 Hz, 1H), 4.30 - 4.23 
(m, 2H), 4.20 - 4.12 (m, 2H), 3.91 (dd, J = 11.5, 4.0 Hz, 1H), 3.72 (dd, J = 11.5, 7.9 Hz, 
1H), 2.06 (s, 3H); 13C-NMR (126 MHz, DMSO-d6) δ =  169.2, 142.5, 121.5, 72.9, 70.4, 
64.3, 60.9, 53.1, 23.0; HRMS (ESI) calc. for C9H15NO5Na+ [M+Na]+: 240.0842; found 
[M+Na]+: 240.0844. 
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3
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Crystallographic Data of Kirkamide 
 
 
 
 
 
 
 
Formula  C9H15N1O5 
Formula weight                    217.22 
Z, calculated density             4, 1.404 Mg · m-3 
F(000)                            464 
Description and size of crystal colourless plate, 0.031 · 0.121 · 0.191 
mm3  
Absorption coefficient           0.978 mm-1 
Min/max  transmission              0.84 / 0.97 
Temperature                       123K 
Radiation(wavelength)             Cu Kα (λ = 1.54178 Å) 
Crystal system, space group:  orthorhombic, P 21 21 21 
a                                 7.3848(7) Å 
b                                 11.2982(10) Å 
c                                 12.3137(11) Å 
α                                90° 
β                                 90° 
γ                                 90° 
V                                 1027.39(16) Å3 
Min/max Θ                        5.313° / 68.379° 
Number of collected reflections   12832 
Number of independent reflections  1849 (merging r = 0.049) 
Number of observed reflections    1736 (I>2.0σ(I)) 
Number of refined parameters      137 
r                                0.0256 
rW                                0.0303 
Flack parameter –0.03(15) 
Goodness of fit                   1.1028 
CCDC 1054238 
  
 
118 
NMR Spectroscopic Data of Valienamine in DMSO-d6 
 
 
 
Valienamine (21) (1 mg) was obtained from Toronto Research Chemicals Inc., dissolved 
in DMSO-d6 and then D2O was added and evaporated in order to suppress the proton 
signals of the primary amine and the hydroxyl groups. 
 
Table 17. NMR Spectroscopic data (600 MHz, DMSO-d6) of valienamine (21). 
C no. δC, type δH (J in Hz) 
1 115.9, CH 5.57, dq[a] (4.5, 1.4) 
2 50.3, CH 3.82, t[a] (4.9) 
3 67.9, CH 3.72, dd (9.7, 5.5) 
4 72.8, CH 3.54, dd (9.7, 7.0) 
5 71.8, CH 3.89, d (7.0) 
6 147.4, C  
7a 62.0, CH2 4.04, d (15.1) 
7b  4.01, dq[a] (15.1, 1.6) 
[a] Apparent splitting pattern. 
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6.2.1.2. Activity Assays of Kirkamide 
Brine Shrimp Toxicity Assay 
Experiment executed by Dr. Aurélien Carlier. Brine shrimp (Artemia salina) eggs 
purchased from Dohse Aquaristik (Zürich, Switzerland) were hatched in salt water (37 
g/L) under constant illumination. Kirkamide (56) solution in methanol was added to the 
wells of 12-well microliter dishes and allowed to dry. Brine shrimp nauplii were then 
added to the wells with 2 mL salt water and incubated at 25°C under shaking. Nauplii 
survival was scored after 48 h incubation. The experiment was done in triplicate. LC50 
value (± SD) was estimated at 0.85 ± 0.31 µg/mL by logistic regression using the “dose” 
function of the MASS package in R.188 
Toxicity Assay on Pollen Beetles 
Experiments executed by Dr. Giselher Grabenweger. Pollen beetles (Meligethes 
aenus) were collected in May and June 2014 in a pesticide-free field of oilseed rape in 
Reckenholz, Switzerland and kept in a climate chamber at 7°C on peat substrate until 
needed. For the assay, an aq. soln. of kirkamide (56) (0.3%, 100 µL), a soln. of a 
commercial insecticide (Audienz, Omya Agro, Switzerland, 0.4%, 100 µL) as a positive 
control or distilled water (100 µL) as a negative control was mixed with 100 mg of pure 
pollen (Bergland, Germany) in small petri dishes (55 mm diameter). Methanol and water 
were allowed to evaporate completely at room temperature. Petri dishes with dried feed 
were put into plastic boxes (100 x 80 x 130 mm), lined with filter paper and provided 
with a moist cotton plug as a water source. 20 pollen beetles were added per box. Boxes 
were closed with perforated lids and plugged with gauze to allow for gas exchange. 
Treatments were replicated 5 times and boxes with beetles were kept at 22°C and 75% 
humidity for the duration of the experiment. Mortality was assessed at 3, 7, 10 and 14 
days after transfer. Mean pollen beetle mortality (± SD) in the kirkamide treatment was 
20 ± 11.9, 48.3 ± 26.3, 67.7 ± 27.9 and 80.9 ± 28.3% at 3, 7, 10 and 14 dpi, respectively. 
The insecticide treatment reached 96.3 ± 8.5% mortality 3 dpi and 100% mortality after 7 
dpi, respectively, while mean mortality in the distilled water control was 5.2 ± 3.6, 8.6 ± 
                                                
188 J. Carballo, Z. L. Hernández-Inda, P. Pérez, M. D. García-Grávalos, BMC Biotechnol. 2002, 2, 
17–22. 
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6.5, 12.6 ± 7.9 and 16.7 ± 6.9% at 3, 7, 10 and 14 dpi, respectively. Pollen beetle 
mortality between the distilled water control and kirkamide treatment is significantly 
different at 10 and 14 dpi, while it is similar between kirkamide and the insecticide at the 
same observation dates (ANOVA, with Tamhane’s τ post hoc testing). 
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6.2.1.3. Synthesis of Kirkamide 
Synthesis First Generation 
Synthesis of N-((3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-methoxytetra-
hydro-2H-pyran-3-yl)acetamide (75)71 
 
Amberlite® IR-120 (H+ form, 84.0 g), washed with MeOH, was added to a solution 
of N-acetyl-D-glucosamine (65) (35 g, 158 mmol) in MeOH (560 mL) and stirred 16 h at 
reflux. The hot mixture (60°C) was filtered, washed with MeOH (60°C, 2 x 300 mL) and 
evaporated under reduced pressure to afford the triol 75 (32.6 g, 11:1 α:β, 80%) as a 
white powder: Rf = 0.52 (CH2Cl2:MeOH 7:3). The product was used in the next step 
without further purification. The analytical data match those reported in the literature.71 
Synthesis of N-((2R,4aR,6S,7R,8R,8aS)-8-hydroxy-6-methoxy-2-phenylhexahydro-
pyrano[3,2-d][1,3]dioxin-7-yl)acetamide (190)72 
 
Benzaldehyde dimethyl acetal (156 mmol, 23.4 ml) and pTsOH (1.56 mmol, 296 
mg) were added to a solution of the triol 75 (18.3 g, 77.8 mmol, 11:1 α:β) in DMF (150 
mL) and the mixture was stirred at 70°C for 2.5 h. The orange solution was evaporated 
under reduced pressure, the residue was dissolved in CH2Cl2 (500 mL), a sat. aq. 
NaHCO3 soln. (250 mL) was added and the precipitates were filtered. The crystallization 
was repeated by evaporating the organic layer under reduce pressure, dissolving the 
residue in CH2Cl2 (100 mL) and adding a sat. aq. NaHCO3 soln. (100 mL). The solids 
were combined to afford the benzylidene 190 (24.4 g) as a white solid: Rf = 0.56 
O
HO
HO
AcHN OMe
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HO
HO
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(CH2Cl2:MeOH 9:1). The product was used in the next step without further purification. 
The analytical data match those reported in the literature.189 
Synthesis of N-((2R,4aR,6S,7R,8R,8aS)-8-(benzyloxy)-6-methoxy-2-phenylhexahydro 
pyrano[3,2-d][1,3]dioxin-7-yl)acetamide (67)73 
 
To a solution of the benzylidene 190 (30.0 g, 92.8 mmol) in DMF (200 mL), 
barium oxide (42.7 g, 278 mmol), barium hydroxyde octahydrate (13.3 g, 41.2 mmol) 
and benzyl bromide (16.2 mL, 135 mmol) were added sequentially and the solution was 
stirred for 2 h 40 at RT. The mixture was diluted with CH2Cl2 (1.2 L), the organic phase 
was washed with aq. HCl soln. (1 M, 400 mL), sat. aq. NaHCO3 soln. (400 mL), washed 
with brine (3 x 400 ml), dried over Na2SO4 and concentrated under reduced pressure. 
Et2O (50 mL) was added to the concentrated solution and the precipitates were filtered to 
afford the benzyl protected 67 (31.4 g) as a white solid. The product was used in the next 
step without further purification. The analytical data match those reported in the 
literature.73  
Synthesis of N-((2S,3R,4R,5S,6R)-4-(benzyloxy)-5-hydroxy-6-(hydroxymethyl)-2-
methoxytetrahydro-2H-pyran-3-yl)acetamide (68)69 
 
A solution of the benzyl protected pyranoside 67 (30 g) in aq. AcOH soln. (80%, 360 
mL) was stirred for 1h at 70°C. The reaction mixture was evaporated under reduced 
pressure and the residue was washed with toluene (2 x 200 mL) and pentane (2 x 200 
                                                
189 J. Agarwal, R. K. Peddinti, J. Org. Chem. 2011, 76, 3502–3505. 
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mL) to afford the diol 68 (21.7 g) as a white solid. The product was used in the next step 
without further purification. The analytical data match those reported in the literature.69  
Synthesis of ((2R,3S,4R,5R,6S)-5-acetamido-4-(benzyloxy)-3-hydroxy-6-metho-
xytetra-hydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate (191)69 
 
To a solution of the diol 68 (5 g) in CH2Cl2 (60 mL), 4-toluenesulfonyl chloride 
(5.86 g, 30.7 mmol) and freshly distilled Et3N (6.65 mL) were added at 0°C. The solution 
was stirred for 3 h 20 at RT. The yellow reaction mixture was quenched with H2O (40 
mL) and extracted with CH2Cl2 (2 x 60 mL). The organic layer was washed with sat. aq. 
NH4Cl soln. (3 x 60 mL) and with brine (3 x 60 mL), dried over Na2SO4 and evaporated 
under reduced pressure to afford the tosylated pyranoside 191 (7.37 g) as a yellow 
amorphous solid. The product was used in the next step without further purification. The 
analytical data match those reported in the literature.69  
Synthesis of N-((2S,3R,4R,5S,6S)-4-(benzyloxy)-5-hydroxy-6-(iodomethyl)-2-metho-
xytetrahydro-2H-pyran-3-yl)acetamide (69)69 
 
To a solution of the tosylated pyranoside 191 (7.29 g, 15.3 mmol) in DMF (60 mL), 
sodium iodide (11.4 g, 76.3 mmol) was added and the dark solution was stirred for 2 h at 
100°C. The dark solution was evaporated under reduced pressure, dissolved in CH2Cl2 
(60 mL), washed with sat. aq. Na2SO3 soln. (2 x 60 mL) and brine (3 x 60 mL), dried 
over Na2SO4, evaporated under reduced pressure and purified by column chromatography 
(EtOAc:Et2O 1:1) to afford the iodide 69 (4.34 g, 36% over 5 steps) as a yellow solid: 
O
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Rf  = 0.5 (EtOAc:Et2O 1:1); 1H NMR (500 MHz, CDCl3) δ 7.38 - 7.28 (m, 5H), 5.52 (d, 
J = 9.6 Hz, 1H), 4.72 (d, J = 11.6 Hz, 1H), 4.66 - 4.63 (m, 2H), 4.31 (ddd, J = 10.4, 9.5, 
3.7 Hz, 1H), 3.61 - 3.54 (m, 2H), 3.49 (t, J = 9.0 Hz, 1H), 3.45 - 3.41 (m, 4H), 3.30 (dd, J 
= 10.6, 7.0 Hz, 1H), 1.94 (s, 3H); 13C NMR (126 MHz, CD3OD) δ 169.94, 138.21, 
128.88 (2C), 128.28, 128.24 (2C), 98.96, 80.30, 74.12, 74.02, 70.64, 55.55, 52.13, 23.66, 
6.90; Mp 136-140 °C. The analytical data match those reported in the literature.69 
Synthesis of N-((2S,3R,4R,5S)-4,5-bis(benzyloxy)-2-methoxy-6-methylenetetrahydro-
2H-pyran-3-yl)acetamide (70)69 
 
To a solution of sodium hydride (60% dispersion in mineral oil, 2.19 g, 54.7 mmol) 
in dry DMF (20 mL) at 0°C, a solution of the iodide 69 (4.33 g, 9.95 mmol) in DMF (60 
mL) was added. The mixture was warmed to RT and benzyl bromide (1.3 mL, 10.9 
mmol) was added. The reaction was monitored by 1H NMR and was quenched after 2 h 
with MeOH (2 mL), the mixture was concentrated under reduced pressure, dissolved in 
EtOAc (130 mL), washed with brine (3 x 100 mL), dried over Na2SO4, evaporated under 
reduced pressure and purified by column chromatography (EtOAc:hexane 1:1 and finally 
eluted with CH2Cl2) to afford the olefin 70 (2.94 g, 74%) as a white solid; Rf = 0.5 
(EtOAc:Et2O 1:1); [α]D = +51.2° (c 0.53, CHCl3); IR (film): νmax = 3293, 3086, 3066, 
3032, 2928, 2914, 2871, 2836, 1651, 1553, 1497, 1453, 1401, 1376, 1355, 1319, 1292, 
1210, 1134, 1096, 1075, 1051, 1030, 952 cm-1; 1H NMR (500 MHz, CDCl3) δ = 7.40 - 
7.27 (m, 10H), 5.42 (d, J = 9.2 Hz, 1H), 4.86 - 4.83 (m, 2H), 4.80 - 4.77 (m, 2H), 4.74 - 
4.70 (m, 2H), 4.64 (d, J = 12.0 Hz, 1H), 4.33 (td, J = 9.3, 3.3 Hz, 1H), 4.01 (dt, J = 8.2, 
1.7 Hz, 1H), 3.64 (dd, J = 9.4, 8.3 Hz, 1H), 3.40 (s, 3H), 1.84 (s, 3H); 13C-NMR (126 
MHz, CDCl3) δ = 170.0, 153.8, 138.4, 137.8, 128.6 (2C), 128.6 (2C), 128.3 (2C), 128.0, 
128.0 (2C), 127.9, 99.6, 97.7, 79.8, 78.6, 74.5, 74.0, 55.7, 51.8, 23.5; Mp 150 - 154°C; 
HRMS (ESI) calc. for C23H27NNaO5+ [M+Na]+ : 420.1781; found: [M+Na]+ 420.1778. 
The analytical data match those reported in the literature.69   
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Second Generation Synthesis 
Synthesis of N-((1R,3S,4R,5R,8S)-8-(benzyloxy)-3-methoxy-2,6-dioxabicyclo[3.2.1]oc 
-tan-4-yl)acetamide (77) 
 
To a solution of the iodide 76 (15 mg, 43.0 µmol) in DMF (0.3 mL), benzyl 
bromide (11 µL, 91.3 µmol) was added at 0°C followed by a mixture sodium hydride 
(60% in mineral oil, 11.3 mg, 0.282 mmol) in DMF (0.1 mL). The reaction mixture was 
stirred for 2 h at RT and quenched with MeOH (0.2 mL). The reaction mixture was 
concentrated under reduced pressure, dissolved in EtOAc (10 mL), washed with brine (3 
x 10 mL), dried over Na2SO4, evaporated under reduced pressure and purified by column 
chromatography (Et2O:EtOAc 1:1, 1% Et3N) to afford the bicyclic ether 77 as a 
yellowish oil: Rf = 0.2 (Et2O:EtOAc 1:1, 1% Et3N); [α]D = +39.5° (c 0.43, CH2Cl2); IR 
(film): νmax = 3417, 2952, 2928, 2891, 2852, 1674, 1515, 1454, 1438, 1369, 1313, 1275, 
1220, 1194, 1168, 1117, 1091, 1063, 1037, 1010, 916 cm-1; 1H NMR (500 MHz, 
CD2Cl2) δ = 7.51 - 7.29 (m, 5H), 6.65 (d, J = 9.9 Hz, 1H), 5.00 (d, J = 3.9 Hz, 1H), 4.78 
(d, J = 11.4 Hz, 1H), 4.57 (d, J = 11.4 Hz, 1H), 4.46 (t, J = 2.7 Hz, 1H), 4.36 (dddt, J = 
10.0, 4.5, 3.8, 0.7 Hz, 1H), 4.22 (t, J = 4.9 Hz, 1H), 4.20 (d, J = 10.6 Hz, 1H), 3.92 (ddd, 
J = 5.3, 2.6, 0.6 Hz, 1H), 3.91 (dd, J = 10.7, 3.1 Hz, 1H), 3.48 (s, 3H), 1.78 (s, 3H); 13C-
NMR (126 MHz, CD2Cl2) δ = 169.4, 137.2, 128.6 (2C), 128.1, 127.6 (2C), 97.4, 77.8, 
72.5, 72.3, 71.7, 69.0, 57.0, 50.1, 29.7 (unknown impurity), 23.1; HRMS (ESI) calc. for 
C16H21NNaO5+ [M+Na]+: 330.1312; found: [M+Na]+ 330.1315. 
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Synthesis of (3S,4R,5R,6S)-5-acetamido-6-methoxy-2-methylenetetrahydro-2H-
pyran-3,4-diyl diacetate (76) 
 
  
These compounds were prepared by using a modification of a published 
procedure.75 To a solution of the triol 75 (13.55 g, 57.6 mmol, 11:1 α:β), 
triphenylphosphine (15.2 g, 58.1 mmol) and imidazole (7.26 g, 106 mmol) in THF (150 
mL) at reflux, iodine (14.7 g, 58.1 mmol) in THF (60 mL) was added dropwise using a 
dropping funnel. After complete addition, the yellow solution was kept at reflux for 15 
min, cooled to RT and evaporated under reduced pressure. The residue was dissolved in a 
mixture of EtOAc (700 mL) and sat. aq. Na2S2O3 soln. (750 mL) and the layers were 
separated. The org. layer was extracted with H2O (3 x 750 mL) and the combined aq. 
layers were evaporated under reduced pressure. The solid was suspended in EtOAc 
(60°C, 4 x 500 mL), filtered and evaporated under reduced pressure to afford a mixture of 
iodide 76 and imidazole. This mixture was used in the next step without further 
purification. 
The crude residue was dissolved in pyridine (100 mL) and acetic anhydride (100 
mL) and stirred for 24 h at RT. The reaction mixture was evaporated under reduced 
pressure, dissolved in EtOAc (500 mL), the org. layer was washed with sat. aq. CuSO4 
soln. (500 mL) and with brine (2 x 300 mL), dried over Na2SO4 and evaporated under 
reduced pressure to afford the acetylated pyranoside 78 as a white solid which was used 
in the next step without further purification. 
Silver fluoride (10.0 g, 79 mmol) was added to a solution of the crude material in 
dry pyridine (100 mL), the mixture was stirred in the dark for 48 h and the reaction was 
monitored by 1H NMR. The mixture was then diluted with EtOAc (1 L), the solids were 
filtered through a pad of celite and washed with EtOAc (500 mL). The org. layers were 
washed with aq. HCl soln. (1M, 2 x 500 mL), with brine (2 x 500 mL) until the solution 
was neutral (pH = 7), sat. aq. CuSO4 soln. (500 mL) and brine (500 mL). Each aq. layer 
was extracted with EtOAc (100 mL), the org. layers were combined, dried over Na2SO4, 
O
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evaporated under reduced pressure and the residue was purified by column 
chromatography (Et2O:EtOAc 1:9) to afford the olefin 79 (8.7 g, 50% over three steps) as 
a white solid: Rf = 0.43 (EtOAc); [α]D = +68.9° (c 0.48, CHCl3); IR (film): νmax = 3279, 
2940, 1741, 1665, 1550, 1434, 1373, 1217, 1099, 1046, 1016, 931 cm-1; 1H NMR (500 
MHz, CDCl3) δ = 5.73 (d, J = 9.3 Hz, 1H), 5.49 (dt, J = 9.7, 2.1 Hz, 1H), 5.21 (dd, J = 
10.6, 9.8 Hz, 1H), 4.78 (d, J = 3.4 Hz, 1H), 4.77 (t, J = 2.0 Hz, 1H), 4.55 (t, J = 1.8 Hz, 
1H), 4.45 (ddd, J = 10.7, 9.5, 3.4 Hz, 1H), 3.43 (s, 3H), 2.12 (s, 3H), 2.03 (s, 3H), 1.96 (s, 
3H); 13C NMR (126 MHz, CDCl3) δ = 171.4, 170.0, 169.4, 150.4, 99.0, 97.4, 70.9, 69.2, 
55.7, 52.1, 23.4, 20.9, 20.8; Mp 158 - 164°C; HRMS (ESI) calc. for C13H19NO7Na+ 
[M+Na]+: 324.1054; found: [M+Na]+ 324.1054. 
A purified fraction of the iodide 76 was obtained by column chromatography 
(CH2Cl2:MeOH 95:5 to 85:15): Rf = 0.13 (CH2Cl2:MeOH 9:1); [α]D = +110.1° (c 2.00, 
MeOH); IR (film): νmax = 3302, 2929, 2908, 2836, 1617, 1554, 1473, 1442, 1422, 1374, 
1321, 1195, 1122, 1041, 1026, 957, 943 cm-1; 1H NMR (500 MHz, CD3OD) δ = 4.64 (d, 
J = 3.6 Hz, 1H), 3.92 (dd, J = 10.7, 3.6 Hz, 1H), 3.63 (dd, J = 10.6, 8.4 Hz, 1H), 3.62 (dd, 
J = 10.5, 2.1 Hz, 1H), 3.43 (s, 3H), 3.39 (ddd, J = 9.5, 7.6, 2.1 Hz, 1H), 3.31 (dd, J = 
10.6, 7.4 Hz, 1H), 3.20 (dd, J = 9.3, 8.9 Hz, 1H), 1.98 (s, 3H); 13C-NMR (126 MHz, 
CD3OD) δ = 173.7, 99.9, 76.1, 72.5, 72.4, 55.8, 55.3, 22.6, 7.1; Mp 188 - 190°C; HRMS 
(ESI) calc. for C9H16INO5Na+ [M+Na]+: 367.9965; found: [M+Na]+ 367.9962. 
A purified fraction of the acetylated pyranoside 78 was obtained by column 
chromatography (EtOAc): Rf = 0.43 (EtOAc); [α]D = +72.9° (c 0.15, MeOH); IR (film) : 
νmax = 3324, 2952, 2937, 2922, 2905, 1737, 1657, 1542, 1519, 1434, 1372, 1240, 1223, 
1200, 1121, 1076, 1034, 961, 929 cm-1; 1H NMR (500 MHz, CDCl3) δ = 5.68 (d, J = 9.5 
Hz, 1H), 5.18 (dd, J = 10.8, 9.4 Hz, 1H), 4.90 (t, J = 9.6 Hz, 1H), 4.73 (d, J = 3.7 Hz, 
1H), 4.33 (ddd, J = 10.7, 9.6, 3.7 Hz, 1H), 3.75 (ddd, J = 9.9, 8.9, 2.4 Hz, 1H), 3.47 (s, 
3H), 3.28 (dd, J = 10.9, 2.5 Hz, 1H), 3.13 (dd, J = 10.9, 8.6 Hz, 1H), 2.05 (s, 3H), 2.01 (s, 
3H), 1.95 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ = 171.4, 170.0, 169.6, 98.3, 72.1, 
71.0, 69.5, 55.9, 52.1, 23.4, 20.9 (2C), 3.8; Mp 178 - 182°C; HRMS (ESI) calc. for 
C13H20INO7Na+ [M+Na]+: 452.0177; found: [M+Na]+ 452.0181. 
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Synthesis of N-((2S,3R,4R,5S)-4,5-bis(benzyloxy)-2-methoxy-6-methylenetetrahydro-
2H-pyran-3-yl)acetamide (70) 
 
 
Using a modification of a published procedure,75 NH3 was bubbled through a 
solution of the acetylated pyranoside 78 (8.72 g, 28.9 mmol) in methanol (100 ml) for 3 h 
at RT. The solution was evaporated under reduced pressure, coevaporated with toluene, 
dissolved in DMF (100 mL) and added slowly to a solution of NaH (60% dispersion in 
mineral oil, 5.78 g, 145 mmol) in DMF (60 mL) at 0°C. After 1 h benzyl bromide (7.09 
mL, 59.2 mmol) was added slowly via a syringe pump (0.5 mL/min) at 0°C and then the 
solution was stirred 16 h at RT. The reaction mixture was quenched with MeOH (20 mL), 
diluted with EtOAc (1 L), washed with brine (3 x 500 mL), dried over Na2SO4, 
evaporated under reduced pressure and the residue was purified by column 
chromatography (Et2O:EtOAc 9:1 to 1:1) to afford the benzyl protected 70 (4.09 g, 36% 
over two steps) as a white solid: Rf = 0.5 (EtOAc:Et2O 1:1); [α]D = +51.2° (c 0.53, 
CHCl3); IR (film): νmax = 3293, 3086, 3066, 3032, 2928, 2914, 2871, 2836, 1651, 1553, 
1497, 1453, 1401, 1376, 1355, 1319, 1292, 1210, 1134, 1096, 1075, 1051, 1030, 952 cm-
1; 1H NMR (500 MHz, CDCl3) δ = 7.40 - 7.27 (m, 10H), 5.42 (d, J = 9.2 Hz, 1H), 4.86 - 
4.83 (m, 2H), 4.80 - 4.77 (m, 2H), 4.74 - 4.70 (m, 2H), 4.64 (d, J = 12.0 Hz, 1H), 4.33 
(td, J = 9.3, 3.3 Hz, 1H), 4.01 (dt, J = 8.2, 1.7 Hz, 1H), 3.64 (dd, J = 9.4, 8.3 Hz, 1H), 
3.40 (s, 3H), 1.84 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ = 170.0, 153.8, 138.4, 137.8, 
128.6 (2C), 128.6 (2C), 128.3 (2C), 128.0, 128.0 (2C), 127.9, 99.6, 97.7, 79.8, 78.6, 74.5, 
74.0, 55.7, 51.8, 23.5; Mp 150 - 154°C; HRMS (ESI) calc. for C23H27NO5Na+ [M+Na]+: 
420.1781; found: [M+Na]+ 420.1778. The analytical data match those reported in the 
literature.69  
  
O
AcO
AcO
AcHN OMe
1. NH3, MeOH
2. BnBr, NaH, DMF
O
BnO
BnO
AcHN OMe
79 70, 36% over 2 steps
 
129 
Synthesis of N-((1R,2R,3S,6S)-2,3-bis(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)-4-
oxocyclohexyl)acetamide (80) 
 
Using a modification of published procedures,70,79 HgSO4 (0.452 g, 1.52 mmol) 
was added to a solution of the benzyl protected olefin 70 (2.24 g, 5.64 mmol) in 1,4-
dioxane (56 mL) and aq. H2SO4 soln. (5.5 mM, 28 mL) that have been degassed for 10 
min with argon. The mixture was stirred at 60°C in the microwave for 15 min, diluted 
with CH2Cl2 (600 mL), washed with brine (2 x 400 mL), dried over Na2SO4 and 
evaporated under reduced pressure. The solids were washed with Et2O to afford 66 (1.74 
g) as a white powder. 
Using a modification of a published procedure,80 the residue was dissolved in THF 
(160 mL), freshly distilled 2,6-lutidine (2.461 mL, 21.1 mmol) was added at 0°C and the 
reaction was stirred 30 min at 0°C. Then, TBSOTf (1.272 mL, 5.53 mmol) was added via 
a syringe pump (0.06 mL/h) and the reaction mixture was stirred for 1 h. The reaction 
mixture was diluted with CH2Cl2 (500 mL), washed with sat. aq. Na2CO3 soln. (500 mL), 
with sat. aq. CuSO4 soln. (2 x 400 mL) and with brine (400 mL), dried over Na2SO4 and 
evaporated under reduced pressure. The residue was purified by column chromatography 
(Et2O:pentane 7:3) to afford the TBS-protected cyclohexanone 80 (1.76 g, 63% over two 
steps) as a white solid: Rf = 0.63 (EtOAc:Et2O 1:1); [α]D = +33.3° (c 0.27, CHCl3); IR 
(film): νmax = 3439, 3312, 3064, 3033, 2955, 2928, 2888, 2857, 1736, 1656, 1548, 1539, 
1519, 1498, 1471, 1463, 1455, 1373, 1255, 1137, 1098, 1047, 1028, 933 cm-1; 1H NMR 
(500 MHz, CDCl3) δ = 7.45 - 7.42 (m, 2H), 7.40 - 7.29 (m, 8H), 4.98 (d, J = 11.7 Hz, 
1H), 4.89 (d, J = 12.1 Hz, 1H), 4.84 (d, J = 7.5 Hz, 1H), 4.66 (d, J = 12.1 Hz, 1H), 4.61 
(d, J = 11.7 Hz, 1H), 4.23 (dt, J = 3.3, 2.7 Hz, 1H), 4.14 - 4.09 (m, 2H), 3.78 (dd, J = 
10.3, 9.3 Hz, 1H), 2.56 (ddd, J = 14.0, 2.6, 0.6 Hz, 1H), 2.44 (dd, J = 14.2, 3.7 Hz, 1H), 
1.72 (s, 3H), 0.79 (s, 9H), 0.00 (s, 3H), –0.11 (s, 3H); 13C NMR (126 MHz, CDCl3) δ = 
203.8, 169.8, 138.2, 137.7, 129.4 (2C), 128.9 (2C), 128.6 (2C), 128.4, 128.3 (2C), 128.1, 
O
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86.7, 77.4, 74.6, 73.7, 68.5, 54.9, 45.7, 25.7 (3C), 23.4, 18.0, –4.7, –5.0; Mp 101-104°C; 
HRMS (ESI) calc. for C28H39NO5SiNa+ [M+Na]+: 520.2490; found: [M+Na]+ 520.2483. 
Synthesis of (3R,4S,5R,6R)-4-acetamido-5,6-bis(benzyloxy)-3-((tert-butyldimethylsil-
yl)oxy)cyclohex-1-en-1-yl trifluoromethanesulfonate (81) 
 
  
The compound was prepared by using a modification of a published procedure.81 
To a solution of the TBS-protected cyclohexanone 80 (900 mg, 1.81 mmol) in THF (40 
mL) at –78°C Comins' reagent (1.8 g, 4.4 mmol) in THF (40 mL) was added. NaHMDS 
(2M in THF, 1.9 mL, 3.8 mmol) was added slowly via a syringe pump (1.3 mL/h) to the 
reaction mixture at –78°C. The orange solution was stirred for 5 min, quenched with aq. 
NaOH soln. (1M, 40 ml) and warmed to RT. The mixture was diluted with EtOAc (400 
mL), washed with aq. NaOH soln. (1M, 400 mL), with brine (2 x 200 mL), the org. layer 
was dried over Na2SO4, evaporated under reduced pressure and purified by column 
chromatography (Et2O:pentane 1:1 to Et2O, 1% Et3N) to afford the enol triflate 81 (699 
mg, 62%) as a yellowish oil: Rf = 0.63 (Et2O, 1% Et3N); [α]D = +9.1° (c 1, CHCl3); IR 
(film) : νmax = 3442, 3433, 3323, 3068, 3032, 2954, 2930, 2886, 2859, 1678, 1516, 1472, 
1456, 1423, 1365, 1247, 1210, 1142, 1086, 1043, 985, 937 cm-1; 1H NMR (500 MHz, 
CDCl3) δ = 7.42 - 7.29 (m, 10H), 5.76 (dd, J = 4.1, 0.8 Hz, 1H), 5.42 (d, J = 8.2 Hz, 1H), 
4.69 (d, J = 10.7 Hz, 1H), 4.68 (d, J = 11.8 Hz, 1H), 4.59 (d, J = 10.8 Hz, 1H), 4.58 (d, J 
= 11.9 Hz, 1H), 4.55 (t, J = 4.1 Hz, 1H), 4.28 (td, J = 8.1, 4.4 Hz, 1H), 4.16 (d, J = 4.9 
Hz, 1H), 4.03 (dd, J = 7.8, 4.9 Hz, 1H), 1.78 (s, 3H), 0.85 (s, 9H), 0.07 (s, 3H), 0.02 (s, 
3H); 13C NMR (126 MHz, CDCl3) δ = 170.0, 147.3, 137.6, 136.9, 128.9 (2C), 128.7 
(2C), 128.6 (4C), 128.4, 128.4, 121.5, 118.6 (q, J = 319.9 Hz), 77.0, 75.3, 74.5, 73.6, 
65.1, 49.9, 25.8 (3C), 23.4, 18.1, –4.7, –4.9; HRMS (ESI) calc. for C29H38F3NO7SSiNa+ 
[M+Na]+: 652.1983; found: [M+Na]+ 652.1978. 
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Synthesis of N-((1S,2R,5S,6R)-5,6-bis(benzyloxy)-2-((tert-butyldimethylsilyl)oxy)-4-
(hydroxylmethyl)cyclohex-3-en-1-yl)acetamide (82) 
 
 
Using a modification of a published procedure,82 a solution of the enol triflate 81 
(1.54 g, 2.45 mmol), n-Bu3SnCH2OH (3.01 g, 9.38 mmol)190 and LiCl (3.92 g, 92.4 
mmol) in dioxane (60 mL) was degassed with argon for 10 min and Pd(PPh3)4 (283 mg, 
0.245 mmol) was added. The reaction mixture was heated to 105°C in a microwave oven 
for 1 h. The mixture was cooled to RT, diluted with CH2Cl2 (600 mL), washed with brine 
(2 x 400 mL), dried over Na2SO4, evaporated under reduced pressure and the residue was 
purified by column chromatography (Et2O to Et2O:EtOAc 1:1) to afford the alcohol 82 
(1.06 g, 85%) as a yellowish oil: Rf = 0.2 (Et2O); [α]D = +30.7° (c 0.26, CHCl3); IR 
(film): νmax = 3429, 3362, 3334, 3087, 3065, 3032, 2953, 2929, 2884, 2857, 1656, 1523, 
1498, 1461, 1369, 1304, 1254, 1210, 1078, 1028, 1006, 938 cm-1; 1H NMR (500 MHz, 
CDCl3) δ = 7.40 - 7.29 (m, 10H), 5.69 (ddd, J = 3.7, 2.4, 1.1 Hz, 1H), 5.54 (d, J = 8.7 Hz, 
1H), 4.77 (d, J = 11.8 Hz, 1H), 4.73 (d, J = 11.0 Hz, 1H), 4.69 (d, J = 11.8 Hz, 1H), 4.58 
(d, J = 11.0 Hz, 1H), 4.38 (t, J = 3.8 Hz, 1H), 4.29 (td, J = 8.4, 4.5 Hz, 1H), 4.14 - 4.09 
(m, 3H), 4.01 (dd, J = 8.1, 5.4 Hz, 1H), 1.83 (dd, J = 7.3, 5.1 Hz, 1H), 1.80 (s, 3H), 0.86 
(s, 9H), 0.07 (s, 3H), 0.03 (s, 3H); 13C NMR (126 MHz, CDCl3) δ = 169.9, 139.0, 138.2, 
137.7, 128.8 (4C), 128.5 (2C), 128.4 (2C), 128.3, 128.2, 126.8, 78.3, 76.0, 73.9, 73.5, 
66.3, 64.3, 50.3, 25.9 (3C), 23.56, 18.21, –4.36, –4.80; HRMS (ESI) calc. for 
C29H41NO5SiNa+ [M+Na]+: 534.2646; found: [M+Na]+ 534.2640. 
  
                                                
190 R. L. Danheiser, K. R. Romines, H. Koyama, S. K. Gee, C. R. Johnson, J. R. Medich, Org. 
Synth. 1998, 9, 704–708. 
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Synthesis of N-((1R,2R,5S,6R)-5,6-bis(benzyloxy)-2-hydroxy-4-(hydroxymethyl)cy-
clohex-3-en-1-yl)acetamide (192) 
 
 
Using a modification of a published procedure,191 TBAF (1M in THF, 2.97 mL, 
2.97 mmol) was added to a solution of the protected alcohol 82 (1.38 g, 2.7 mmol) in 
THF (100 mL) at 0°C. The reaction mixture was stirred for 3 h at RT and then evaporated 
under reduced pressure. The residue was purified by column chromatography (EtOAc to 
EtOAc:MeOH 9:1) to afford the diol 192 (1.05 g, 98%) as a white amorphous solid: Rf = 
0.33 (EtOAc:MeOH 9:1); [α]D = –27.8° (c 0.26, MeOH); IR (film): νmax = 3282, 2908, 
2860, 1655, 1626, 1556, 1544, 1133, 1068, 1028 cm-1; 1H NMR (500 MHz, CD3OD) δ = 
7.34 - 7.25 (m, 10H), 5.87 - 5.85 (m, 1H), 4.74 (s, 2H), 4.71 (d, J = 11.1 Hz, 1H), 4.68 (d, 
J = 11.1 Hz, 1H), 4.26 - 4.22 (m, 2H), 4.19 (d, J = 6.6 Hz, 1H), 4.18 - 4.15 (m, 1H), 4.13 
(d, J = 13.9 Hz, 1H), 4.00 - 3.95 (m, 1H), 1.92 (s, 3H); 13C NMR (126 MHz, CD3OD) = 
173.4, 142.3, 140.0, 139.8, 129.4 (2C), 129.4 (2C), 129.1 (2C), 128.8 (3C), 128.7, 125.3, 
79.9, 78.9, 74.9, 74.7, 66.4, 63.1, 53.0, 22.9; HRMS (ESI) calc. for C23H27NO5Na+ 
[M+Na]+: 420.1781; found: [M+Na]+ 420.1777. 
 
  
                                                
191 L. Song, E. N. Duesler, P. S. Mariano, J. Org. Chem. 2004, 69, 7284–7293. 
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Synthesis of N-((1R,2R,5S,6R)-2,5,6-trihydroxy-4-(hydroxymethyl)cyclohex-3-en-1-
yl)acetamide, Kirkamide (56) 
 
Using a modification of a published procedure,192 NH3 (8 mL) was condensed in a 
solution of THF (1 mL) at –78°C and sodium (30 mg, 1.29 mmol) was added. To the blue 
mixture a solution of the diol 192 (40 mg, 0.101 mmol) in THF (4 mL) was added and 
stirred for 30 min. More sodium (30 mg, 1.29 mmol) was added as soon as the blue color 
disappeared. After 30 min of remaining color, the reaction mixture was quenched with 
MeOH (1 mL), stirred for 30 min, water (1 mL) was added and the reaction mixture was 
warmed to RT. The solution was evaporated under reduced pressure, purified by a 
column loaded with Amberlite® IR-120 (H+ form), by column chromatography 
(CH2Cl2:MeOH 8:2) and crystallization (Et2O:MeOH) to afford kirkamide (56) (12.8 mg, 
59%) as a white solid: Rf = 0.13 (CH2Cl2:MeOH 8:2). The analytical data were in good 
agreement with those reported for isolated product. The chemical shifts of the OH 
protons could be assigned. 
  
                                                
192 X. Lu, G. Arthur, R. Bittman, Org. Lett. 2005, 7, 1645–1648. 
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Table 18. NMR spectroscopic data (500 MHz, DMSO-d6) of the synthetic  
kirkamide (56). 
C/N/O no. δC, type δH (3JH-H in Hz) 
1 121.5, CH 5.63, dq[a] (4.8, 1.5) 
2 64.3, CH 3.98, m 
OH(1)  4.80, d (5.5) 
3 53.1, CH 3.63, ddd (10.9, 8.1, 3.9) 
NH  7.35, d (8.1) 
4 70.4, CH 3.55, ddd (10.9, 7.1, 5.2) 
OH(2)  4.55, d (5.2) 
5 72.9, CH 3.79, ddd[a] (7.1, 6.1, 0.8) 
OH(3)  4.97, d (6.1) 
6 142.5, C  
7a 60.9, CH2 3.98, m 
7b  3.98, m 
OH(4)  4.63, t (5.6) 
8 169.3, C  
9 23.0, CH3 1.85, s 
[a] Apparent splitting pattern. 
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Crystallographic Data of TBS Protected Cyclohexanone 80 
 
Table 1. Crystal data for 80 
Formula                           C28H39NO5Si 
Formula weight                    497.71 
Z, calculated density             6, 1.179 Mg · m-3 
F(000)                            1608.001 
Description and size of crystal   colourless needle, 0.020 · 0.040 · 0.210 
mm3 
absorption coefficient            1.028 mm-1 
min/max transmission              0.98 / 0.98 
Temperature                       123K 
Radiation(wavelength)             Cu Kα (λ = 1.54178 Å) 
Crystal system, space group       hexagonal, P 65 
a                                 12.8301(10) Å 
b                                 12.8301(10) Å 
c                                 29.514(3) Å 
α                                 90° 
β                                 90° 
γ                                 120° 
V                                 4207.4(4) Å3 
min/max Θ                         3.978° / 69.031° 
number of collected reflections   29531 
number of independent reflections  5119 (merging r = 0.039) 
number of observed reflections    4252 (I>2.0σ(I)) 
number of refined parameters     393 
r 0.0403 
rW   0.0551 
Goodness of fit  1.1114 
Flack parameter 0.01 (4)   
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6.2.2. Streptol Glucoside 
6.2.2.1. Isolation and Structure Elucidation 
Bioassay-Guided-Fractionation of Streptol Glucoside 
The extract from the leaves of Psychotria kirkii (88.6 mg) that was purified with a 
aminopropyl SPE, was dissolved in H2O (2.2 mL), filtered and separated using semi-
preparative HPLC runs (Phenomenex Synergi Hydro-RP 10 µm; 150 x 10 mm at a flow 
of 2 mL/min). The column was equilibrated for 10 min with 100% H2O and the 
MeCN/H2O applied gradient was changed from 0% to 1.0% and finally to 100% MeCN 
in 20 and 10 min, respectively. The column was then washed with MeCN for 10 min. The 
activities of the fractions were tested in the lettuce seeds growth-inhibition assay 
described in a section below (table 19). The most potent fraction (P_II_3) was chosen for 
further separation using the same analytical method affording a fraction containing 
streptol glucoside (57) (0.6 mg) as a white solid with a retention time of 7 min. The 
HPLC separation procedure was repeated on a crude extract of the leaves of Psychotria 
kirkii (1.23 g) to afford streptol glucoside (57) (1.13 mg). 
Streptol glucoside (57) as a white solid; HRMS (ESI) calc. for C13H21O10– [M–H]–: 
337.1140; found [M–H]–, 337.1144. 
Table 19. Bioassay-guided fractionation of streptol glucoside (57). 
Fraction Weight [mg] Amount tested [mg] Activity 
P_II_1 36.71 0.87 - 
P_II_2 31.32 0.53 + 
P_II_3 2.09 0.56 ++ 
P_II_4 0.59 0.25 - 
P_II_5 1.18 0.40 - 
P_II_6 0.09 0.02 - 
P_II_7 6.32 0.64 - 
P_II_8 1.38 0.07 - 
+: active, ++: very active, -: no effect could be detected. 
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Table 20. NMR Spectroscopic data (500 MHz, D2O) of streptol glucoside (57). 
C no. δH (3JH-H in Hz) COSY NOESY 
1 5.92, dd (5.4, 1.1) 2 2, 3, 7b 
2 4.27, t (4.8) 1, 3 1, 3, 
3 3.64, dd (10.5, 4.2) 2  4 2, 4 
4 3.89, d (10.7, 7.2) 3, 5 3, 5, 1’ 
5 4.26, d (8.3) 4 4, 1’ 
6    
7a 4.29, dd (13.0, 0.8) 7b 7b, 1’ 
7b 4.18, d (13.9) 7a 7a, 1’ 
1’ 4.63, d (8.0) 2’ 4, 5, 7, 2’, 3’, 4’ 
2’ 3.33 dd (9.4, 8.0) 1’, 3’ 1’, 3’, 4’ 
3’ 3.51, t (9.3) 2’, 4’ 1’, 2’ 
4’ 3.41, t (9.4) 3’, 5’ 1’, 2’, 6’a, 6’b 
5’ 3.52, ddd (9.9, 6.1, 2.3) 6’ 6’a, 6’b 
6’a 3.72, dd (12.4, 6.2) 5’, 6’b 4’, 6’b 
6’b 3.91, dd (12.6, 2.2) 6’a 6’b, 5’ 
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Table 21. NMR Spectroscopic data (500 MHz, DMSO-d6) of streptol glucoside 
(57). 
C no. δC, type δH (3JH-H in Hz) COSY HMBC[a] 
1 123.1, CH 5.69, d (5.3) 2, 5, 7a, 7b 3, 5, 7 
2 65.5, CH 3.98, t (4.6) 1, 3 1, 3, 4, 6 
3 70.7, CH 3.26, dd (10.1, 4.0) 2, 4 4 
4 71.1, CH 3.68, d (10.1,7.0) 3, 5 3, 5 
5 84.3, CH 3.88, d (6.9) 1, 4, 7a 1, 4, 6, 4’ 
6 140.0, C    
7a 61.2, CH2 4.07, d (14.4) 7b 1, 6 
7b  4.02, d (14.3) 1, 7a 1, 6 
1’ 104.2, CH 4.3, d (7.9) 2’ 5 
2’ 73.6, CH 3.03 t (8.6) 1’, 3’ 1’, 3’ 
3’ 76.6, CH 3.18, t (9.5) 2’, 4’ 4’ 
4’ 70.2, CH 3.04, t (9.6) 3’, 5’ 3’, 5’, 6’ 
5’ 76.9, CH 3.21, ddd (9.2, 7.5, 1.8) 6’  
6’a 61.2, CH2 3.72, dd (11.2,1.4) 5’, 6’b  
6’b  3.40, dd (11.5, 7.1) 5’, 6’a 5’ 
[a] HMBC correlations are given from proton(s) stated to the indicated carbon atom. 
Biological Assay 
Growth Inhibition Assay of Lettuce Seeds 
The HPLC fractions (0.1 – 0.9 mg) were placed in a Petri dish (50 mm diameter) 
equipped with a filter paper (Whatman), H2O (1 mL) and lettuce seeds (Krachsalat 
Grazer Krauthäuptel 3, Migros, Switzerland) were added and the Petri dish sealed with 
Parafilm was incubated in the dark for one day. The control experiment was done in the 
same conditions by adding only H2O (1 mL) and in the positive control the crude extract 
of Psychotria kirkii was used. 
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6.2.3. Detection and Quantification of Kirkamide and Streptol Glucoside 
6.2.3.1. Detection of Kirkamide by GC-MS 
Whole leaves of several plants were grounded to a powder, macerated in methanol 
for 24 h, filtered and dried. Part of the extract was dissolved in water (500 µL), filtered, 
transferred into a HPLC vial and dried by lyophilization. MSTFA (Sigma) was added, the 
mixture was stirred for 30 min at 70°C, pyridine (dry, same volume as MSTFA) was 
added, and the reaction was filtered. Samples of 5 µL were analyzed on a Thermo 
ScientificTM TRACETM 1300 Series gas chromatograph equipped with a Thermo 
ScientificTM ISQTM Series Single Quadrupole mass spectrometer using a HP-Ultra-1 
column (Agilent Technologies, 25 m x 0.200 mm, 0.35 µm). The GC runs were 
performed using an initial temperature of 40°C (kept for 1 min) a ramp of 7 °C/min and a 
final temperature of 330°C (kept for 10 min). As a control, derivatization and GC 
analysis was also carried out with synthetic kirkamide and the data were used as 
analytical standard. 
6.2.3.2. Quantification by 1H NMR Spectroscopy 
A solution of maleic acid as internal standard (Sigma Aldrich, TraceCERT®) was 
prepared at a concentration of 0.52 µmol/mL in D2O (99.9% deuterated) and the NMR 
experiments were performed on a Bruker Avance III NMR spectrometer operating at 500 
MHz proton frequency. 
The protons chosen for maleic acid displayed a chemical shift between 6.30 - 6.20 
ppm, for asperuloside (86) between 5.997 - 5.981 ppm, for streptol glucoside (57) 
between 5.966 - 5.941 ppm and for kirkamide (56) between 5.887–5.874 ppm. The delay 
times were determined for these protons and values of 7.5 sec for maleic acid, 1.4 sec for 
asperuloside (86), 1.7 sec for streptol glucoside (57) and 2.2 sec for kirkamide (56) were 
found. The quantitative 1H NMR measurements were operating with a relaxation delay 
(D1) of 40 sec, a number of scans (ns) of 128 or 256, a spectral width (sw) of 1.2 ppm 
and a transmitter offset (O1) of 6 ppm. The water peak at 4.79 ppm was used as the 
reference for calibration of the maleic acid peak based on a second 1H NMR spectrum 
recorded for every measurement. The concentrations of asperuloside (86), streptol 
glucoside (57) and kirkamide (56) were calculated by comparing their peak integration 
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with the one measured for maleic acid. For the determination of kirkamide (56) in the P. 
kirkii leaves extract a mixing experiment was carried out by spiking with 40 µg of 
synthetic kirkamide (56). The leaves extracts, prepared as described for the GC 
measurement, were weighted using an analytical balance.  
Dried leaves from Psychotria kirkii (1.0507 g) were ground to small pieces in a 
mortar with liquid nitrogen. The green powder was stirred in an aq. soln. of MeOH (80%, 
100 mL) at rt for 18 h and in an aq. soln. of MeOH (50%, 100 mL) at RT for 18 h. The 
solutions were filtered, combined, evaporated under reduced pressure and dried by 
lyophilization to afford the crude extract (372 mg) as a green powder. A portion of the 
crude extract (9.75 mg) was used for NMR measurement. The integration of kirkamide 
was corrected by removing a part of a peak, from an unknown compound, possessing a 
ddd multiplet pattern and a spectra was recorded with co-addition of kirkamide (40 µg) to 
confirm the result. 
The same procedure was applied on the leaves of Psychotria punctata (548.0 mg) 
using different volumes for extraction, 50 mL instead of 100 mL. A portion (17.23 mg) of 
the crude extract (191.4 mg) was used for the NMR measurement. 
Similar procedures were used for the quantification of the natural products in the 
different parts of the plant. The different extracts were weighed and suspended in a 
solution of maleic acid (0.52 µmol/mL) in D2O (500 µL). 
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6.3. Experimental Fragin 
6.3.1. Isolation and Structure Elucidation of Fragin 
Genome-driven Bioassay-Guided Fractionation of Fragin 
After a comparison of the extracts from B. cenocepacia H111 and the mutant 
ΔhamD fragin (133) was chosen for the separation and the antifungal activity was tested. 
The separation was achieved by HPLC using a reversed phase column (Phenomenex 
Gemini-NX 5 µm; 250 x 4.6 mm with flow of 1 mL/min). The column was equilibrated 
for 5 min with 20% MeCN/H2O and the MeCN/H2O applied gradient was changed from 
20% to 80% and finally to 100% MeCN in 15 and 1 min, respectively. The column was 
then washed with MeCN for 8 min. A peak at 14.8 min, identified only in the wild type 
strain, was isolated and the antifungal activity was tested. The procedure was repeated 
using multiple HPLC runs with the same conditions described above and fragin (1.4 mg) 
was obtained as a white solid. NMR experiments were performed in CDCl3 that was 
filtered through aluminum oxide (activated, basic). By dissolving fragin (1.4 mg) in 
warm toluene (40°C) and cooling slowly to RT, a single crystal was obtained. Using a 
similar procedure, Christophe Daeppen obtained a single crystal of synthetic fragin (133) 
where the absolution configuration could be determined by X-ray crystallography 
structure analysis. The conformations of the synthetic and isolated products were found 
to be identical due to the negative values for the optical rotation obtained in both cases as 
well as the same single crystal X-ray structure. 
Fragin (133): white solid; MS (ESI) [M+H]+: 244.2 and 274.2; [M–H]–: 272.2; [α]D  
–12.5° (c 0.1, MeOH); 1HNMR (500 MHz, CDCl3) δ 11.72 (s, 1H), 5.69 (s, 1H), 4.20 
(td, J = 9.2, 3.1 Hz, 1H), 3.86 (ddd, J = 14.4, 6.0, 3.1 Hz, 1H), 3.60 (ddd, J = 14.4, 9.4, 
6.1 Hz, 1H), 2.25 - 2.17 (m, 1H), 2.14 (td, J = 7.4, 1.8 Hz, 2H), 1.61 - 152 (m, 9H),  
1.31 - 1.23 (m, 8H), 1.07 (d, J = 6.8 Hz, 3H), 0.90 (d, J = 6.7 Hz, 3H), 0.87 (t, J = 6.8 Hz, 
3H); 13C NMR (126 MHz, CDCl3) δ 173.7, 78.0, 39.1, 36.7, 31.8, 29.3, 29.1, 29.1, 25.7, 
22.7, 19.2, 18.9,14.2 
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Table 22. NMR spectroscopic data (CDCl3, 500 MHz) of fragin (133). 
C/N no. δC, type δH (3JH-H in Hz) COSY 
1+1’ 18.9, CH3 0.90, d (6.7) 2 
 19.2, CH3 0.87, d (6.8) 2 
2 29.1, CH 2.25 - 2.17, m 1, 3 
3 78.0, CH 4.20, td (9.2, 3.1) 2, 4a, 4b 
NOH  11.72  
4 39.1, CH2 3.86, ddd (14.4, 6.0, 3.1) NH, 3, 4b 
  3.60, ddd (14.4, 9.4, 6.1) NH, 3, 4a 
NH  5.69 4a, 4b 
5 C   
6 36.7, CH2 2.14, td (7.4, 1.8) 7 
7 25.7, CH2 1.61 - 1.52, m 6, 8-11 
8 - 11 22.7, 29.1, 29.3, 
31.8 (4x, CH2) 
1.31 - 1.23, m 7, 12 
12 14.2, CH3 0.87, t (6.8) 8-11 
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Crystallographic Data of Fragin 
 
Formula                           C13H27N3O3 
Formula weight                   273.38 
Z, calculated density          4, 1.145 Mg · m-3 
F(000)                            600 
Description and size of crystal   colourless block, 0.050 · 0.110 · 0.190 
mm3 
Absorption coefficient            0.660 mm-1 
Min/max transmission              0.93 / 0.97 
Temperature                       123K 
Radiation(wavelength)             Cu Kα (λ = 1.54178 Å) 
Crystal system, space group       orthorhombic, P 21 21 21 
a                                 5.6786(4) Å 
b                                 9.1130(6) Å 
c                                 30.633(2) Å 
α                                 90° 
β                                 90° 
γ                                 90° 
V                                 1585.26(19) Å3 
Min/max Θ                         5.063° / 68.828° 
Number of collected reflections   19332 
Number of independent reflections  2887 (merging r = 0.036) 
Number of observed reflections    2847 (I>2.0σ(I)) 
Number of refined parameters      173 
r                                 0.0290 
rW                                0.0241 
Goodness of fit                   0.9594 
Flack 0.08(6) 
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6.3.2. Biosynthetic Investigations 
General HPLC-MS Analysis 
The solvent system used was composed of MeCN and H2O both containing 0.1% of 
formic acid. The separation was achieved by HPLC using a reversed phase column 
(Phenomenex Gemini-NX 5 µm; 250 x 4.6 mm with a flow of 1 mL/min). The column 
was equilibrated for 5 min with 2% MeCN/H2O and the MeCN/H2O applied gradient was 
changed from 2% to 100% in 25 min. The column was then washed with MeCN for 7 
min. For the experiments involving salts, during 10 min after injection the flow was 
redirected to a waste channel before the UV and MS detectors to avoid salt contamination 
of the MS. The mass chromatograms were recorded in positive and negative ion modes 
and after each sample at least one wash run was performed. 
HPLC Analysis of Synthetic Intermediates 
Intermediates were synthesized by Christophe Daeppen on the basis of a suggested 
fragin (133) biosynthesis and they were used as analytical standards for HPLC-MS (ESI 
+ mode) measurements. The amine 143 was detected at 11.6 min with a m/z of 229 Da, 
the hydroxylamine 144 at 12.3 min with a m/z = 245 Da, the oxime 145 at 19.1 with a m/z 
= 243 Da, fragin 133 at 20.3 min with a m/z = 244 Da and 274 Da, the ketone 142 at 20.3 
min with a m/z = 228, the nitro 147 at 22.3 with a m/z = 300 Da and the nitroso 146 at 
28.4 min with a m/z = 243 Da. 
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Reactivity of the Hydroxylamine 144 with Various Salts 
To a solution of the hydroxylamine 144 (0.5 µM, 1.5 mL) in aq. MeOH (50%) a 
selected salt was added obtaining a final molarity of 67 µM and the solution was filtered. 
The salts used for the test were NH4OOCH, NH4NO3, NaNO3, NaNO2 and NH4OAc. 
Reactivity of the Hydroxylamine 144 in Various Conditions 
For each experiment a solution of the hydroxylamine 144 (0.9 µM) in MeOH was 
used. Aq. phosphate buffer (10 mM) solns. at different pH (6.5 and 7.85) were prepared 
and yeast extract was obtained from Sigma Aldrich. The reactivity of the hydroxylamine 
144 was tested in different conditions, which are listed in table (23). 
 
Table 23. Reactivity of the hydroxylamine 144 in various conditions. 
Experiments 1 2 3 4 5 6 7 8 9 
144 (0.9 µM, mL) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
H2O (mL) 0.5 0.5        
Buffer (pH = 6.5, mL)   0.5       
Buffer (pH = 7.85, mL)    0.5     0.5 
NaNO2 (mg)  6.9 6.9 6.9      
Yeast extract (mg)     1.4 5    
    
Synthesis of 15N-labeled Fragin 
To a solution of the hydroxylamine 144 (1.4 µM, 0.5 mL) in MeOH Na15NO2 and 
water (0.5 mL) were added. The solution was filtered and analyzed by HPLC-MS (ESI 
positive mode). Three data points were recorded: after the preparation of the sample, after 
24 h and after 44 h. 
Detection of Nitrate/Nitrite  
To detect nitrate and nitrite Merckoquant® test stripes (Merck) were used. A pink 
color at the top indicated the presence of nitrite and at the bottom the presence of nitrate. 
Solutions of yeast extract were prepared by dissolving 1 g in 2, 4, 8 and 16 mL of water 
and as a negative control water was chosen. 
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6.4. Cyclic Peptides Isolated from Cyanobacteria 
6.4.1. Balgacyclamides 
6.4.1.1.Extraction and Isolation 
M. aeruginosa EAWAG 251 was obtained from the EAWAG (Swiss Federal 
Institute of Aquatic Science and Technology) Culture Collection of Cyanobacteria, 
currently at the University of Basel. This strain is identical as the M. aeruginosa PCC 
7820 from the Pasteur Culture Collection of Cyanobacteria, Paris, France. The strain was 
grown in a 20 L batch reactor (Zehnder medium193) with continuous aeration and a 
light/dark cycle of 12:12 h. The biomass was isolated by centrifugation and subsequently 
kept frozen until extraction. 
The biomass was extracted with 100% MeOH and then twice with 60% MeOH. 
The extract was separated from the biomass by centrifugation. MeOH was removed from 
the combined extracts by evaporation under reduced pressure and the mixture was then 
dried by lyophilization. The resulting powder was dissolved in 80% MeOH and 
centrifuged to remove remaining particles. The solutions were then sequentially loaded to 
a C18 SPE column (Supelco Discovery DSC-18, 10 g, conditioned with 10% aqueous 
MeOH), and eluted with 30%, 60%, 80%, and 100% aqueous MeOH solutions. MeOH 
was removed from the combined extract by evaporation under reduced pressure and the 
mixture was then dried by lyophilization. The resulting oil from the 80% MeOH fraction 
was redissolved in 80% MeOH, and the compounds were isolated using multiple C18 RP-
HPLC runs (Phenomenex Gemini C18 5 µm; 150 × 10 mm). The gradient MeOH/H2O at a 
flow of 5 mL/min was 35% MeOH to 100% over 30 min. The column was then washed 
for 10 min with 100% MeOH and stabilized for the next cycle during 10 min with 35% 
MeOH. MeOH was removed under reduced pressure and the compounds were then dried 
with a stream of N2. Balgacyclamides A, B and C eluted at 17.4, 13.2 and 14.3 min 
respectively. Balgacyclamide B and C were further purified by HPLC using multiple runs 
on an analytical column C18 RP-HPLC (Phenomenex Gemini C18 5 µm; 150 × 4.6 mm). 
The gradient MeCN/H2O at a flow of 1 mL/min was 30% MeCN to 100% over 60 min. 
The column was then washed for 10 min with 100% MeCN and stabilized for the next 
                                                
193 P. Mian, J. Heilmann, H. R. Bürgi, O. Sticher, Pharm. Biol. 2003, 41, 243–247. 
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cycle in 10 min with 30% MeCN. Balgacyclamide B and C eluted at 10.0 and 11.2 min 
respectively. The compounds were dried as described above. The isolation yields of the 
balgacyclamides A (177), B (178) and C (179) were 0.55 mg, 0.15 mg and 0.80 mg per 
15 liters of culture, respectively. 
6.4.1.2. Structure Elucidation 
Ozonolysis 
Each compound (0.1 mg, 0.2 µmol) was dissolved in dry CH2Cl2 (0.3 mL), 
ozonized at RT for 5 min and the solvent was removed under a stream of N2. 
Hydrolysis  
Each ozonized compound was hydrolyzed in a closed microwave tube by adding 
freshly prepared aq. HCl soln. (6 M, 0.5 mL) and the reaction was let at 108 °C for 20 h. 
The solvent was concentrated by with a gentle stream of N2 and removed by 
lyophilization and then the residue was dissolved in H2O (0.06 mL). 
Marfey’s Derivatiziation and Analysis181 
Half of the solution of the hydrolyzed compounds was treated with a FDAA soln. 
(1% in acetone, 0.03 mL) and an aq. Et3N soln. (6%, 0.03 mL), the reaction was let at 
50°C for 1 h in a closed HPLC vial. The reaction was quenched with an aq. acetic acid 
soln. (5%, 0.03 mL) and the solvent was removed by lyophilization. The residue was 
solved in MeOH (0.03 mL) and analyzed by RP-HPLC using an Agilent Zorbax SB-C18 
(3.55 µm 150 x 2.1 mm). The mobile phases were A, an aq. acetic acid soln. (5%), and B, 
MeCN/MeOH (9:1) mixture. The column was stabilized for 20 min with 5% of B, then 
the gradient went from 5-50% in 50 min and the column was washed with 100% of B for 
20 min. The flow was set at 0.25 mL/min and the temperature of the column oven at 
50°C. 
By comparison of the retention times of the derivatized commercially available 
amino acids the configuration can be determined except for isoleucine. The retention 
times (min) for the derivatized standard amino acids were: L-Ala 28.25; D-Ala 32.21; L-
Val 35.89; D-Val 40.64; L-Phe 41.01; D-Phe 46.39; L-Thr 21.09; L-allo-Thr 22.22; D-
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allo-Thr 24.73; D-Thr 28.89; L-Ile 40.47; L-allo-Ile 40.45; D-Ile 47.38 and D-allo-Ile 
47.46. 
TFA Derivatization and GC Analysis 
The hydrolyzed compound solution (0.03 mL) was transferred to a GC vial and the 
solvent was evaporated. The residue was treated with trifluoroacetic acid anhydride (0.03 
mL) at RT for 12 h and quenched with MeOH (0.03 mL). The configuration of isoleucine 
was determined after analyses on a chiral GC column (Permabond-L-Chirasil-Val; 25 m, 
0.25 mm, Marcherey-Nagel, Düren, Germany) with the following conditions: 2 min at 80 
°C, 80 to 180 °C at rate of 8 °C min-1 and 10 min at 180 °C with a split ratio 10:1, at a 
flow of 1mL/min and a FID detector at 250 °C. 
The four commercially available stereoisomers of isoleucine were derivatized with 
the same method as presented above and the retention times (min) were: D-allo-Ile 6.20, 
L-allo-Ile 6.35, D-Ile 6.39 and L-Ile 6.45. 
Absolute Configuration 
Balgacyclamide A (177): from ozonolysis−hydrolysis−Marfey D-Ala, L-Thr 
(confirmed by a co-injection with L-allo-Thr), L-Val and D-Ile or D-allo-Ile and from 
ozonolysis−hydrolysis−TFA D-allo-Ile (confirmed by a co-injection with D-Ile). 
Balgacyclamide B (178): from ozonolysis−hydrolysis−Marfey D-Ala, L-Thr, L-Val 
and D-Ile or D-allo-Ile and from ozonolysis−hydrolysis−TFA D-allo-Ile (confirmed by a 
co-injection with D-Ile). 
Balgacyclamide C (179): from ozonolysis−hydrolysis−Marfey L-Thr, L-Phe and D-
Ile or D-allo-Ile and from ozonolysis−hydrolysis−TFA D-allo-Ile (confirmed by a co-
injection with D-Ile). 
6.4.1.3. Activity Assays 
Plasmodium falciparum, Trypanosoma b. rhodesiense and cytotoxicity in vitro 
assay were performed according to procedures previously described.173 
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6.4.2.Glycolipopeptides 
6.4.2.1.Extraction and Isolation 
Sources and Cultivation of M. aeruginosa EAWAG 251 
The cyanobacteria strain Tolypothrix distorta var. symplocoides EAWAG 224a was 
obtained from the EAWAG (Swiss Federal Institute of Aquatic Science and Technology) 
Culture Collection of Cyanobacteria, currently at the University of Basel. The 
cyanobacteria cultures were grown in 250 mL culture flasks, 20 L tank (EAWAG 
224a_VI) and a 500 mL Erlenmeyer in Z2 medium with continuous aeration and a 
light/dark cycle of 12:12 h.193 The biomass was isolated by centrifugation. 
Extraction and Isolation 
The biomass of EAWAG 224a culture was collected by centrifugation at 9000 G 
for 30 min, followed by decantation of the media. For the extraction MeOH (100 mL) 
was added to the residual biomass and a sonification (3 x 3 min), a centrifugation at 9000 
G for 30 min and filtration over a Büchner filter were performed. This procedure was 
repeated with MeOH (100 mL) and with an aq. MeOH soln. (40%, 2 x 100 mL). The 
combined filtrates were evaporated under reduced pressure at 35°C and lyophilized to 
yield a green crude extract. 
The crude extract (90.3 mg) was dissolved in an. aq. MeOH soln. (60%) and eluted 
with an aq. MeOH soln. (80%) through a RP-SPE column (Supleco Discovery DSC-18, 
500 mg) that was washed with MeOH and H2O and conditioned with an aq. MeOH soln. 
(80%). The filtrate was evaporated under reduced pressure at 30°C and resuspended in an 
aq. MeOH soln. (60%). The green liquid was centrifuged (Eppendorf Centrifuge 5415D) 
for 5 min at 9000 G, filtered and transferred into a HPLC vial. The extract was purified 
by HPLC using a RP preparative column (Phenomenex Gemini-NX 5 µm; 75 x 21.1 mm, 
flow of 9 mL/min). The column was equilibrated for 5 min with 10% MeCN, then the 
MeCN/H2O gradient was changed from 10% to 60% to 100% MeCN respectively in 25 
to 3 min and the column was then washed with MeCN for 14 min. Multiple HPLC runs 
were conducted to obtain the fraction VIII_F5 (eluted between 18.4 min to 19.3 min, 0.72 
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mg), which was chosen for further separation. All fractions were evaporated under 
reduced pressure at 35°C.  
The fraction VIII_F5 (0.72 mg) was dissolved in an aq. MeOH soln. (60%), filtered 
and transferred into an HPLC vial. The sample was purified by HPLC using an analytical 
column (Phenomenex Synergi Hydro-RP 4 µm; 150 x 4.6 mm, flow of 1 mL/min). The 
column was equilibrated for 5 min with 40% MeCN, then the MeCN/H2O gradient was 
changed from 40% to 50% to 100% MeCN in respectively 35 to 2 min and the column 
was then washed with MeCN for 9 min. Multiple HPLC runs were conducted to obtain 
the fractions GLCP-1 (182) (eluted between 13.2 min to 13.5 min, 0.29 mg) and GLCP-2 
(183) (eluted between 13.8 min to 14.5 min, 28.45 mg, 0.4 mg), which were lyophilized.  
6.4.2.2. Structure Elucidation 
Synthesis N-methylated Threonines 
 
General procedure186 
The synthesis route was identical for the three non-proteinogenic threonines and here is 
described, as an example, the procedure for D-threonine (193). 
 
SOCl2 (0.26 mL, 426 mg, 3.58 mmol) was added to MeOH (1 mL, 24.7 mmol) 
cooled at 0°C and the mixture was stirred at 0°C for 30 min. D-Threonine (193) (100 mg, 
0.83 mmol) was added to the reaction in one portion and after 10 min the mixture was 
∗ ∗ OH
OH O
NH2
SOCl2, MeOH, 0°C
then RT, 12 h
∗ ∗ O
OH O
NH2.HCl
TFA, DCM, CH2O, 0°C
then RT, 8 h ∗
∗
O
O
NH
TFA, DCM, SiHEt3, 0°C
then RT, 24 h
O
∗ ∗ O
OH O
HN
HCl, 110°C, 16 h
∗ ∗ OH
OH O
HN
OH
OH O
NH2
SOCl2, MeOH, 0°C
then RT, 12 h
O
OH O
NH2.HCl
193 194
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warmed at RT, stirred for 12 h and evaporated under reduced pressure to give D-threonine 
methylester hydrochloride (194). The compound was used in the next step without any 
further purification. 
 
D-Threonine methylester hydrochloride (194) was dissolved in CH2Cl2 (12.5 mL) 
and cooled at 0°C in an ice bath for 20 min. An aq. TFA soln. (0.1 M, 12.5 mL, 1.25 
mmol) was added to the solution and the biphasic mixture was stirred vigorously for 15 
min at 0°C. An aq. formaldehyde soln. (37%, 77.5 µL, 1.04 mmol) was added dropwise 
to the mixture. After 10 min the mixture was stirred for 8 h at RT. The reaction mixture 
was neutralized with a sat. aq. NaHCO3 soln. extracted with CH2Cl2 (4 x 15 mL), the 
organic layers were combined, dried over NaSO4 and evaporated under reduced pressure 
to yield the oxazolidine 195. The compound was used in the next step without any further 
purification. 
 
To a solution of the crude oxazolidine 195 (52.45 mg) in CH2Cl2 (4.9 mL) at 0°C, 
TFA (4.9 mL, 66.2 mmol) cooled at 0°C was added followed by a dropwise addition of 
triethylsilane (0.49 mL, 3.04 mmol) and after 10 min the reaction was stirred for 24 h at 
RT. The mixture was evaporated under reduced pressure. The yellow oil was resuspended 
in an aq. HCl soln. (1 M) and extracted with pentane. The aq. layer was collected and 
evaporated under reduced pressure giving an oil which was then directly used for the 
following hydrolysis in an aq. HCl soln. (6 M, 1 mL) at 110°C for 16 h. The solvent was 
evaporated under reduced pressure yielding a 2:1 mixture (41.5 mg), interpreted from 
NMR analysis, of N-Me-D-threonine 196 (27.6 mg, 0.207 mmol, 5.8 % over 4 steps) with 
N,N-dimethyl-D-threonine 197 (13. 8 mg, 0.094 mmol, 2.6% over 4 steps). The analytical 
data were in agreement with those reported.180 
O
OH O
NH2.HCl
TFA, CH2Cl2, CH2O, 0°C
then RT, 8 h
O
O
NHO
194 195
O
O
NH
TFA, DCM, SiHEt3, 0°C
then RT, 24 hO
195
OH
OH O
HN
196
OH
OH O
N
197
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Hydrolysis 
GLCP-2 (183) (150 µg) was transferred into a microwave tube with MeOH and the 
solvent was evaporated under reduced pressure at 40°C. A freshly prepared aq. HCl soln. 
(6 M, 275 µL) was added and the reaction was degassed with argon. Then the reaction 
was stirred at 108°C for 24 h. The solvent was removed under a gentle stream of N2 at 
40°C. The residue was dissolved in H2O (0.5 mL), transferred into a vial and dried by 
lyophilisation. 
Marfey’s Derivatization and Analysis of GLCP-2  
The procedure of the Marfey’s derivatization was identical as the one described for 
the structure analysis of the balgacyclamides. 
The retention times of the derivatized standard amino acids were compared to the 
values observed for the derivatized amino acid from GPLC-2 (183) confirming the 
presence of L-tyrosine, D-tyrosine, D-glutamic acid, L-threonine (confirmed by coinjection 
with L-threonine), D-threonine, D-allo-threonine, glycine and N-Me-L-allo-threonine 
(confirmed by coinjection with N-Me-L-allo-threonine and N-Me-D-threonine). The 
retention times (min) for the derivatized standard amino acids were: L-Tyr 
24.33/48.92194; D-Tyr 25.19/54.09194; L-Gln 20.09; D-Gln 21.65; L-Glu 25.67; D-Glu 
22.27; L-Thr 19.99; D-Thr 26.58; L-allo-Thr 21.10; D-allo-Thr 23.90; Gly 22.51; N-Me-L-
Thr 22.24; N-Me-D-Thr 24.97; N-Me-L-allo-Thr 28.54; N-Me-D-allo-Thr 29.25 
NMR Spectroscopy Analysis of GLCP-2  
GLCP-2 (183) (0.4 mg) was dissolved in CD3OD (35 µL) and transferred into a 
NMR capillary tube (1.7 mm). NMR experiments (1H-NMR, COSY, TOCSY, NOESY 
and HSQC) were measured on 600.13 MHz equipped with a 1.7 mm TCI cryoprobe. 
Activity Assays 
Plasmodium falciparum, Trypanosoma b. rhodesiense and cytotoxicity in vitro 
assay were performed according to procedures previously described.173 
 
                                                
194 The value are for threnonine containing two Marfey’s reagent 
!
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1H> 1H!COSY!NMR!spectrum!of!streptol!glucoside!(57)!in!DMSO>d6 !(600!MHz).!
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13C!NMR!Spectrum!of!streptol!glucoside!(57)!in!DMSO>d6 !(600!MHz).!
!
!
197!
1H!NMR!Spectrum!of!streptol!glucoside!(57)!in!D2 O!(500!MHz).!
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GC!spectrum!of!kirkamide!(56)!after!MSTFA!derivatization!and!MS!spectrum!from!400!to!600!m
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A
AAAAAAAAAAAAAAAAA
AA
AAAAAAAAA
AAAAA
AAAA
333333333333A33A33
AAAAAA
AAA3AAAA3A
AAAA
:
AA
3303330333033
33
33
33
33
33
33
36
37
38
33
33
33
33
33
33
33
36
37
38
33
33
AAA
A3)A
AA)
3
333333333
333333333
333333333
333333333
333333333
633333333
733333333
833333333
333333333
3333333333
3333333333
3333333333
3333333333
3333333333
:AAAAAeA3AAAAAAAAA
37073
37038
33033
38033
33036
33033
38038
37033
36036
33038
33073
33033
33073
38063
37033
36036
33083
33033
33033
33083
33076
:
:A
303893
A A
33A
A3
AAAAAA
AAAA
A
A
AAA
AAAAAA
AAAAA
AAAA
3#3333
:
AA
37073
A:A
3
:
:A
703396
AA
]3]3]33]3A39
 3AAAA3A
]3]330330633033]
333
333
333
333
333
333
363
373
383
333
333
333
333
333
333
333
363
373
383
333
633
A
3A
3
3333333
3333333
3333333
3333333
3333333
6333333
7333333
:AAAAAeA3AAAAAAAAA
363037363038
388036
377033
363033
387033
378033
383036
373033373036
333033
373033
333033
363037
373036
336033
333036
366033
333033
333033
383033
333033
363033
333033
333033
363033
333033
337088
333033
333073!
!
200!
GC!spectrum!of!kirkamide!(56)!after!MSTFA!derivatization!and!MS!spectrum!of!the!peak!a!27.38!min.!
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GC!spectrum!of!kirkamide!(56)!after!MSTFA!derivatization!and!MS!spectrum!from!400!to!600!m
/z!of!the!peak!a!27.38!min.!
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GC!spectrum!of!Psychotria/hum
ilis!leaves!extract!after!MSTFA!derivatization!and!MS!spectrum!from!400!to!600!m
/z!of!the!peak!a!27.29!min.!
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GC!spectrum!of!Psychotria/hum
ilis!leaves!extract!after!MSTFA!derivatization!and!MS!spectrum!from!400!to!600!m
/z!of!the!peak!a!27.63!min.!
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GC!spectrum!of!Psychotria/verschuerenii/leaves!extract!after!MSTFA!derivatization!and!MS!spectrum!from!400!to!600!m
/z!of!the!peak!a!27.28!min.!
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GC!spectrum!of!Psychotria/verschuerenii!leaves!extract!after!MSTFA!derivatization!and!MS!spectrum!from!400!to!600!m
/z!of!the!peak!a!27.64!min.!
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GC!spectrum!of!Psychotria/kirkii!leaves!extract!after!MSTFA!derivatization!and!MS!spectrum!from!400!to!600!m
/z!of!the!peak!a!27.25!min.!
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GC!spectrum!of!Psychotria/kirkii!leaves!extract!after!MSTFA!derivatization!and!MS!spectrum!from!400!to!600!m/z!of!the!peak!a!27.62!min.!
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GC!spectrum!of!Psychotria/pum
ila/leaves!extract!after!MSTFA!derivatization!and!MS!spectrum!from!400!to!600!m
/z!of!the!peak!a!27.27!min.!
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GC!spectrum!of!Psychotria/pum
ila/leaves!extract!after!MSTFA!derivatization!and!MS!spectrum!from!400!to!600!m
/z!of!the!peak!a!27.62!min.!
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GC!spectrum!of!Psychotria/punctata/leaves!extract!after!MSTFA!derivatization!and!MS!spectrum!from!400!to!600!m
/z!of!the!peak!a!27.30!min.!
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N
M
R
 Spectra for the Q
uantification of K
irkam
ide, Streptol glucoside and A
speruloside 
1H!NMR!Spectrum!of!leaves!extract!from!Psychotria/kirkii!in!D2 O!(500!MHz).!
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1H!NMR!Spectrum!of!shoot!extract!from!Psychotria/kirkii!in!D2 O!(500!MHz).!
!
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1H!NMR!Spectrum!of!root!extract!from!Psychotria/kirkii!in!D2 O!(500!MHz).!
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1H!NMR!Spectrum!of!soil!extract!from!Psychotria/kirkii!in!D2 O!(500!MHz).!
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1H!NMR!Spectrum!of!Psychotria/kirkii/leaves!in!D2 O!(500!MHz).!
!
!
216!
1H!NMR!Spectrum!of!Psychotria/kirkii/leaves!mixed!with!kirkamide!(40!µg)!in!D2 O!(500!MHz).!
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1H!NMR!Spectrum!of!Psychotria/punctata/leaves!in!D2 O!(500!MHz).!
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N
M
R
 Spectra of Fragin 
1H!NMR!Spectrum!of!fragin!(133)!in!CDCl3 !(500!MHz).!!
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1H> 1H!COSY!NMR!Spectrum!of!fragin!(133)!in!CDCl3 !(500!MHz).!
!
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1H> 13C!HMQC!NMR!Spectrum!of!fragin!(133)!in!CDCl3 !(500!MHz).!
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1H!NMR!Spectra!comparison!between!synthetic!!and!isolated!fragin!(133)!in!CDCl3 !(500!MHz).!
Isolated!fragin!(133)!
Synthetic!fragin!(133)!
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13C!NMR!Spectrum!of!synthetic!fragin!(133)!in!CDCl3 !(500!MHz).!
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 C
hrom
atogram
s of the Proposed Interm
ediates Involved in the B
iosynthetis of Fragin 
M
ass chrom
atogram
s of B./cenocepacia!H
111/crude!extract!and!amine!143!extract!at!229!Da.!
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M
ass chrom
atogram
s of B./cenocepacia!H
111/crude!extract!and!hydroxylamine!144!extract!at!245!Da.!
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hydroxylamine!144((m
/z!=!245!Da)!
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crude!extract!
synthetic!compound!
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M
ass chrom
atogram
s of B./cenocepacia!H
111/crude!extract,!oxime!145!and!nitroso!146!extract!at!243!Da.!
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PL
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 and M
ass C
hrom
atogram
s of the H
ydroxylam
ine 144 in V
arious C
onditions 
M
ass chrom
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s of the reaction betw
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 top to bottom
: N
H
4 C
O
2 H
, N
H
4 O
A
c, N
aN
O
3 , N
aN
O
2 , N
H
4 N
O
3  and w
ithout). 
O
p
e
r a t o
r : D
i o
n
e
x
 
 T i m
e b
a
s e
: M
S Q _ S
u
m
m
i t
 
 
 S
e q
u
e
n
c e
: h y d
r o
x y l a
m
i n
e
P a g
e
 1
- 1
5 . 4 . 2 0 1 5  
 1 2 : 2 0  P M
S i m
o
n
_
r e p
o
r t
_ 4 / O
v e
r l a y
 P r i n t
C h
r o
m
e l e
o
n
 ( c )
 D
i o
n
e
x
 1 9 9 6
- 2 0 0 6
V e
r s i o
n
 6
. 8 0
 D U
1 1
c
 B u i l d
 3 1 9 9
 ( 1 9 0 6 7 0 )
O
v e r l a y
 o f
 S a m
p l e s  f r o
m
 I n t e g
r a t i o
n
 V i e w
- 2 0
' 0 0 0
' 0 0 0
1 8 0 ' 0 0 0 ' 0 0 0
1  
-
 h y d r o
x y l a
m
i n
e
 # 2 2  [ t i m
e
 c o
r r e
c t e d  b y
 
- 0 . 2 4 0  m
i n ]
N
H
4 O
O
C H
T I C
F _ 0 2
c o
u
n t s
1
1 0 0 . 0 - 2 0 0 0 . 0  m
/ z
- 2 0
' 0 0 0
' 0 0 0
1 8 0 ' 0 0 0 ' 0 0 0
2  
-
 h y d r o
x y l a
m
i n
e
 # 2 3  [ t i m
e
 c o
r r e
c t e d  b y
 
- 0 . 2 4 0  m
i n ]
N
H
4 O
A
c
T I C
F _ 0 2
c o
u
n t s
2
1 0 0 . 0 - 2 0 0 0 . 0  m
/ z
- 2 0
' 0 0 0
' 0 0 0
1 8 0 ' 0 0 0 ' 0 0 0
3  
-
 h y d r o
x y l a
m
i n
e
 # 2 4  [ t i m
e
 c o
r r e
c t e d  b y
 
- 0 . 2 4 0  m
i n ]
N
a N O
3
T I C
F _ 0 2
c o
u
n t s
3
1 0 0 . 0 - 2 0 0 0 . 0  m
/ z
- 1 0
' 0 0 0
' 0 0 0
1 0 0 ' 0 0 0 ' 0 0 0
4  
-
 h y d r o
x y l a
m
i n
e
 # 2 5  [ t i m
e
 c o
r r e
c t e d  b y
 
- 0 . 2 4 0  m
i n ]
N
a N O
2
T I C
F _ 0 2
c o
u
n t s
4
1 0 0 . 0 - 2 0 0 0 . 0  m
/ z
- 2 0
' 0 0 0
' 0 0 0
1 8 0 ' 0 0 0 ' 0 0 0
5  
-
 h y d r o
x y l a
m
i n
e
 # 2 6  [ t i m
e
 c o
r r e
c t e d  b y
 
- 0 . 2 4 0  m
i n ]
N
H
4 N O
3
T I C
F _ 0 2
c o
u
n t s
5
1 0 0 . 0 - 2 0 0 0 . 0  m
/ z
0 . 0
2 . 0
4 . 0
6 . 0
8 . 0
1 0 . 0
1 2 . 0
1 4 . 0
1 6 . 0
1 8 . 0
2 0 . 0
2 2 . 0
2 4 . 0
2 6 . 0
2 8 . 0
3 1 . 7
- 2 0
' 0 0 0
' 0 0 0
1 6 0 ' 0 0 0 ' 0 0 0
6  
-
 h y d r o
x y l a
m
i n
e
 # 2 7  [ t i m
e
 c o
r r e
c t e d  b y
 
- 0 . 2 4 0  m
i n ]
H
2 O
+ h y d
r o
x y l a
m
i n
e
T I C
F _ 0 2
c o
u
n t s
m
i n
6
1 0 0 . 0 - 2 0 0 0 . 0  m
/ z
 
hydroxylamine!144!
oxime!145!fragin!(133)!
!
227!
H
PLC
 and m
ass chrom
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s extracted at 229, 243, 245 and 300 D
a of reaction betw
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O
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ithout buffer and w
ith buffer at pH
 = 6.5 and 7.85. 
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H
PLC
 and m
ass chrom
atogram
s extracted at 229, 243, 245 and 300 D
a of the reaction betw
een hydroxylam
ine 144 and N
aN
O
2  w
ith B
uffer at pH
 = 7.85. 
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C
om
parison of H
PLC
 chrom
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s of hydroxylam
ine 144 w
ith N
aN
15O
2  at three different reaction tim
es. 
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M
ass chrom
atogram
s extracted at 229 D
a of the reaction betw
een the hydroxylam
ine 144 and N
aN
15O
2  at three different reaction tim
es. 
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M
ass chrom
atogram
s extracted at 245 D
a of the reaction betw
een the hydroxylam
ine 144 and N
aN
15O
2  at three different reaction tim
es. 
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M
ass chrom
atogram
s extracted at 243 D
a of the reaction betw
een the hydroxylam
ine 144 and N
aN
15O
2  at three different reaction tim
es. 
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M
ass chrom
atogram
s extracted at 275 D
a of the reaction betw
een the hydroxylam
ine 144 and N
aN
15O
2  at three different reaction tim
es. 
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M
ass chrom
atogram
s extracted at 228 D
a of the reaction betw
een the hydroxylam
ine 144 and N
aN
15O
2  at three different reaction tim
es. 
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M
ass chrom
atogram
s extracted at 300 D
a of the reaction betw
een the hydroxylam
ine 144 and N
aN
15O
2  at three different reaction tim
es. 
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H
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m
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S
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_ T 1
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u
n t s
2
3 0 0 . 2 0 - 3 0 0 . 6 0 m
/ z
1 0 . 8
1 2 . 5
1 3 . 8
1 5 . 0
1 6 . 3
1 7 . 5
1 8 . 8
2 0 . 0
2 1 . 3
2 2 . 5
2 3 . 8
2 5 . 0
2 6 . 3
2 7 . 5
2 8 . 8
3 0 . 1
- 5
' 0 0 0
' 0 0 0
2 0 ' 0 0 0 ' 0 0 0
4 5 ' 0 0 0 ' 0 0 0
3  
-
 D
a t a
_ t h e s i s
 # 1 0 7  [ t i m
e
 c o
r r e
c t e d  b y
 
- 0 . 2 4 0  m
i n ]
N
H O
H
 N
a N
1 5 N O
2
 6
. 9
m
g
M
S
_ 3 0 0
_ T 1
_ N
1
c o
u
n t s
m
i n
3
3 0 0 . 2 0 - 3 0 0 . 6 0 m
/ z!
After!sample!preparation!
After!1!day!
After!2!days!
nitro!147((m
/z!=!300!Da)!
nitro!147((m
/z!=!300!Da)!
nitro!147((m
/z!=!300!Da)!
!
238!
M
ass chrom
atogram
s and N
M
R
 Spectra of the Project on G
lycolipopetides 
HRMS 2!spectrum!of!the!pseudomolecular!ion![M+2H] 2+!with!a!m
/z!of!817.90078!Da!corresponding!to!GPLC>1!(182).!
!
!
!
239!
HRMS 2!spectrum!of!the!pseudomolecular!ion![M+2H] 2+!with!a!m
/z!of!839.40274!Da!corresponding!to!GPLC>2!(183).!
!
!
240!
1H>NMR!Spectrum!of!GPLC>2!(183)!with!the!lactone!opened.!
!
!
GLCP>2!(183)!with!the!
lactone!opened!
!
241!
HSQC!Spectrum!of!GPLC>2!(183)!with!the!lactone!opened.!
GLCP>2!(183)!with!the!
lactone!opened!
!
242!
G
LC
P-2 (183), m
ass chrom
atogram
s m
onitored at m
/z 686 for the protonated tyrosine M
arfey’s derivatives. 183 w
as hydrolyzed prior to derivatization.!
!
!
L>Tyr!D>Tyr!GLCP>2!(183)!
!
243!
G
LC
P-2 (183), m
ass chrom
atogram
s m
onitored at m
/z 400 for the protonated glutam
ine M
arfey’s derivatives. 183 w
as hydrolyzed prior to derivatization. 
!
L>Glu!D>Glu!GLCP>2!(183)!
!
244!
G
LC
P-2 (183), m
ass chrom
atogram
s m
onitored at m
/z 372 for the protonated threonine M
arfey’s derivatives. 183 w
as hydrolyzed prior to derivatization. 
 
L>Thr!L>allo>Thr!
GLCP>2!(183)!
D>Thr!D>allo>Thr!
!
245!
G
LC
P-2 (183), m
ass chrom
atogram
s m
onitored at m
/z 372 for the protonated threonine M
arfey’s derivatives. 183 w
as hydrolyzed prior to derivatization. 
!
L>Thr!L>allo>Thr!
GLCP>2!(183)!
D>Thr!D>allo>Thr!GLCP>2!(183)!coinjection!
with!L>Thr!
!
246!
G
LC
P-2 (183), m
ass chrom
atogram
s m
onitored at m
/z 328 for the protonated glutam
ine M
arfey’s derivatives. 183 w
as hydrolyzed prior to derivatization. 
!
GLCP>2!(183)!
Gly!
!
247!
G
LC
P-2 (183), m
ass chrom
atogram
s m
onitored at m
/z 386 for the protonated N
-m
ethylate threonine M
arfey’s derivatives. 183 w
as hydrolyzed prior to 
derivatization. 
!
N>Me>L>Thr!
N>Me>L>allo>Thr!
GLCP>2!(183)!
N>Me>D>Thr!
N>Me>D>allo>Thr!
GLCP>2!(183)!coinjection!with!N>Me!D>Thr!
GLCP>2!(183)!coinjection!with!N>Me!L>allo>Thr!
!
248!
!
! 249!
Amino Acid Analysis of Balgacyclamides 
Balgacyclamide A (177), mass chromatograms monitored at m/z 368 with negative APCI 
mode for the deprotonated valine Marfey’s derivatives. 177 was ozonolyzed and hydrolyzed 
prior to the derivatization. 
  
Operator:Dionex  Timebase:MSQ_Summit   Sequence:Eawag_251_Marfey Page 1-1
24.4.2013  10:13 AM
Simon_report/Overlay Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Overlay of Sampl s from Int gration View
-1'000'000
2'000'000
4'000'000
6'000'000
8'000'000 1 - Eawag_251_Marfey #3 [time corrected by -0.080 min] MS_368_T0_N1
counts
1
367.50-368.50m/z
-1'000'000
1'250'000
2'500'000
3'750'000
5'000'000
7'000'000 2 - Eawag_251_Marfey #10 [time corrected by -0.240 min] MS_368_T0_N1
counts
2
367.50-368.50m/z
0.0 10.0 20.0 30.0 40.0 50.0 60.0 74.9
-10'000'000
0
12'500'000
25'000'000
37'500'000
50'000'000
60'000'000 3 - Eawag_251_Marfey #11 [time corrected by -0.080 min] MS_368_T0_N1
counts
min
3
367.50-368.50m/z
177 
D-Val 
L-Val 
! 250!
Balgacyclamide A (177), mass chromatograms monitored at m/z 340 with negative APCI 
mode for the deprotonated alanine Marfey’s derivatives. 177 was ozonolyzed and hydrolyzed 
prior to the derivatization. 
 
  
Operator:Dionex  Timebase:MSQ_Summit   Sequence:Eawag_251_Marfey Page 1-1
24.4.2013  4:55 PM
Simon_report/Overlay Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Ov rlay of Sampl s from Integration View
-500'000
0
500'000
1'000'000
1'500'000
2'000'000
2'500'000 1 - Eawag_251_Marfey #3 [time corrected by -0.080 min] MS_340_T0_N1
counts
1
339.50-340.50m/z
-5'000'000
10'000'000
20'000'000
30'000'000
40'000'000
50'000'000 2 - Eawag_251_Marfey #16 [time corrected by -0.240 min] MS_340_T0_N1
counts
2
339.50-340.50m/z
0.0 10.0 20.0 30.0 40.0 50.0 60.0 74.9
-2'000'000
5'000'000
10'000'000
16'000'000 3 - Eawag_251_Marfey #17 [time corrected by -0.240 min] MS_340_T0_N1
counts
min
3
339.50-340.50m/z
177 
D-Ala 
L-Ala 
! 251!
Balgacyclamide A (177), mass chromatograms monitored at m/z 382 with negative APCI 
mode for the deprotonated isoleucine Marfey’s derivatives. 177 was ozonolyzed and 
hydrolyzed prior to the derivatization. 
 
  
Operator:Dionex  Timebase:MSQ_Summit   Sequence:Eawag_251_Marfey Page 1-1
25.4.2013  4:38 PM
Simon_report/Overlay Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Ov rlay of Samples from Integration View
-500'000
1'000'000
2'500'000 1 - Eawag_251_Marfey #5 [time corrected by -0.080 min] MS_382_T0_N1
counts
1
381.50-382.50m/z
-2'000'000
5'000'000
10'000'000
16'000'000 2 - Eawag_251_Marfey #13 [time corrected by -0.240 min] MS_382_T0_N1
counts
2
381.50-382.50m/z
-500'000
2'000'000
4'500'000 3 - Eawag_251_Marfey #14 [time corrected by -0.240 min] MS_382_T0_N1
counts
3
381.50-382.50m/z
-10'000'000
20'000'000
40'000'000
60'000'000 4 - Eawag_251_Marfey #15 [time corrected by -0.080 min] MS_382_T0_N1
counts
4
381.50-382.50m/z
0.0 10.0 20.0 30.0 40.0 50.0 60.0 74.9
-5'000'000
20'000'000
40'000'000
55'000'000 5 - Eawag_251_Marfey #16 [time corrected by -0.080 min] MS_382_T0_N1
counts
min
5
381.50-382.50m/z
177 
L-Ile 
L-allo-Ile 
D-Ile 
D-allo-Ile 
! 252!
Balgacyclamide A (177), mass chromatograms monitored at m/z 370 with negative APCI 
mode for the deprotonated threonine Marfey’s derivatives. 177 was ozonolyzed and 
hydrolyzed prior to the derivatization. 
 
  
Operator:Dionex  Timebase:MSQ_Summit   Sequence:Eawag_251_Marfey Page 1-1
26.4.2013  1:26 PM
Simon_report/Overlay Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Ov rlay of Samples from I tegration View
-500'000
2'000'000
4'500'000 1 - Eawag_251_Marfey #3 [time corrected by -0.080 min] MS_370_T0_N1
counts
1
369.50-370.50m/z
-20'000
50'000
100'000
160'000 2 - Eawag_251_Marfey #10 [time corrected by -0.080 min] MS_370_T0_N1
counts
2
369.50-370.50m/z
-2'000
10'000
20'000 3 - Eawag_251_Marfey #1 [time corrected by -0.080 min] MS_370_T0_N1
counts
3
369.50-370.50m/z
-5'000
20'000
40'000
55'000 4 - Eawag_251_Marfey #9 [time corrected by -0.240 min] MS_370_T0_N1
counts
4
369.50-370.50m/z
0.0 10.0 20.0 30.0 40.0 50.0 60.0 74.9
-2'000'000
5'000'000
10'000'000
14'000'000 5 - Eawag_251_Marfey #8 [time corrected by -0.240 min] MS_370_T0_N1
counts
min
5
369.50-370.50m/z
L-Thr 
L-allo-Ile 
D-Thr 
L-allo-Thr X 
D-allo-Thr 
177 
! 253!
Balgacyclamide A (177), mass chromatograms monitored at m/z 370 with negative APCI 
mode for the deprotonated threonine Marfey’s derivatives, L-Thr and L-allo-Thr, and 
coinjection of 177 with L-allo-Thr. 177 was ozonolyzed and hydrolyzed prior to the 
derivatization. 
 
  
Operator:Dionex  Timebase:MSQ_Summit   Sequence:Eawag_251_Marfey Page 1-1
25.4.2013  4:45 PM
Simon_report/Overlay Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Ov rlay  Samples from Integration View
-500'000
1'000'000
2'000'000
3'000'000 1 - Eawag_251_Marfey #5 [time corrected by -0.080 min] MS_370_T0_N1
counts
1
369.50-370.50m/z
-20'000
50'000
100'000
160'000 2 - Eawag_251_Marfey #10 [time corrected by -0.080 min] MS_370_T0_N1
counts
2
369.50-370.50m/z
-2'000
5'000
10'000
15'000
20'000 3 - Eawag_251_Marfey #1 [time corrected by -0.080 min] MS_370_T0_N1
counts
3
369.50-370.50m/z
0.0 10.0 20.0 30.0 40.0 50.0 60.0 74.9
-10'000
25'000
50'000
75'000
100'000 4 - Eawag_251_Marfey #4 [time corrected by -0.080 min] MS_370_T0_N1
counts
min
4
369.50-370.50m/z
L-Thr 
L-allo-Thr 
X 
177 
L-allo-Thr 
177 
X 
X 
! 254!
 
Balgacyclamide A (177), GC chromatograms of the derivatized D-allo-Ile, D-Ile and 
coinjection of derivatized 177 with D-Ile. 177 was hydrolyzed prior to derivatization with 
trifluoroacetic acid. 
 
   
D-Ile 
D-allo-Ile 
D-Ile 177 X 
! 255!
Balgacyclamide B (178), mass chromatograms monitored at m/z 368 with negative APCI 
mode for the deprotonated valine Marfey’s derivatives. 178 was ozonolyzed and hydrolyzed 
prior to the derivatization. 
 
  
Operator:Dionex  Timebase:MSQ_Summit   Sequence:Eawag_251_Marfey Page 1-1
24.4.2013  10:14 AM
Simon_report/Overlay Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Ov rlay of Sampl s from Int gration Vi w
-2'000'000
5'000'000
10'000'000
16'000'000 1 - Eawag_251_Marfey #4 [time corrected by -0.080 min] MS_368_T0_N1
counts
1
367.50-368.50m/z
-1'000'000
1'250'000
2'500'000
3'750'000
5'000'000
7'000'000 2 - Eawag_251_Marfey #10 [time corrected by -0.240 min] MS_368_T0_N1
counts
2
367.50-368.50m/z
0.0 10.0 20.0 30.0 40.0 50.0 60.0 74.9
-10'000'000
0
12'500'000
25'000'000
37'500'000
50'000'000
60'000'000 3 - Eawag_251_Marfey #11 [time corrected by -0.080 min] MS_368_T0_N1
counts
min
3
367.50-368.50m/z
178 
D-Val 
L-Val 
! 256!
Balgacyclamide B (178), mass chromatograms monitored at m/z 340 with negative APCI 
mode for the deprotonated alanine Marfey’s derivatives. 178 was ozonolyzed and hydrolyzed 
prior to the derivatization. 
 
  
Operator:Dionex  Timebase:MSQ_Summit   Sequence:Eawag_251_Marfey Page 1-1
25.4.2013  4:39 PM
Simon_report/Overlay Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Ov rlay of Sampl s from Integration Vi w
-2'000'000
5'000'000
10'000'000
15'000'000
18'000'000 1 - Eawag_251_Marfey #6 [time corrected by -0.080 min] MS_340_T0_N1
counts
1
339.50-340.50m/z
-5'000'000
10'000'000
20'000'000
30'000'000
40'000'000
50'000'000 2 - Eawag_251_Marfey #17 [time corrected by -0.240 min] MS_340_T0_N1
counts
2
339.50-340.50m/z
0.0 10.0 20.0 30.0 40.0 50.0 60.0 74.9
-2'000'000
5'000'000
10'000'000
16'000'000 3 - Eawag_251_Marfey #18 [time corrected by -0.240 min] MS_340_T0_N1
counts
min
3
339.50-340.50m/z
178 
D-Ala 
L-Ala 
! 257!
Balgacyclamide B (178), mass chromatograms monitored at m/z 382 with negative APCI 
mode for the deprotonated isoleucine Marfey’s derivatives. 178 was ozonolyzed and 
hydrolyzed prior to the derivatization. 
 
  
Operator:Dionex  Timebase:MSQ_Summit   Sequence:Eawag_251_Marfey Page 1-1
25.4.2013  4:39 PM
Simon_report/Overlay Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Ov rlay of Samples from Integration View
-2'000'000
5'000'000
10'000'000
16'000'000 1 - Eawag_251_Marfey #6 [time corrected by -0.080 min] MS_382_T0_N1
counts
1
381.50-382.50m/z
-2'000'000
5'000'000
10'000'000
16'000'000 2 - Eawag_251_Marfey #13 [time corrected by -0.240 min] MS_382_T0_N1
counts
2
381.50-382.50m/z
-500'000
2'000'000
4'500'000 3 - Eawag_251_Marfey #14 [time corrected by -0.240 min] MS_382_T0_N1
counts
3
381.50-382.50m/z
-10'000'000
20'000'000
40'000'000
60'000'000 4 - Eawag_251_Marfey #15 [time corrected by -0.080 min] MS_382_T0_N1
counts
4
381.50-382.50m/z
0.0 10.0 20.0 30.0 40.0 50.0 60.0 74.9
-5'000'000
20'000'000
40'000'000
55'000'000 5 - Eawag_251_Marfey #16 [time corrected by -0.080 min] MS_382_T0_N1
counts
min
5
381.50-382.50m/z
178 
L-Ile 
L-allo-Ile 
D-Ile 
D-allo-Ile 
! 258!
Balgacyclamide B (178), mass chromatograms monitored at m/z 370 with negative APCI 
mode for the deprotonated threonine Marfey’s derivatives. 178 was ozonolyzed and 
hydrolyzed prior to the derivatization. 
 
  
Operator:Dionex  Timebase:MSQ_Summit   Sequence:Eawag_251_Marfey Page 1-1
24.4.2013  6:03 PM
Simon_report/Overlay Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Overlay of Sam les from Integration View
-1'000'000
2'500'000
5'000'000
8'000'000 1 - Eawag_251_Marfey #5 [time corrected by -0.080 min] MS_370_T0_N1
counts
1
369.50-370.50m/z
-20'000
50'000
100'000
160'000 2 - Eawag_251_Marfey #9 [time corrected by -0.080 min] MS_370_T0_N1
counts
2
369.50-370.50m/z
-2'000
10'000
20'000 3 - Eawag_251_Marfey #1 [time corrected by -0.080 min] MS_370_T0_N1
counts
3
369.50-370.50m/z
-5'000
20'000
40'000
55'000 4 - Eawag_251_Marfey #8 [time corrected by -0.240 min] MS_370_T0_N1
counts
4
369.50-370.50m/z
0.0 10.0 20.0 30.0 40.0 50.0 60.0 74.9
-2'000'000
5'000'000
10'000'000
14'000'000 5 - Eawag_251_Marfey #7 [time corrected by -0.240 min] MS_370_T0_N1
counts
min
5
369.50-370.50m/z
L-Thr 
L-allo-Ile 
D-Thr 
L-allo-Thr X 
D-allo-Thr 
178 
! 259!
Balgacyclamide B (178), GC chromatograms of the derivatized D-allo-Ile, D-Ile and 
coinjection of derivatized 178 with D-Ile. 178 was hydrolyzed prior to derivatization with 
trifluoroacetic acid. 
 
 
 
  
D-Ile 
D-Ile 
D-allo-Ile 
178 X D-Ile 
! 260!
Balgacyclamide C (179), mass chromatograms monitored at m/z 416 with negative APCI 
mode for the deprotonated phenylalanine Marfey’s derivatives. 179 was ozonolyzed and 
hydrolyzed prior to the derivatization. 
 
  
Operator:Dionex  Timebase:MSQ_Summit   Sequence:Eawag_251_Marfey Page 1-1
24.4.2013  5:10 PM
Simon_report/Overlay Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Overlay of Samples from Integration View
-5'000'000
0
5'000'000
10'000'000
15'000'000
20'000'000
25'000'000 1 - Eawag_251_Marfey #6 [time corrected by -0.080 min] MS_416_T0_N1
counts
1
415.50-416.50m/z
-500'000
1'000'000
2'000'000
3'000'000
4'000'000
5'000'000 2 - Eawag_251_Marfey #18 [time corrected by -0.240 min] MS_416_T0_N1
counts
2
415.50-416.50m/z
0.0 10.0 20.0 30.0 40.0 50.0 60.0 74.9
-500'000
1'000'000
2'000'000
3'000'000
4'000'000
5'000'000 3 - Eawag_251_Marfey #21 [time corrected by -0.240 min] MS_416_T0_N1
counts
min
3
415.50-416.50m/z
179 
L-Phe 
D-Phe 
! 261!
Balgacyclamide C (179), mass chromatograms monitored at m/z 382 with negative APCI 
mode for the deprotonated isoleucine Marfey’s derivatives. 179 was ozonolyzed and 
hydrolyzed prior to the derivatization. 
 
  
Operator:Dionex  Timebase:MSQ_Summit   Sequence:Eawag_251_Marfey Page 1-1
25.4.2013  4:42 PM
Simon_report/Overlay Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Ov rlay of Samples from Integration View
-1'000'000
5'000'000
10'000'000 1 - Eawag_251_Marfey #7 [time corrected by -0.080 min] MS_382_T0_N1
counts
1
381.50-382.50m/z
-2'000'000
5'000'000
10'000'000
16'000'000 2 - Eawag_251_Marfey #13 [time corrected by -0.240 min] MS_382_T0_N1
counts
2
381.50-382.50m/z
-500'000
2'000'000
4'500'000 3 - Eawag_251_Marfey #14 [time corrected by -0.240 min] MS_382_T0_N1
counts
3
381.50-382.50m/z
-10'000'000
20'000'000
40'000'000
60'000'000 4 - Eawag_251_Marfey #15 [time corrected by -0.080 min] MS_382_T0_N1
counts
4
381.50-382.50m/z
0.0 10.0 20.0 30.0 40.0 50.0 60.0 74.9
-5'000'000
20'000'000
40'000'000
55'000'000 5 - Eawag_251_Marfey #16 [time corrected by -0.080 min] MS_382_T0_N1
counts
min
5
381.50-382.50m/z
179 
L-Ile 
L-allo-Ile 
D-Ile 
D-allo-Ile 
! 262!
Balgacyclamide C (179), mass chromatograms monitored at m/z 370 with negative APCI 
mode for the deprotonated threonine Marfey’s derivatives. 179 was ozonolyzed and 
hydrolyzed prior to the derivatization. 
 
  
Operator:Dionex  Timebase:MSQ_Summit   Sequence:Eawag_251_Marfey Page 1-1
25.4.2013  4:43 PM
Simon_report/Overlay Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Ov rlay of Samples from I tegration View
-1'000'000
2'500'000
5'000'000
8'000'000 1 - Eawag_251_Marfey #7 [time corrected by -0.080 min] MS_370_T0_N1
counts
1
369.50-370.50m/z
-20'000
50'000
100'000
160'000 2 - Eawag_251_Marfey #10 [time corrected by -0.080 min] MS_370_T0_N1
counts
2
369.50-370.50m/z
-2'000
10'000
20'000 3 - Eawag_251_Marfey #1 [time corrected by -0.080 min] MS_370_T0_N1
counts
3
369.50-370.50m/z
-5'000
20'000
40'000
55'000 4 - Eawag_251_Marfey #9 [time corrected by -0.240 min] MS_370_T0_N1
counts
4
369.50-370.50m/z
0.0 10.0 20.0 30.0 40.0 50.0 60.0 74.9
-2'000'000
5'000'000
10'000'000
14'000'000 5 - Eawag_251_Marfey #8 [time corrected by -0.240 min] MS_370_T0_N1
counts
min
5
369.50-370.50m/z
L-Thr 
L-allo-Ile 
D-Thr 
L-allo-Thr X 
D-allo-Thr 
179 
! 263!
Balgacyclamide C (179), GC chromatograms of the derivatized D-allo-Ile, D-Ile and 
coinjection of 179 with D-Ile. 179 was hydrolyzed prior to derivatization with trifluoroacetic 
acid. 
 
 
 
D-Ile 
3 
D-Ile 
D-allo-Ile 
X 
D-Ile 
179 
